**List of publications, Marcus Maurer, M.D.**

### **Original Publications in peer-reviewed Journals**

|  |  |
| --- | --- |
|  | Ali, Z.+, Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Allerup, J. A. C., **Maurer, M.**, Kocatürk, E., Vestergaard, C., and Thomsen, S. F.: Smartphone photographs of chronic urticaria taken by patients are of good quality and useful in the clinic. *Dermatology* 2023: *in press*. IF: TBD (IF 2022: 3.40) |
|  | Baumann, K., Jørgensen, A. R., Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Skov, P. S., Woetmann, A., Vestergaard, C., **Maurer, M.**, and Thomsen, S. F.+: Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria. *Clin. Exp. Allergy* 2023: *in press*. IF: TBD (IF 2022: 6.10) |
|  | Buttgereit, T.\*, Nicola, S.\*, Vera, C., Brussino, L., **Maurer, M.**+\*, and Magerl, M.\*: Significant response to berotralstat in 3 patients with hereditary angioedema of unknown origin. *J. Allergy Clin. Immunol. Pract*. 2023: *in press*. IF: TBD (IF 2022: 9.40) |
|  | Chularojanamontri, L., Kulthanan, K.+, Tuchinda, P., Rujitharanawong, C., Munprom, K., Pochanapan, O., Panjapakkul, W., **Maurer, M.**, and Weller, K.: The validity and reliability of a Thai version of the angioedema control test: which recall period is preferable? *Asian Pac. J. Allergy Immunol*. 2023: *in press.* IF: TBD (IF 2022: 5.00) |
|  | Kovalkova, E.+, Fomina, D., Borzova, E., Maltseva, N., Chernov, A., Serdoteckova, S., Weller, K., and **Maurer, M.**: Сomorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights. *J. Allergy Clin. Immunol. Pract*. 2023: *in press*. IF: TBD (IF 2022: 9.40) |
|  | **Maurer, M.**, Albuquerque, M., Boursiquot, J.-N., Dery, E., Giménez-Arnau, A., Godse, K., Guitiérrez, G., Kanani, A., Lacuesta, G., McCarthy, J., Nigen, S., and Winders, T.+: A patient charter for chronic urticaria. *Adv. Ther.* 2023: *in press*. IF: TBD (IF 2022: 3.80) |
|  | **Maurer, M.**+, Ensina, L. F., Giménez-Arnau, A. M., Sussman, G., Hide, M., Saini, S., Grattan, C., Fomina, D., Rigopoulos, D., Berard, F., Canonica, G. W., Rockmann, H., Irani, C., Szepietowski, J. C., Leflein, J., Bernstein, J. A., Peter, J., Kulthanan, K., Godse, K., Ardusso, L., Ukhanova, O., Staubach, P., Sinclair, R., Gogate, S., Thomsen, S. F., Tanus, T., Ye, Y. M., Burciu, A., Barve, A., Modi, D., Scoryrev, E., Hua, E., Letzelter, K., Varanasi, V., Patekar, M., Severin, T., and Pearl-1 and PEARL2 trial investigators: Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. *Lancet* 2023: *in press*. IF: TBD (IF 2022: 168.9) |
|  | **Maurer, M.**+, Lumry, W. R., Li, H. H., Aygören-Pürsün, E., Busse, P. J., Jacobs, J., Nurse, C., Ahmed, M. A., Watt, M., Yu, M., and SPRING Investigators: Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: results from the phase 3 SPRING study.*J. Allergy Clin. Immunol. Pract*. 2023: *in press*. IF: TBD (IF 2022: 9.40) |
|  | Metz, M.+, Zeidler, C., Hawro, T., Pereira, M., **Maurer, M.**, Bonnekoh, H., Krause, K., Pritchard, T., Kwatra, S. G., Ständer, S., and Weller, K.+: Development and validation of the prurigo control test - a patient-reported outcome measure to assess disease control in chronic prurigo. *JAMA Dermatol*. 2023: *in press*. IF: TBD (IF 2022: 10.90) |
|  | Moñino-Romero, S., Kolkhir, P., Ohanyan, T., Szépfalusi, Z., Weller, K., Metz, M., Scheffel, J., **Maurer, M.**+, and Altrichter, S.: Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria. *J. Eur. Acad. Dermatol. Venereol*. 2023: *in press*. IF: TBD (IF 2022: 9.20) |
|  | Moon, S., Stasikowska-Kanicka, O., Wagrowska-Danilewicz, M., Hawro, M., Metz, M., **Maurer, M.**, and Hawro, T.+: Clinically uninvolved but not healthy – the skin of patients with atopic dermatitis is primed for itch and inflammation. *J. Eur. Acad. Dermatol. Venereol*. 2023: *in press*. IF: TBD (IF 2022: 9.20) |
|  | Salameh, P., Gutsche, A., Aulenbacher, F., Buttgereit, T., Weller, K., Siebenhaar, F., and **Maurer, M.**+: Urticaria control test real-world performance: a post hoc analysis. *Allergy* 2023: *in press*. IF: TBD (IF 2022: 12.40)Gutsche, A., Salameh, P., Aulenbacher, F., Buttgereit, T., Weller, K., Siebenhaar, F., and **Maurer, M.**+: Reply to: Zhang et al.: Clinical applicability of the Urticaria Control Test in patients with chronic urticaria: further evidence from 622 adult and pediatric patients with different disease subtypes. *Allergy* 2023: *in press*. |
|  | Türk, M., Yilmaz, I., Bahcecioglu, S. N., Cetin, G. P., Komi, D. E.-A., and **Maurer, M.**+: Capsaicin pretreatment increases mast cell-mediated but not histamine-induced wheal and erythema responses: a proof-of-concept study. *Asthma Allergy* *Immunol*. 2023: *in press*. IF: TBD (IF 2022: 0.2) |
|  | Weller, K., Giménez-Arnau, A. M., Baron, J., Brehler, R., Ferrer, M., Groffik, A., Grundmann, S., Jakob, T., Labrador-Horrillo, M., Müller, S., Staubach, P., Wurpts, G., Metz, M., and **Maurer, M.**+: Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: a randomized trial. *Allergy* 2023: *in press*. IF: TBD (IF 2022: 12.40) |
|  | Zhu, L.\*, Jian, X.\*, Zhou, B.\*, Liu, R.\*, Munoz, M., Sun, W., Xie, L.+, Chen, X., Peng, C., **Maurer, M.**+, and Li, J.: Gut microbiota facilitate chronic spontaneous urticaria. *Nat. Commun*. 2023: *in press*. IF: TBD (IF 2022: 16.60) |
| 564. | Buttgereit, T., Salameh, P., Sydorenko, O., Zuberbier, T., Metz, M., Weller, K., and **Maurer, M.+**: The 7-day recall period version of the urticaria control test – UCT7. *J. Allergy Clin. Immunol*. 2023:152; 1210-1217. IF: TBD (IF 2022: 14.20) |
| 563. | Pyatilova, P., Bernstein, J. A., Aulenbacher, F., Sanchez Borges, M., Dimitrijević, S., Hoehn, G., **Maurer, M.**, Kolkhir, P.\*, and Siebenhaar, F.\*+: The diagnostic workup for systemic mastocytosis differs from consensus recommendations: results of a worldwide survey. *World Allergy Organ J.* 2023: 16; 100838. IF: TBD (IF 2022: 5.10) |
| 562. | Hu, M., Pyatilova, P., Altrichter, S., Sheng, C., Liu, N., Terhorst-Molawi, D., Lohse, K., Ginter, K., Puhl, V., **Maurer, M.**, Metz, M., and Kolkhir, P.+: In the skin lesions of patients with mycosis fungoides, the number of MRGPRX2-expressing cells is increased and correlates with mast cell numbers. *Front. Immunol*. 2023: 14; 1197821. IF: TBD (IF 2022: 7.30) |
| 561. | Kocatürk, E.+, Salameh, P., Sarac, E., Vera Ayala, C. E., Thomsen, S. F., Zuberbier, T., Ensina, L. F., Popov, T. A., van Doorn, M., Giménez-Arnau, A. M., Asero, R., Criado, P. R., Grattan, C., Conlon, N., Cherrez-Ojeda, I., Aarestrup, F. M., Abdul Hameed Ansari, Z., Al Abri, S., Al Ahmad, M., Al Hinai, B., Al-Nesf, M., Allenova, A., Altrichter, S., Arnaout, R., Bartosinska, J., Bastos, Palitot, E., Bauer, A., Bernstein, J. A., Bizjak, M., Bonnekoh, H., Bouillet, L., Brzoza, Z., Carne, E., Cherichi Puravil, S., Chong-Neto, H. J., Christoff, G., Criado, R. F. J., Cvenkel, K., Damadoglu, E., Danilycheva, I., Day, C., De Montjoye, S., Ferucci, S. M., Fomina, D., Fuat Kalyoncu, A., Fukunaga, A., Garcia, E., Gelincik, A., Göbel, J. H., Godse, K., Goncalo, M., Gotua, M., Gugala, A., Guillet, C., Karakaya, G., Kasperska-Zajac, A., Katelaris, C., Khoshkhui, M., Kleinheinz, A., Kolacinska-Flont, M., Kolkhir, P., Kosnik, M., Krasowska, D., Kumaran, M. S., Kuprys-Lipinska, I., Kurowski, M., Larenas-Linnemann, D., Lee, Y., Campinhos, F. L., Makris, M. P., Maximiliano Gómez, R., Meshkova, R., Moura, A. C., Nasr, I., Neisinger, S., Oda, Y., Öztas Kara, R., Papapostolou, N., Parisi, C. A. S., Pesque, D., Peter, J., Petkova, E., Ridge, K., Rudenko, M., Rutkowski, C., Saini, S., Salman, A., Sanchez, J., Sekerel, B., Serpa, F. S., Sevimli Dikicier, B., Sidiropoulos, N., Sørensen, J. A., Soria, A., Su Kucuk, O., Thalappil, S. R., Tomaszewska, K., Tuncay, G., Unal, D., Valle, S., van Lindonk, E., Vestergaard, C., Vitchuk, A., Xepapadaki, P., Ye, Y.-M., Zalewska-Janowska, A., Sikora, A., Zamlynski, M., Serdotetskova, S. A., Lebedkina, M. S., Kuznetsova, E. V., and **Maurer, M.**+: Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: results of the UCARE COVAC-CU study. *J. Allergy Clin. Immunol*. 2023: 152; 1095-1106. IF: TBD (IF 2022: 14.20) |
| 560. | Krause, K., Bonnekoh, H., Jelden-Thurm, J., Asero, R., Giménez-Arnau, A. M., Cardoso, J. C., Grattan, C., Kocatürk, E., Lippert, U., **Maurer, M.**, Metz, M., Staubach, P., Goncalo, M., and Kolkhir, P.+: Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: an international Delphi survey. *Clin. Transl. Allergy* 2023: 13; e12305. IF: TBD (IF 2022: 4.40) |
| 559. | Frischbutter, S+\*., Durek, P.\*, Witkowski, M.\*, Angermair, S., Treskatsch, S., **Maurer, M.**,Radbruch, A.,and Mashreghi, M.-F.: Serum TGFβ as a predictive biomarker for severe disease and fatality of COVID-19. *Eur. J. Immunol*. 2023: 53; 2350433. IF: TBD (IF 2022: 5.40) |
| 558. | Bonnekoh, H., Jelden-Thurm, J., Allenova, A., Chen, Y., Cherrez-Ojeda, I., Danilycheva, I., Dorofeeva, I., Jardim Criado, R. F., Criado, P. R., Gelincik Akkor, A., Hawro, T., Kocatürk, E., Khoshkhui, M., Metz, M., Nasr, I., Steć, M., Zhao, Z., Aulenbacher, F., Salameh, P., Altrichter, S., Gonçalo, M., Giménez-Arnau, A., **Maurer, M.**, Krause, K., and Kolkhir, P.+: Urticarial vasculitis differs from chronic spontaneous urticaria in time to diagnosis, clinical presentation, and need for anti-inflammatory treatment: an international prospective UCARE study. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 2900-2910. IF: TBD (IF 2022: 9.40) |
| 557. | Kulthanan, K., Tuchinda, P., Eimpunth, S., Chuthapisith, S., Rushatamukayanumt, P., Limphoka, P., Panjapakkul, W., Pochanapan, O., and **Maurer, M.**+: “Blue wheals” and “blue angioedema” induced by blue dyes: a systematic review. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 3223-3234. IF: TBD (IF 2022: 9.40) |
| 556. | Öztaş Kara, R., Demir, S., Saraç, E., Sevimli Dikicier, B., Ünal, D., Gelincik, A., Thomsen, S. F., **Maurer, M.**, and Kocatürk, E.+: Features of chronic spontaneous urticaria induced by COVID-19. *Int. Arch. Allergy Immunol*. 2023: 184; 792-796. IF: TBD (IF 2022: 2.80) |
| 555. | Xiang, Y.-K., Kolkhir, P., Scheffel, J., Sauer, M., Vera, C., Frischbutter, S., Krause, K., Siebenhaar, F., Metz, M., **Maurer, M.**+, and Altrichter, S.: Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 2417-2425. IF: TBD (IF 2022: 9.40) |
| 554. | Karstali Bakay, O. S., Demir, B., Cicek, D., Erol, D., Aşçı Toraman, Z., Gural, Y., and **Maurer, M.**+: In chronic spontaneous urticaria, IgE and CRP are linked to distinct microRNAs and interleukin-31. *Clin. Transl. Allergy* 2023: 13; e12290. IF: TBD (IF 2022: 4.40) |
| 553. | Bonnekoh, H., Kiefer, L., Buttgereit, T., Kolkhir, P., Lütke-Eversloh, M., Scheffel, J., **Maurer, M.**, and Metz, M.+: Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria – a case series. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 2578-2580. IF: TBD (IF 2022: 9.40) |
| 552. | Mobayed, H.+, Al-Nesf, M. A., Robles-Velasco, K., Cherrez-Ojeda, I., Ensina, L. F., and **Maurer, M**.: Severe exercise-induced anaphylaxis in a hot and humid area successfully treated with omalizumab: a case report. *Front. Allergy* 2023: 4; 1228495. IF: N/A |
| 551. | Siebenhaar, F., Altrichter, S., Bonnekoh, H., Hawro, T., Hawro, M., Michaelis, E. G., Kantor, A. M., Chang, A. T., Youngblood, B. A., Sing, B., Rasmussen, H. S., and **Maurer, M.**+: Safety and efficacy of Lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. *Brit. J. Dermatol*. 2023: *189; 511-519*. IF: TBD (IF 2022: 10.30) |
| 550. | Su, H., Kolkhir, P., Scheffel, J., Xiang, Y.-K., Yao, X., **Maurer, M.**+, and Altrichter, S.: One in five patients with chronic spontaneous urticaria has IgE to tissue transglutaminase 2. *Allergy* 2023: 78; 2537-2539. IF: TBD (IF 2022: 12.40) |
| 549. | Cohn, D. M.+, Aygören-Pürsün, E., Bernstein, J. A., Farkas, SH., Lumry, W. R., **Maurer, M.**, Zanichelli, A., Iverson, M., Hao, J., Smith, M. D., Yea, C. M., Audhya, P. K., and Riedl, M. A.: Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of Sebetralstat. *Clin. Transl. Allergy* 2023: 23; e12288. IF: TBD (IF 2022: 4.40) |
| 548. | Fijen, L. M.+, Vera, C., Buttgereit, T., Bonnekoh, H., **Maurer, M.**, Magerl, M., and Weller, K.: Sensitivity to change and minimal clinically important difference of the angioedema control test. *Clin. Transl. Allergy* 2023: 13; e12295. IF: TBD (IF 2022: 4.40) |
| 547. | Moñino-Romero, S., Hackler, Y., Okas, T.-L., Grekowitz, E. M., Fluhr, J. W., Hultsch, V., Kiefer, L. A., Pyatilova, P., Terhorst-Molawi, D., Xiang, Y.-K., Siebenhaar, F., **Maurer, M.**, and Kolkhir, P.+: Positive basophil tests are linked to high disease activity and other features of autoimmune chronic spontaneous urticaria: a systematic review. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 2411-2416. IF: TBD (IF 2022: 9.40) |
| 546. | Metz, M.+, Elberskirch, M., Reuter, C., Liedtke, L., and **Maurer, M.**: Efficacy of concentrated heat for treatment of insect bites: results of a real-world study. *Act. Derm. Venereol*. 2023: 103; adv11592. IF: TBD (IF 2022: 3.60) |
| 545. | Richtig, G+, Berger, M., Koeller, M., Richtig, M., Richtig, E., Scheffel, J., **Maurer, M.**+, and Siebenhaar, F.+: Predatory journals: perception, impact and use of Beall’s list by the scientific community – a bibliometric big data study. *PLoS One* 2023:18; e0287547. IF: TBD (IF 2022: 3.70) |
| 544. | Ertas, R.+, Türk, M., Yücel, M. B., Muñoz, M., Ertas, S., K., Atasoy, M., and **Maurer, M.**: Eating increases and exercise decreases disease activity in patients with symptomatic dermographism. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 932-940. IF: TBD (IF 2022: 9.40) |
| 543. | Terhorst-Molawi, D.\*, Hawro, T.\*, Grekowitz, E., Kiefer, L., Merchant, K., Alvarado, D., Thomas, L. J., Hawthorne, T., Crowley, E., Heath-Chiozzi, M., Metz, M., and **Maurer, M.**+: Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. *Allergy* 2023: 78; 1269-1279. IF: TBD (IF 2022: 12.40) |
| 542. | Türk, M.\*, Ertas, R.\*, Sahiner, Ü. M., Kolkhir, P., Sekerel, B. E., Soyer, Ö., Avci, Atil, Atasoy, M., Özyurt, K., Türk, Y., Zeydan, E., and **Maurer, M.**+: In chronic spontaneous urticaria, complete response to antihistamine treatment is linked to low disease activity. *Int. Arch. Allergy Immunol*. 2023:184; 421-432. IF: TBD (IF 2022: 2.80) |
| 541. | Staubach, P. Alvaro-Lozano, M., Sekerel, B. E., **Maurer, M.**, Ben-Shoshan, M., Porter, M., Hua, E., Ji, Y., Burciu, A., Savelieva, M., Severin, T., Drollmann, A.+, and Bienczak, A.: Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. *Pediat. Allergy Immunol*. 2023: 34; e13982. IF: TBD (IF 2022: 4.40) |
| 540. | Kulthanan, K., Ungprasert, P., Jirapongsananuruk, O., Rujitharanawong, C., Munprom, K., Trakanwittayarak, S., Pochanapan, O., Panjapakkul, W., and **Maurer, M.**+: Food-dependent exercise-induced wheals/angioedema, anaphylaxis, or both: a systematic review of phenotypes. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 1926-1933. IF: TBD (IF 2022: 9.40) |
| 539. | Bousquet, J.+, Shamji, M. H., Anto, J. M., Schünemann, H. J., Canonica, G. W., Jutel, M., Del Giacco, S., Zuberbier, T., Pfaar, O., Fonseca, J. A., Sousa-Pinto, B., Klimek, L., Czarlewski, W., Bedbrook, A., Amaral, R., Ansotegui, I. J., Bosnic-Anticevich, S., Braido, F., Loureiro, C. C., Gemicioglu, B., Haahtela, T., Kulus, M., Kuna, P., Kupczyk, M., Matricardi, P. M., Regateiro, F. S., Samolinski, B., Sofiev, M., Toppila-Salmi, S., Valiulis, A., Ventura, M. T., Barbara, C., Bergmann, K. C., Bewick, M., Blain, H., Bonini, M., Boulet, L. P., Bourret, R., Brusselle, G., Brussino, L., Buhl, R., Cardona, V., Casale, T., Cecchi, L., Charpin, D., Cherrez-Ojeda, I., Chu, D. K., Cingi, C., Costa, E. M., Cruz, A. A., Devillier, P., Dramburg, S., Fokkens, W. J., Gotua, M., Heffler, E., Ispayeva, Z., Ivancevich, J. C., Joos, G., Kaidashev, I., Kraxner, H., Kvedariene, V., Larenas-Linnemann, D. E., Laune, D., Lourenço, O., Louis, R., Makela, M., Makris, M., **Maurer, M.**, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedoszytko M, O'Hehir R, Okamoto Y, Olze H, Papadopoulos NG, Papi A, Patella V, Pétré B, Pham-Thi N, Puggioni F, Quirce S, Roche N, Rouadi PW, Sá-Sousa A, Sagara H, Sastre J, Scichilone N, Sheikh A, Sova M, Ulrik CS, Taborda-Barata L, Todo-Bom A, Torres MJ, Tsiligianni I, Usmani OS, Valovirta E, Vasankari T, Vieira RJ, Wallace D, Waserman S, Zidarn M, Yorgancioglu A, Zhang L, Chivato T, and Ollert M.: Patient-centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA-EAACI approach. *Allergy* 2023: 78; 1758-1776. IF: TBD (IF 2022: 12.40) |
| 538. | Lumry, W. R, **Maurer, M.**, Weller, K., Riedl, M. A., Watt, M., Yu, M., Devercelli, G., Meunier, J., Banerji, A.; HELP OLE Study Group: Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema. *Ann. Allergy Asthma Immunol*. 2023: 13; 101-108. IF: TBD (IF 2022: 5.90) |
| 537. | Moñino-Romero, S., Kolkhir, P., Szépfalusi, Z., Schoepke, N., Metz, M., Asero, R., Ferrer, M., Giménez-Arnau, A., Grattan, C. E. H., Jakob, T., Konstantinou, G. N., Raap, U., Staubach, P., Zhang, K., Bindslev-Jensen, C., Daschner, A., Kinaciyan, T., Makris, M., Marrouche, N., Schmid-Grendelmeier, P., Sussman, G., Toubi, E., **Maurer, M.**+, and Altrichter, S.: In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria. *Clin. Transl. Allergy*. 2023: 13; e12272. IF: TBD (IF 2022: 4.40) |
| 536. | Church, M. K.+, Canonica, G. W., Kuna, P., **Maurer, M.**, Mösges, R., Novak, Z., Papadopoulos, N. G., Rodriguez del Rio, P., and the Delphi Study Group: An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options. *Expert Rev. Clin. Immunol*. 2023: 19; 813-820. IF: TBD (IF 2022: 4.40) |
| 535. | Buttgereit, T., Vera, C., Aulenbacher, F., Church, M. K., Hawro, T., Asero, R., Bauer, A., Bizjak, M., Bouillet, L., Dissemond, J., Fomina, D., Giménez, A. M., Grattan, C., Gregoriou, S., Kulthanan, K., Kasperska-Zajac, A., Kocatür, E., Makris, M., Kolkhir, P., Weller, K., Magerl, M., and **Maurer, M.+**: Patients with chronic spontaneous urticaria who have wheals, angioedema, or both, differ demographically, clinically, and in response to treatment – results from CURE. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 3515-3524. IF: TBD (IF 2022: 9.40) |
| 534. | Gotlib, J.+\*, Castells, M.+\*, Oude Elberink, H., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T. I., Panse, J., Alvarez-Twose, I., Radia, D. H., Tashi, T., Bulai Livideanu, C., Sabato, V., Heaney, M., van Daele, P., Cerquozzi, S., Dybedal, I., Reiter, A., Pongdee, T., Barete, S., Ustun, C., Schwartz, L., Ward, B. R., Schafhausen, P., Vadas, P., Bose, P., DeAngelo, D. J., Rein, L., Vachhani, P., Triggiani, M., Bonadonna, P., Rafferty, M., Butt, N. M., Oh, S. T., Wortmann, F., Ungerstedt, J., Guilarte, M., Taparia, M., Kuykendall, A. T., Yi, C. A., Ogbogu, P., Gaudy-Marqueste, C., Mattsson, M., Shomali, W., Giannetti, M. P., Bidollari, I., Lin, H.-M., Sullivan, E., Mar, B., Scherber, R., Roche, M., Akin, C., and **Maurer, M.**: Avapritinib versus placebo in indolent systemic mastocytosis. *NEJM Evid*. 2023: 2. IF: N/A |
| 533. | Bernstein, J. A.+, Giménez-Arnau, A., **Maurer, M.**, Staubach, P., Barbier, N., Hua, E., Severin, T., Laires, P. A., and Balp, M.-M.: Why a complete response is the treatment aim in chronic spontaneous urticaria. *J. Clin. Med*. 2023: 12; 3561. IF: TBD (IF 2022: 3.90) |
| 532. | Li, P. H.+\*, Pawankar, R.+\*, Thong, B. Y.-H., Fok, J. S., Chantaphakul, H., Hide, M., Jindal, A. K., Kang, H.-R., Latiff, A. H. A., Lobo, R. C. M., Munkhbayarlakh, S., Van Nguyen, D., Shyur, S.-D., Zhi, Y., and **Maurer, M.**: Epidemiology, management and treatment access of hereditary angioedema in the Asia Pacific region: outcomes from an international survey. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 1253-1260. IF: TBD (IF 2022: 9.40) |
| 531. | Bonnekoh, H., Butze, M., Spittler, S., Staubach, P., Weller, K., Scheffel, J., **Maurer, M.**, and Krause, K.+: Inhibition of interleukin-1 with rilonacept is not effective in cold urticaria – results of a randomized, placebo-controlled study. *Clin. Transl. Allergy* 2023: 13; e12226. IF: TBD (IF 2022:4.40) |
| 530. | Hackler, Y., Siebenhaar, F., **Maurer, M.**, and Muñoz-Roldan, M.+: Virus-infected mast cells directly activate virus-specific CD8+ T cells. *Scand. J. Immunol*. 2023: 98; e13272. IF: TBD (IF 2022: 3.70) |
| 529. | Kocatürk, E.+, Thomsen, S. F., Al-Ahmad, M., Giménez-Arnau, A., Conlon, N., Savk, E., Criado, R. F., Danilycheva, I., Fomina, D., Khoshkui, M., Gelincik, A., Degirmentepe, E. N., Demir, S., Ensina, L. F., Kasperska-Zajac, A., Rudenko, M., Bauer, A., Medina, I., and **Maurer, M.**: Total IgE levels are linked to the course of chronic spontaneous urticaria during pregnancy. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 350-353. IF: TBD (IF 2022: 9.40) |
| 528. | Kocatürk, E.+, Al-Ahmad, M., Krause, K., Giménez-Arnau, A. M., Thomsen, S. F., Conlon, N., Marsland, A., Savk, E., Criado, R. F., Danilycheva, I., Fomina, D., Godse, K., Khoshkhui, M., Gelincik, A., Degirmentepe, E. .N, Demir, S., Ensina, L. F., Kasperska-Zajac, A., Rudenko, M., Valle, S., Medina, I., Bauer, A., Zhao, Z., Staubach, P., Bouillet, L., Küçük, Ö. S., Baygül, A., and **Maurer, M.**: Treatment patterns and outcomes in patients with chronic urticaria during pregnancy: results of PREG-CU, a UCARE study. *J. Eur. Acad. Dermatol. Venereol*. 2023: 37; 356-364. IF: TBD (IF 2022: 9.20) |
| 527. | Tawil, S.+, Irani, C., Kfoury, R., Abramian, S., Salameh, P., Weller, K., **Maurer, M.**, and Ezzedine, K.: Association of chronic urticaria with psychological distress: a multicentre cross-sectional study. *Acta Derm. Venereol*. 2023: 14; 103. IF: TBD (IF 2022: 3.60) |
| 526. | Bousquet, J.+, Anto, J. M., Sousa-Pinto, B., Czarlewski, W., Bedbrook, A., Haahtela, T., Klimek, L., Pfaar, O., Kuna, P., Kupczyk, M., Regateiro, F. S., Samolinski, B., Valiulis, A., Yorgancioglu, A., Arnavielhe, S., Basagaña, X., Bergmann, K. C., Bosnic-Anticevich, S., Brussino, L., Canonica, G. W., Cardona, V., Cecchi, L., Chaves-Loureiro, C., Costa, E., Cruz, A. A., Gemicioglu, B., Fokkens, W. J., Ivancevich, J. C., Kraxner, H., Kvedariene, V., Larenas-Linnemann, D. E., Laune, D., Louis, R., Makris, M., **Maurer, M.**, Melén, E., Micheli, Y., Morais-Almeida, M., Mullol, J., Niedoszytko, M., Okamoto, Y., Papadopoulos, N. G., Patella, V., Pham-Thi, N., Rouadi, P. W., Sastre, J., Scichilone, N., Sheikh, A., Sofiev, M., Taborda-Barata, L., Toppila-Salmi, S., Tsiligianni, I., Valovirta, E., Ventura, M. T., Vieira, R. J., Zidarn, M., Amaral, R., Ansotegui, I. J., Bédard, A., Benveniste, S., Bewick, M., Bindslev-Jensen, C., Blain, H., Bonini, M., Bourret, R., Braido, F., Carreiro-Martins, P., Charpin, D., Cherrez-Ojeda, I., Chivato, T., Chu, D. K., Cingi, C., Del Giacco, S., de Blay, F., Devillier, P., De Vries, G., Doulaptsi, M., Doyen, V., Dray, G., Fontaine, J. F., Gomez, R. M., Hagemann, J., Heffler, E., Hofmann, M., Jassem, E., Jutel, M., Keil, T., Kritikos, V., Kull, I., Kulus, M., Lourenço, O., Mathieu-Dupas, E., Menditto, E., Mösges, R., Murray, R., Nadif, R., Neffen, H., Nicola, S., O'Hehir, R., Olze, H., Palamarchuk, Y., Pépin, J. L., Pétré, B., Picard, R., Pitsios, C., Puggioni, F., Quirce, S., Raciborski, F., Reitsma, S., Roche, N., Rodriguez-Gonzalez, M., Romantowski, J., Sá-Sousa, A., Serpa, F. S., Savouré, M., Shamji, M. H., Sova, M., Sperl, A., Stellato, C., Todo-Bom, A., Tomazic, P. V., Vandenplas, O., Van Eerd, M., Vasankari, T., Viart, F., Waserman, S., Fonseca, J. A., and Zuberbier, T.: Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: the ARIA-MASK-air® approach. *Clin. Transl. Allergy* 2023: 13; e12215. IF: TBD (IF 2022: 4.40) |
| 525. | Steinert, C., Moñino-Romero, S., Butze, M., Scheffel, J., Dölle-Bierke, S., Dobbertin-Welsch, J., Beyer, K., Worm, M., **Maurer, M.**, and Altrichter, S.+: Soluble IgE-binding factors in the serum of food-allergic patients: possible pathophysiological role of soluble FcεRI as protective factor. *Clin. Transl. Allergy* 2023: 13; e12222. IF: TBD (IF 2022: 4.40) |
| 524. | Kolkhir, P., Laires, P. A., Salameh, P., Asero, R., Bizjak, M., Košnik, M., Dissemond, J., van Doorn, M., Hawro, T., Kasperska-Zajac, A., Zajac, M., Kocatürk, E., Peter, J., Parisi, C. A. S., Ritchie, C. A., Kulthanan, K., Tuchinda, P., Fomina, D., Kovalkova, E., Khoshkhui, M., Kouzegaran, S., Papapostolou, N., Du-Thanh, A., Kamegashira, A., Meshkova, R., Vitchuk, A., Bauer, A., Grattan, C., Staubach, P., Bouillet, L., Giménez-Arnau, A. M., **Maurer, M.**, and Weller, K.+: The benefit of complete response to treatment in patients with chronic spontaneous urticaria – CURE results. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 610-620. IF: TBD (IF 2022: 9.40) |
| 523. | Aygören-Pürsün, E.\*, Zanichelli, A.\*, Cohn, D. M., Cancian, M., Hakl, R., Kinaciyan, T., Magerl, M., Martinez-Saguer, I., Stobiecki, M., Farkas, H., Kiani-Alikhan, S., Grivcheva-Panovska, V., Bernstein, J. A., Li, H., Longhurst, H. J., Audhya, P. K., Smith, M. D., Yea, C. M., Mätzel, A., Lee, D. K., Feener, E. P., Gower, R., Lumry, W. R., Banerji, A., Riedl, M. A., and **Maurer, M.**+: An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomized, double-blind, placebo-controlled, crossover phase 2 trial. *Lancet* 2023: 401; 458-469. IF: TBD (IF 2022: 168.90) |
| 522. | Ngouateu Tateng, A., Ngouateu, O. B., Vincent, K. P., **Maurer. M**., von Stebut, E., Krüger, A., and Dondji, B.: Ecological site distribution of sand fly species of Mokolo, an endemic focus of cutaneous leishmaniasis in northern Cameroon. *Acta Trop*. 2023: 239; 106809. IF: TBD (IF 2022: 2.70) |
| 521. | Zuberbier, T.+, Altrichter, S., Bauer, S., Brehler, R., Brockow, K., Dressler, C., Fluhr, J., Gaskins, M., Hamelmann, E., Kühne, K., Merk, H., Mülleneisen, N. K., Olze, H., Ott, H., Pleimes, M., Ruëff, F., Staubach-Renz, P., Wedi, B., and **Maurer, M.**: S3-Leitlinie: Klassifikation, Diagnostik und Therapie der Urtikaria. *Allergologie* 2023: 46; 9-40. IF: TBD (IF 2022: 0.50) |
| 520. | **Maurer, M.**+, Abuzakouk, M., Al-Ahmad, M., Al-Herz, W., Alrayees, H., Al-Tamemi, S., Arnaout, R., Binghadeer, H., Gutta, R., Irani, C., Mobayed, H., Nasr, I., Shendi, H., and Zaitoun, F.: Consensus on diagnosis and management of hereditary angioedema in the Middle East: a Delphi initiative. *World Allergy Organ. J.* 2023: 16; 100729. IF: TBD (IF 2022: 5.10) |
| 519. | Zhu, C.\*, Fok, J., Lin, L.+, Su, H.+\*, and **Maurer, M.**: Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab. *JAAD Case Rep*. 2023: 32; 109-112*.* IF: N/A |
| 518. | Buttgereit, T., Fijen, L. M., Vera, C., Bergmann, K.-C., **Maurer, M.**, and Magerl, M.+: Recurrent angioedema: diagnosing the rare and the frequent. *Front. Med*. 2022: 9; 1048480. IF: 8.10 |
| 517. | **Maurer, M.**+, Berger, W., Giménez-Arnau, A., Hayama, K., Jain, V., Reich, A., Haemmerle, S., Lheritier, K., Walsh, P., Xia, S., and Storim, J.: Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. *J. Allergy Clin. Immunol*. 2022: 6; 1498-1506. IF: 14.20 |
| 516. | **Maurer, M.**+, Cheung, D. S., Theess, W., Yang, X., Dolton, M., Guttman, A., Choy, D. F., Dash, A., Grimbaldeston, M. A., and Soong, W.: Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. *J. Allergy Clin. Immunol*. 2022: 6; 1517-1524. IF: 14.20 |
| 515. | Terhorst-Molawi, D., Lohse, K., Ginter, K., Puhl, V., Metz, M., Hu, M., **Maurer, M.**+, and Altrichter, S.: Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: results of a pilot study. *Front. Immunol*. 2022: 13; 930979. IF: 7.30 |
| 514. | Mangan, M. S. J.+\*, Gorki, F., Krause, K., Heinz, A., Pankow, A., Ebert, T., Jahn, D., Hiller, K., Hornung, V., **Maurer, M.**, Schmidt, F. I., Gerhard, R., and Latz, E.\*: Transcriptional licensing is required for pyrin inflammasome activation in human macrophages and bypassed by mutations causing familial Mediterranean fever. *PLoS Biol*. 2022: 20; e3001351. IF: 9.8 |
| 513. | **Maurer, M.**, Saini, S. S., McLendon, K., Wabnitz, P., Kim, S., Ahn, K., Kim, S., Lee, S., and Grattan, C.+: Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: a randomized double-blind, parallel-group, phase 1 trial. *Clin. Transl. Allergy* 2022: e12204. IF: 4.40 |
| 512. | Metz, M.+, Bernstein, J. A., Giménez-Arnau, A. M., Hide, M., **Maurer, M.**, Sitz, K., Soong, W., Sussman, G., Hua, E., Barve, A., Barbier, N., Balp, M.-M., and Severin, T.: Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria. *World Allergy Organ. J.* 2022: 15; 100716. IF: 5.10 |
| 511. | Parsopoulou, F., Loules, G., Zamanakou, M., Csuka, D., Szilagyi, A., Kompoti, M., Porebski, G., Psarros, G., Psarros, F., Magerl, M., Valerieva, A., Staevska, M., Obtulowicz, K., **Maurer, M.**, Speletas, M., Farkas, H., and Germenis, A. E.+: Searching for genetic biomarkers for hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE). *Front. Allergy* 2022: 3; 868185. IF: N/A |
| 510. | Altrichter, S., Mellerowicz, E., Terhorst-Molawi, D., Grekowitz, E., Weller, K., and **Maurer, M.**+: Disease impact, diagnostic delay, and unmet medical needs of patients with cholinergic urticaria in German-speaking countries. *Front. Allergy* 2022: 3; 867227. IF: N/A |
| 509. | Martinez-Saguer, I., Dominas, N., Straben, U., Greve, J., Brehler, R., Magerl, M., Knipps, L. M., Knop, J., Flemming, A., Schubert, T., and **Maurer, M.**+: Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study. *Eur. J. Dermatol*. 2022: 32; 487-494. IF: 2.50 |
| 508. | Badloe, F. M. S., De Vriese, S., De Bruyn Carlier, T., Vandersichel, E., Scheffel, J., **Maurer, M.**, Ring, J., Gutermuth, J., and Kortekaas Krohn, I.+: A novel method for total IgE purification from human serum. *J. Immunol*. 2022: 208; 2436-2442. IF: 4.40 |
| 507. | Pyatilova, P., Ashry, T., Luo, Y., He, J., Bonnekoh, H., Jiao, Q., Moñino-Romero, S., Hu, M., Scheffel, J., Frischbutter, S., Hermans, M. A. W., Youngblood, B. A., **Maurer, M.**, Siebenhaar, F.\*, and Kolkhir, P.+\*: The number of MRGPRX2-expressing cells is increased in skin lesions of patients with indolent systemic mastocytosis, but is not linked to symptom severity. *Front. Immunol*. 2022: 13; 930945. IF: 7.30 |
| 506. | Su, W.\*, Zhang, J.\*, Yang, S., Tang, M., Shen, Y., Liu, C., Ji, J.+, **Maurer, M.**+, and Jiao, Q.+: Galectin-9 contributes to the pathogenesis of atopic dermatitis via T cell immunoglobulin mucin-3. *Front. Immunol*. 2022: 13; 952338. IF: 7.30 |
| 505. | Bonnekoh, H., Jelden-Thurm, J., Butze, M., Krause, K., **Maurer, M.**, and Kolkhir, P.+: In urticarial vasculitis, long disease duration, high symptom burden, and high need for therapy are linked to low patient-reported quality of life. *J. Allergy Clin. Immunol. Pract*. 2022: 10; 2734-2741. IF: 9.40 |
| 504. | Sauer, M., Scheffel, J., Frischbutter, S., Mahnke, N., **Maurer, M.**, Burmeister, T., Krause, K., and Metz, M.+: STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria. *Front. Immunol*. 2022: 13; 902652. IF: 7.30 |
| 503. | Ahsan, D. M., Altrichter, S., Gutsche, A., Bernstein, J. A., Altunergil, T., Brockstaedt, M., **Maurer, M.**+, Weller, K., and Terhorst-Molawi, D.: Development of the cold urticaria activity score. *Allergy* 2022: 77; 2509-2519. IF: 12.40 |
| 502. | Kulthanan, K., Church, M. K., Grekowitz, E. M., Hawro, T., Kiefer, L. A., Munprom, K., Nanchaipruek, Y., Rujitharanawong, C., Terhorst-Molawi, D., and **Maurer, M.**+: Evidence for histamine release in chronic inducible urticaria – a systematic review. *Front. Immunol*. 2022: 13; 901851. IF; 7.30 |
| 501. | Wang, Y., Scheffel, J., Vera, C. A., Lui, W., Günzel, D., Terhorst-Molawi, D., **Maurer, M.**+, and Altrichter, S.: Impaired sweating in patients with cholinergic urticaria is linked to low expression of acetylcholine receptor CHRM3 and acetylcholine esterase in sweat glands. *Front. Immunol*. 2022: 13; 955161. IF: 7.30 |
| 500. | Du, X., Chen, Y., Chang, J., Sun, X., Zhang, Y., Zhang, M., **Maurer, M.**, Li, Y., Zhao, Z., and Tong, X.+: Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome. *J. Am. Acad. Dermatol*. 2022: 29; 106-109. IF: 13.80 |
| 499. | Hawro, M., Sahin, E., Steć, M., Różewicka-Czabańska, M., Raducha, E., Garanyan, L., Philipp, S., Kokolakis, G., Christou, D., Kolkhir, P., Pogorelov, D., Weller, K., Metz, M., Sabat, R., Maleszka, R., Olisova, O., **Maurer, M.**, and Hawro, T.+: A comprehensive, tri-national, cross-sectional analysis of characteristics and impact of pruritus in psoriasis. *J. Eur. Acad. Dermatol. Venereol*. 2022: 36; 2064-2075. IF: 9.20 |
| 498. | Buttgereit, T.+, Pfeiffenberger, M., Frischbutter, S., Krauß, P. L., Chen, Y., **Maurer, M.**, Buttgereit, F., and Gaber, T.: Inhibition of complex I of the respiratory chain, but not complex III, attenuates degranulation and cytokine secretion in human skin mast cells. *Int. J. Mol. Sci*. 2022: 23; 11591. IF: 5.60 |
| 497. | Buttgereit, T., Gu, S., Carneiro-Leão, L., Gutsche, A., **Maurer, M.**+, and Siebenhaar, F.: Idiopathic mast cell activation syndrome is more often suspected than diagnosed - a prospective real-life study. *Allergy* 2022: 77; 2794-2802. IF: 12.40 |
| 496. | Martinez-Saguer, I., Knop, J.+, Flemming, A., Thomann, M., and **Maurer. M.**: Real world treatment patterns of hereditary angioedema with lanadelumab in Germany: a prescription data analysis. *J. Dtsch. Dermatol. Ges*. 2022: 20; 1127-1129. IF: 3.60 |
| 495. | Brzoza, Z.+, Badura-Brzoza, K., **Maurer, M.**, Hawro, T., and Weller, K.: Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria - results from the validation of the Polish urticaria control test. *World Allergy Organ J*. 2022: 15; 100635. IF: 5.10 |
| 494. | Rujitharanawong, C., Kulthanan, K., Tuchinda, P., Chularojanamontri, L., Metz, M., and **Maurer, M.**+: A systematic review of aquagenic urticaria-subgroups and treatment options. *J. Allergy Clin. Immunol. Pract*. 2022: 10; 2154-2162. IF: 9.40 |
| 493. | Kolkhir, P., Pyatilova, P., Ashry, T., Jiao, Q., Abad-Perez, A. T., Altrichter, S., Vera Ayala, C. E., Church, M. K., He, J., Lohse, K., Metz, M., Scheffel, J., Türk, M., Frischbutter, S.\*, and **Maurer, M.**+\*: Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo. *J. Allergy Clin. Immunol*. 2022: 149; 1998-2009. IF: 14.20 |
| 492. | Bizjak, M., Košnik, M., Dinevski, D., Thomsen, S. F., Fomina, D., Borzova, E., Kulthanan, K., Meshkova, R., Aarestrup, F. M., Ahsan, D. M., Al-Ahmad, M., Altrichter, S., Bauer, A., Brockstädt, M., Costa, C., Demir, S., Criado, R. F., Ensina, L. F., Gelincik, A., Giménez-Arnau, A. M., Gonçalo, M., Gotua, M., Holm, J. G., Inomata, N., Kasperska-Zajac, A., Khoshkhui, M., Klyucharova, A., Kocatürk, E., Lu, R., Makris, M., Maltseva, N., Pasali, M., Paulino, M., Pesqué, D., Peter, J., Ramón, G. D., Ritchie, C., Rodrigues Valle, S. O., Rudenko, M., Sikora, A., Wagner, N., Xepapadaki, P., Xue, X., Zhao, Z., Terhorst-Molawi, D., and **Maurer, M.**+: Adrenaline autoinjector is under-prescribed in typical cold urticaria patients living in tropical climate countries. *Qatar Med. J*. 2022: 2; 19. IF: N/A  |
| 491. | Bizjak, M.+, Košnik, M., Dinevski, D., Thomsen, S. F., Fomina, D., Borzova, E., Kulthanan, K., Meshkova, R., Aarestrup, F. M., Ahsan, D. M., Al-Ahmad, M., Altrichter, S., Bauer, A., Brockstädt, M., Costa, C., Demir, S., Criado, R. F., Ensina, L. F., Gelincik, A., Giménez-Arnau, A. M., Gonçalo, M., Gotua, M., Holm, J. G., Inomata, N., Kasperska-Zajac, A., Khoshkhui, M., Klyucharova, A., Kocatürk, E., Lu, R., Makris, M., Maltseva, N., Pasali, M., Paulino, M., Pesqué, D., Peter, J., Ramón, G. D., Ritchie, C., Rodrigues Valle, S. O., Rudenko, M., Sikora, A., Wagner, N., Xepapadaki, P., Xue, X., Zhao, Z., Terhorst-Molawi, D., and **Maurer, M.**: Adrenaline autoinjector is underprescribed in typical cold urticaria patients. *Allergy* 2022: 77; 2224-2229. IF: 12.40 |
| 490. | Alvarado, D.+, **Maurer, M.**, Gedrich, R., Seibel, S. B., Murphy, M. B., Crew, L., Goldstein, J., Crocker, A., Vitale, L. A., Morani, P. A., Thomas, L. J., Hawthorne, T. R., Keler, T., Young, D., Crowley, E., Kankam, M., and Heath-Chiozzi, M.: Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. *Allergy* 2022: 77; 2393-2403. IF: 12.40 |
| 489. | Kröger, M.+, Scheffel, J., Shirshin, E. A., Schleusener, J., Meinke, M. C., Lademann, J., **Maurer, M.**, and Darvin, M. E.: Label-free imaging of M1 and M2 macrophage phenotypes in the human dermis in vivo using two-photon excited FLIM. *ELIFE* 2022: 11; e72819. IF: 7.70 |
| 488. | Kulthanan, K., Ungprasert, P., Jirapongsananuruk, O., Rujitharanawong, C., Munprom, K., Trakanwittayarak, S., Pochanapan, O., Panjapakkul, W., and **Maurer, M.**+: Food-dependent exercise-induced wheals, angioedema, and anaphylaxis: a systematic review. *J. Allergy Clin. Immunol. Pract*. 2022: 10; 2280-2296. IF: 9.40 |
| 487. | Abuzakouk, M.+, Ghorab, O., Namas, R., and **Maurer, M.**: Long-term efficacy and safety of omalizumab monotherapy in a patient with normocomplementemic urticarial vasculitis. *J. Drugs Dermatol*. 2022: 21; 1124-1126. IF: 1.50 |
| 486. | Abuzakouk, M., Ghorab, O., Al-Hameli, H., Salvo, F., Grandon, D., and **Maurer, M.**+: Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience. *World Allergy Organ. J.* 2022: 14; e100610. IF: 5.10 |
| 485. | Zhang, X., Song, X., Zhang, M., Li, C., Huang, Z., Liu, B., Yu, M., Liao, S., Luan, T., Zuberbier, T.\*, **Maurer, M.**+\*, Zhao, Z., and Wang, L.: Prevalence and risk factors of chronic urticaria in China: a nationwide cross-sectional study. *Allergy* 2022:77; 2233-2236*.* IF: 12.40 |
| 484. | Türk, M., Yilmaz, I., Sahiner, Ü. M., Kocatürk, E., Sekerel, B. E., Zuberbier, T.\*, and **Maurer, M.**+\*: Experience-based advice on stepping up and stepping down the therapeutic management of chronic spontaneous urticaria: where is the guidance? *Allergy* 2022:77; 1626-1630*.* IF: 12.40 |
| 483. | **Maurer, M.**+, Magerl, M.+\*, Betschel, S.\*, Aberer, W., Ansotegui, I. J., Aygören-Pürsün, E., Banerji, A., Bara, N.-A., Boccon-Gibod, I., Bork, K., Bouillet, L., Boysen, H. B., Brodszki, N., Busse, P. J., Bygum, A., Caballero, T., Cancian, M., Castaldo, A., Cohn, D. M., Csuka, D., Farkas, H., Gompels, M., Gower, R., Grumach, A. S., Guidos-Fogelbach, G., Hide, M., Kang, H.-R., Kaplan, A. P., Katelaris, C., Kiani-Alikhan, S., Lei, W.-T., Lockey, R., Longhurst, H., Lumry, W. R., MacGinnitie, A., Malbran, A., Martinez Saguer, I., Matta, J J., Nast, A., Nguyen, D., Nieto-Martinez, S. A., Pawankar, R., Peter, J., Porebski, G., Prior, N., Reshef, A., Riedl, M., Ritchie, B., Sheikh, F. R., Smith, W. B., Spaeth, P. J., Stobiecki, M., Toubi, E., Varga, L. A., Weller, K., Zanichelli, A., Zhi, Y., Zuraw, B., and Craig, T.\*: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update. *World Allergy Organ. J*. 2022: 15; 100627. IF: 5.10 |
| 482. | **Maurer, M.**+, Magerl, M., Aygören-Pürsün, E., Bork, K., Farkas, H., Longhurst, H., Kiani-Alikhan, S., Boullet, L., Boccon-Gibod, I., Cancian, M., Zanichelli, A., and Launay, D.: Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series. *Allergy Asthma Clin. Immunol*. 2022: 18; 4. IF: 2.70 |
| 481. | Sahin, E., Hawro, M., Weller, K., Sabat, R., Philipp, S., Kokolakis, G., Christou, D., Metz, M., **Maurer, M.**, and Hawro, T.+: Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. *J. Eur. Acad. Dermatol. Venereol.* 2022: 688-697. IF: 9.20 |
| 480. | Altrichter, S., Staubach, P., Pasha, M., Sing, B., Chang, A. T., Bernstein, J. A., Rasmussen, H. S., Siebenhaar, F., and **Maurer, M.**+: An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. *J. Allergy Clin. Immunol*. 2022: 149; 1683-1690. IF: 14.20 |
| 479. | Bizjak, M.+, Košnik, M., Dinevski, D., Thomsen, S. F., Fomina, D., Borzova, E., Kulthanan, K., Meshkova, R., Ahsan, D. M., Al-Ahmad, M., Altrichter, S., Bauer, A., Brockstädt, M., Costa, C., Demir, S., Criado, R. F., Ensina, L. F., Gelincik, A., Giménez-Arnau, A. M., Gonçalo, M., Gotua, M., Holm, J. G., Inomata, N., Kasperska-Zajac, A., Khoshkhui, M., Klyucharova, A., Kocatürk, E., Lu, R., Makris, M., Maltseva, N., Miljković, J., Pasali, M., Paulino, M., Pesqué, D., Peter, J., Dario Ramón, G., Ritchie,. C, Valle, S. O. R., Rudenko, M., Sikora, A., de Souza Lima, E. M., Wagner, N., Xepapadaki, P., Xue, X., Zhao, Z., Terhorst-Molawi, D., and **Maurer, M.**+: Risk factors for systemic reactions in typical cold urticaria: results from the COLD-CE study. *Allergy* 2022:77; 2185-2199*.* IF: 12.40 |
| 478. | **Maurer, M.**+, Giménez-Arnau, A., Bernstein, J. A., Chu, C. Y., Danilycheva, I., Hide, M., Makris, M., Metz, M., Savic, S., Sitz, K., Soong, W., Staubach, P., Sussman, G., Barve, A., Burciu, A., Hua, E., Janocha, R., and Severin, T.: Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study. *Allergy* 2022:77; 2175-2184*.* IF: 12.40 |
| 477. | Yücel, M. B., Ertas, R.+, Türk, M., Muñoz, M., Atasoy, M., and **Maurer, M.**: Food-dependent and food-exacerbated symptomatic dermographism: new variants of symptomatic dermographism. *J. Allergy Clin. Immunol*. 2022: 149; 788-790. IF: 14.20 |
| 476. | Luo, Y., Fernandez Vallone, V., Frischbutter, S., Stachelscheid, H., Streu-Haddad, V., He, J., **Maurer, M.**+, Siebenhaar, F.\*, and Scheffel, J.+\*: A novel approach for studying mast cell-driven disorders: mast cells derived from induced pluripotent stem cells. *J. Allergy Clin. Immunol*. 2022: 149; 1060-1068. IF: 14.20 |
| 475. | Weller, K.+, **Maurer, M.**, Bauer, A., Wedi, B., Wagner, N., Schliemann, S., Kramps, T., Baeumer, D., Multmeier, J., Hillmann, E., and Staubach, P.: Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. *J. Eur. Acad. Dermatol. Venereol.* 2022: 36; 91-99. IF: 9.20 |
| 474. | Stroet, L. C., Hermans, M. A. W.+, **Maurer, M.**, and van Doorn, M. B. A.: Cold-induced urticaria associated with type I cryoglobulinemia, successfully treated with rituximab. *J. Am. Acad. Dermatol*. 2022: 19; 18-20. IF: 13.80 |
| 473. | Chuamanochan, M., Chiewchanvit, S., Tovanabutra, N., Rujiwetpongstorn, R., Laosakul, K., and **Maurer, M.**+: A case of dengue fever presenting with acute urticaria. *Asian Pac. J. Allergy Immunol*. 2022: 40; 72-74*.* IF: 5.00 |
| 472. | **Maurer, M.**+, Magerl, M.+\*, Betschel, S.\*, Aberer, W., Ansotegui, I. J., Aygören-Pürsün, E., Banerji, A., Bara, N.-A., Boccon-Gibod, I., Bork, K., Bouillet, L., Boysen, H. B., Brodszki, N., Busse, P. J., Bygum, A., Caballero, T., Cancian, M., Castaldo, A., Cohn, D. M., Csuka, D., Farkas, H., Gompels, M., Gower, R., Grumach, A. S., Guidos-Fogelbach, G., Hide, M., Kang, H.-R., Kaplan, A. P., Katelaris, C., Kiani-Alikhan, S., Lei, W.-T., Lockey, R., Longhurst, H., Lumry, W. R., MacGinnitie, A., Malbran, A., Martinez Saguer, I., Matta, J J., Nast, A., Nguyen, D., Nieto-Martinez, S. A., Pawankar, R., Peter, J., Porebski, G., Prior, N., Reshef, A., Riedl, M., Ritchie, B., Sheikh, F. R., Smith, W. B., Spaeth, P. J., Stobiecki, M., Toubi, E., Varga, L. A., Weller, K., Zanichelli, A., Zhi, Y., Zuraw, B., and Craig, T.\*: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update. *Allergy* 2022: 77; 1961-1990IF: 12.40 |
| 471. | Zuberbier, T.+, Abdul Latiff, A. H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., Ballmer-Weber, B., Bangert, C., Ben-Shoshan, M., Bernstein, J. A., Bindslev-Jensen, C., Brockow, K., Brzoza, Z., Chong Neto, H. J., Church, M. K., Criado, P. R., Danilycheva, I. V., Dressler, C., Ensina, L. F., Fonacier, L., Gaskins, M., Gáspár, K., Gelincik, A., Giménez-Arnau, A., Godse, K., Gonçalo, M., Grattan, C., Grosber, M., Hamelmann, E., Hébert, J,. Hide, M., Kaplan, A., Kapp, A., Kessel, A., Kocatürk, E., Kulthanan, K., Larenas-Linnemann, D., Lauerma, A., Leslie, T. A., Magerl, M., Makris, M., Meshkova, R. Y., Metz, M., Micallef, D., Mortz, C. G., Nast, A., Oude-Elberink, H., Pawankar, R., Pigatto, P. D., Ratti Sisa, H., Rojo Gutiérrez, M. I., Saini, S. S., Schmid-Grendelmeier, P., Sekerel, B. E., Siebenhaar, F., Siiskonen, H., Soria, A., Staubach-Renz, P., Stingeni, L., Sussman, G., Szegedi, A., Thomsen, S. F., Vadasz, Z., Vestergaard, C., Wedi, B., Zhao, Z., and **Maurer M.**: The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy* 2022:77; 734-766*.* IF: 12.40 |
| 470. | Banerji, A.+, Bernstein, J. A., Johnston, D. T., Lumry, W. R., Magerl, M., **Maurer, M.**, Martinez-Saguer, I., Zanichelli, A., Hao, J., Inhaber, N., Yu, M., Riedl, M. A., and HELP OLE Investigators: Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. *Allergy* 2022:77; 979-990*.* IF: 12.40 |
| 469. | Giménez-Arnau, A.+, **Maurer, M.**, Bernstein, J. A., Staubach, P., Barbier, N., Hua, E., Severin, T., Joubert, Y., Janocha, R., and Balp, M.-M.: Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria. *Clin. Transl. Allergy* 2022: 12; e12121. IF: 4.40 |
| 468. | Türk, M.\*, Ertas, R.\*, Zeyan, E., Türk, Y., Atasoy, M., Gutsche, A., and **Maurer, M.**+: Identification of chronic urticaria subtypes using machine learning algorithms. *Allergy* 2022:77; 323-326*.* IF: 12.40 |
| 467. | Agache, I.+, Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., **Maurer, M.**, Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., and Jutel, M.: EAACI biological guidelines – omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. *Allergy* 2022*:* 77; 17-38. IF: 12.40 |
| 466. | Dickson, M. C.\*, Walker, A.+\*, Grattan, C., Perry, H., Williams, N., Ratia, N., Dewit, O., Gisbert, S., Metz, M.\*, and **Maurer, M.**\*: Effects of a topical treatment with spleen tyrosine kinase (SYK) inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a Phase 1a/b randomised double-blind placebo-controlled study. *Br. J. Clin. Pharmacol.* 2021: 87; 4797-4808. IF: 3.72 |
| 465. | Elst, J., Sabato, V., Faber, M. A., Bridts, C. H., Mertens, C., Van Houdt, M., Van Gasse, A. L., Hagendorens, M. M., Van Tendeloo, V., **Maurer, M.**, Campillo-Davo, D., Timmermans, J. P., Pintelon, I., and Ebo, D. G.+: MRGPRX2 and immediate drug hypersensitivity: insights from cultured human mast cells. *J. Investig. Allergol. Clin. Immunol.* 2021: 31; 489-499. IF: 8.18 |
| 464. | Cherrez-Ojeda, I.+, **Maurer, M.**, Felix, M., Bernstein, J. A., Ramon, G. D., Jardim Criado, R. F., Mata, V. L., Cherrez, A., Morfin-Maciel, B. M., Larco, J. I., Tinoco, I. O., Chorzepa, G. F., Gómez, R. M., Raad, R. J., Thomsen, S. F., Schmid-Grendelmeier, P., Guillet, C., Cherrez, S., and Vanegas, E.: Chronic urticaria and obstructive sleep apnea: Is there a significant association? *World Allergy Organ. J*. 2021: 14; 100577. IF: 5.52 |
| 463. | Cherrez-Ojeda, I.+, Vanegas, E., Cherrez, A., Felix, M., Weller, K., Magerl, M., Maurer, R. R., Mata, V. L., Kasperska-Zajac, A., Sikora, A., Fomina, D., Kovalkova, E., Godse, K., Rao, N. D., Khoshkhui, M., Rastgoo, S., Criado, R. F. J., Abuzakouk, M., Grandon, D., Van Doorn, M. B. A., Rodrigues Valle, S. O., Magalhaes, E., De Souza Lima, E. M., Thomsen, S. F., Ramón, G. D., Matos Benavides, E. E., Bauer, A., Giménez-Arnau, A. M., Kocatürk, E., Guillet, C., Larco, J. I., Zhao, Z. T., Makris, M., Ritchie, C., Xepapadaki, P., Ensina, L. F., Cherrez, S., and **Maurer, M.**: Chronic urticaria patients are interested in apps to monitor their disease activity and control: a UCARE CURICT analysis. *Clin. Transl. Allergy* 2021: 11; e12089. IF: 5.66 |
| 462. | **Maurer, M.**+, Caballero, T., Aberer, W., Zanichelli, A., Bouillet, L., Bygum, A., Grumach, A. S., Botha, J., Andresen, I., Longhurst, H. J., and IOS study group: Variability of disease activity in patients with hereditary angioedema typ 1/2: longitudinal data from the Icatibant Outcome Survey. *J. Eur. Acad. Dermatol. Venereol.* 2021: 35; 2421-2430. IF: 9.23 |
| 461. | Förster, T. M.+, Magerl, M., **Maurer, M.**, Zülbahar, S., Zielke, S., Inhaber, N., Crocetta, D., Rolfs, A., and Skrahina, V.: HAE patient self-sampling for biomarker establishment. *Orphanet J. Rare Dis.* 2021: 16; 399. IF: 4.31 |
| 460. | Antó, A.\*, Maurer, R.\*, Gimenez-Arnau, A., Cherrez-Ojeda, I., Hawro, T., Magerl, M., Metz, M., Weller, K., Zuberbier, T., Bousquet, J., and **Maurer, M.**+: Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. *Allergy* 2021: 76; 3810-3813. IF: 14.71 |
| 459. | Witkowski, M.+, Tizian, C., Ferreira-Gomes, M., Niemeyer, D., Jones, T. C., Heinrich, F., Frischbutter, S., Angermair, S., Hohnstein, T., Mattiola, I., Nawrath, P., McEwen, S., Zocche, S., Viviano, E., Heinz, G. A., **Maurer, M.**, Kölsch, U., Chua, R. L., Aschman, T., Meisel, C., Radke, J., Sawitzki, B., Roehmel, J., Allers, K., Moos, V., Schneider, T., Hanitsch, L., Mall, M. A., Conrad, C., Radbruch, H., Duerr, C. U., Trapani, J. A., Marcenaro, E., Kallinich, T., Corman, V. M., Kurth, F., Sander, L. E., Drosten, C., Treskatsch, S., Durek, P., Kruglov, A., Radbruch, A., Mashreghi, M. F., and Diefenbach, A.: Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. *Nature* 2021: 600; 295-301. IF: 69.50 |
| 458. | Marcelino, J.+\*, Baumann, K.\*, Skov, P. S., Pereira Santos, M. C., Wyroslak, I., Scheffel, J., Altrichter, S., Woetmann, A., Pereira-Barbosa, M., Costa, C., and **Maurer, M.**+: [What basophil testing tells us about CSU patients - results of the CORSA study.](https://pubmed.ncbi.nlm.nih.gov/34650565/) *Front Immunol*. 2021: 12; 742470. IF: 8.79 |
| 457. | Kulu, H., Atasoy, M., Ozyurt, K., **Maurer, M.**+, Avci, A., Akkus, R., and Ertas, R.: The COVID-19 pandemic affects male patients with chronic spontaneous urticaria more than female patients. *Front. Immunol*. 2021: 12; 722406. IF: 8.79 |
| 456. | Mostmans, Y.+, De Smedt, K., Richert, B., Komi, D. E. A., **Maurer, M.**, and Michel, O.: Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: a systematic review. *Allergy* 2021: 76; 2998-3016. IF: 14.71 |
| 455. | Metz, M., Sussman, G., Gagnon, R., Staubach, P., Tanus, T., Yang, W. H., Lim, J. J., Clarke, H. J., Galanter, J., Chinn, L. W., Chu, T., Teterina, A., Burgess, T., Haddon, J., Lu, T. T., and **Maurer, M.**+: Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. *Nat. Med*. 2021: 27; 1961-1969*.* IF: 87.24 |
| 454. | Johnston, D. T.+, Busse, P. J., Riedl, M. A., **Maurer, M.**, Anderson, J., Nurse, C., Inhaber, N., Yu, M., Banerji, A., and HELP study investigators: Effectiveness of lanadelumab for preventing hereditary angioedema attacks: subgroup analyses from the HELP study. *Clin. Exp. Allergy* 2021: 51; 1391-1395*.* IF: 14.71 |
| 453. | Khoshkhui, M., Weller, K., Fadaee, J., **Maurer, M.**, Azad, F. J., and Emadzadeh, M.+: Evaluation of the reliability and validity of the Persian version of urticaria control test (UCT). *Iran J. Allergy Asthma Immunol.* 2021: 20; 423-431*.* IF: 1.57 |
| 452. | Kolkhir, P., Kovalkova, E., Chernov, A., Danilycheva, I., Krause, K., Sauer, M., Shulzhenko, A., Fomina, D.\*, and **Maurer, M.**+\*: Autoimmune chronic spontaneous urticaria detection with IgG anti-TPO and total IgE. *J. Allergy Clin. Immunol. Pract.* 2021: 9: 41384146*.* IF: 11.02Kolkhir, P., Kovalkova, E., Chernov, A., Danilycheva, I., Krause, K., Sauer, M., Shulzhenko, A., Fomina, D.\*, and **Maurer, M.**+\*: Reply to: Is anti-TPO IgG and total IgE clinically useful for the detection of autoimmune chronic spontaneous urticaria? *J. Allergy Clin. Immunol. Pract.* 2022: 10: 1393 |
| 451. | **Maurer, M.**+, Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Boysen, H. B., Busse, P. J., Bygum, A., Caballero, T., Castaldo, A. J., Christiansen, S. C., Craig, T., Farkas, H., Grumach, A. S., Hide, M., Katelaris, C. H., Li, H., Longhurst, H., Lumry, W. R., Magerl, M., Martinez-Saguer, I., Riedl, M. A., Zhi, Y., and Zuraw, B.: Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. *J. Allergy Clin. Immunol*. 2021: 148; 1526-1532. IF: 14.29 |
| 450. | Buttgereit, T.\*, Vera, C.\*, Weller, K., Gutsche, A., Grekowitz, E. M., Aykanat, S., Wahl, V., Krüger, R., **Maurer, M.**+, and Magerl, M.: Lanadelumab efficacy, safety, and injection interval extension in HAE – a real life study. *J. Allergy Clin. Immunol. Pract.* 2021: 9; 3744-3751*.* IF: 11.02 |
| 449. | Kocatürk, E.+, Al-Ahmad, M., Krause, K., Giménez-Arnau, A., Thomsen, S. F., Conlon, N., Marsland, A., Savk, E., Criado, R. F., Danilycheva, I., Fomina, D., Godse, K., Khoshkhui, M., Gelincik, A., Degirmentepe, E. N., Demir, S., Ensina, L. F., Kasperska-Zajac, A., Rudenko, M., Valle, S., Medina, I., Bauer, A., Zhao, Z., Staubach, P., Bouillet, L., Su Küçük, Ö., Ateş, C., and **Maurer, M.**: Effects of pregnancy on chronic urticaria: results of the PREG-CU UCARE study. *Allergy* 2021: 76; 3133-3144. IF: 14.71 |
| 448. | Tawil, S.+, Irani, C., Kfoury, R., Abramian, S., Salameh, P., Weller, K., **Maurer, M.**, and Ezzedine, K.: Assessment of urticaria using a self-reported diagnosis tool (SRUD): a multicenter validation study. *J. Eur. Acad. Dermatol. Venereol.* 2021: 35; e652-e654. IF: 9.23 |
| 447. | Spindler, M., Przybylowicz, K., Hawro, M., Weller, K., Reidel, U., Metz, M., **Maurer, M.**, and Hawro, T.+: Sleep disturbance in adult dermatological patients: a cross-sectional study on prevalence, burden and associated factors. *J. Am. Acad. Dermatol.* 2021: 85; 910-922. IF: 15.49 |
| 446. | Elst, J., **Maurer, M.**+, Sabato, V., Faber, M. A., Bridts, C. H., Mertens, C., van Houdt, M., van Gasse, A. L., van der Poorten, M.-L. M., de Puysseleyr, L. P., Hagendorens, M. M., van Tendeloo, V. F., Lion, E., Campillo-Davo, D., and Ebo, D. G.: Novel insights on MRGPRX2-mediated hypersensitivity to neuromuscular blocking agents and fluoroquinolones. *Front. Immunol*. 2021: 12; e668962. IF: 8.79 |
| 445. | Can, P. K., Degi Rmentepe, E. N., Etikan, P., Kiziltaç, K., Gelincik, A., Demir, S., Buyukozturk, S., Haşal, E., Bülbül Başkan, E., Aydin, Ö., **Maurer, M.**, Weller, K., and Kocatürk, E.+: Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema. *World Allergy Organ. J*. 2021: 16; 100554. IF: 5.52 |
| 444. | Hackler, Y., Siebenhaar, F., Löhning, M., **Maurer, M.**, and Muñoz, M.+: Mast cells modulate antigen-specific CD8+ T cell activation during LCMV infection. *Front. Immunol*. 2021: 12; 688347. IF: 8.79 |
| 443. | Bonnekoh, H., Vera, C., Abad-Perez, A., Radetzki, S., Neuenschwader, M., Specker, E., Mahnke, N. A., Frischbutter, S., Latz, E., Nazaré, M., Kries, J. V., **Maurer, M.**, Scheffel, J., and Krause, K.+: Topical inflammasome inhibition with disulfiram prevents irritant contact dermatitis. *Clin. Transl. Allergy* 2021: 11; e12045. IF: TBD 5.66 |
| 442. | Altrichter, S., Wang, Y., Schumacher, P., Alraboni, O., Church, M. K., and **Maurer, M.**+: Acetylcholine-induced whealing in cholinergic urticaria – what does it tell us? *J. Dermatol. Sci*. 2021: 103; 10-15. IF: 5.41 |
| 441. | Metz, M., Altrichter, S., Buttgereit, T., Fluhr, J. W., Fok, J. S., Hawro, T., Jiao, Q., Kolkhir, P., Krause, K., Magerl, M., Pyatilova, P., Siebenhaar, F., Su, H., Terhorst-Molawi, D., Weller, K., Xiang, Y.-K., and **Maurer, M.**+: The diagnostic workup in chronic spontaneous urticaria – what to test and why. *J. Allergy Clin. Immunol. Pract.* 2021: 9; 2274-2283*.* IF: 11.02 |
| 440. | Farkas, H., Stobiecki, M., Peter, J., Kinaciyan, T., **Maurer, M.**, Aygören-Pürsün, E., Kiani-Alikhan, S., Wu, A., Reshef, A., Bygum, A., Fain, O., Hagin, D., Huissoon, A., Jeseňák, M., Lindsay, K., Grivcheva Panovska, V., Smith, W., Steiner, U. C., Zubrinich, C., Best, J. M., Cornprobst, M., Dix, D., Dobo, S. M., Iocca, H. A., Murray, S. C., Nagy, E., and Sheridan, W. P.+: Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. *Clin. Transl. Allergy* 2021: 11; e12035. IF: 5.66 |
| 439. | Bizjak, M., **Maurer, M.**+, Košnik, M., Terhorst-Molawi, D., Zver, S., Burmeister, T., and Siebenhaar, F.: Severe cold urticaria can point to an underlying clonal mast cell disorder. *Allergy* 2021: 76; 2609-2613. IF: IF: 14.71 |
| 438. | Engel-Yeger, B., **Maurer, M.**+, Hawro, T., Zubedat, S., Avital, A., and Kessel, A.: Exaggerated neurophysiological responses to stressor in patients with chronic spontaneous urticaria. *Clin. Exp. Allergy* 2021: 51; 936-938*.* IF: 5.40 |
| 437. | Förster-Ruhrmann, U.+\*, Pierchalla, G.\*, Stieber, C., Heilmann-Heimbach, S., Cichon, S., Nöthen, M. M., Ellrich, A., Olze, H., **Maurer, M.**, and Magerl, M.: Analysis of genetic impact on smell impairment in patients with hereditary angioedema type 1 and 2. *J. Dtsch. Dermatol. Ges.* 2021: 19; 1060-1062*.* IF: 5.23 |
| 436. | Bonnekoh, H., Frischbutter, S., Roll, S., **Maurer, M.**, and Krause, K.+: Tocilizumab treatment in patients with Schnitzler syndrome: an open-label study. *J. Allergy Clin. Immunol. Pract.* 2021: 9; 2486-2489*.* IF: 11.02 |
| 435. | Baumann, K.\*, Marcelino, J.\*, Stahl Skov, P. S., Santos, M., Wyroslak, I., Scheffel, J., Altrichter, S., Woetmann, A., Costa, C., and **Maurer, M**.+: Autologous serum skin test reactions in chronic spontaneous urticaria differ from heterologous cell reactions. *J. Eur. Acad. Dermatol. Venereol.* 2021: 35; 1338-1345. IF: 9.23 |
| 434. | Zuraw, B., Lumry, W. R., Johnston, D. T., Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Christiansen, S. C., Jacobs, J. S., Sitz, K. V., Gower, R. G., Gagnon, R., Wedner, J., Kinaciyan, T., Hakl, R., Hanzliková, J., Anderson, J. T., McNeil, D. L., Fritz, S. B., Yang, W., H., Tachdjian, R., Busse, P. J., Craig, T. J., Li, H., Farkas, H., Best, J., M., Clemons, D., Cornpropst, M., Dobo, S. M., Iocca, H. A., Kargl, D., Nagy, E., Murray, S. C., Collis, P., Sheridan, W. P.+, **Maurer, M.**\*, and Riedl, M. A.\*\*: Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. *J. Allergy Clin. Immunol*. 2021: 148; 164-172. IF: 14.29 |
| 433. | Cherrez-Ojeda, I.+, Vanegas, E., Cherrez, A., Felix, M., Weller, K., Magerl, M., Maurer, R. R., Mata, V. L., Kasperska-Zajac, A., Sikora, A., Fomina, D., Kovalkova, E., Godse, K., Rao, N. D., Khoshkhui, M., Rastgoo, S., Criado, R. F. J., Abuzakouk, M., Grandon, D., Van Doorn, M. B. A., Rodrigues Valle, S. O., Magalhaes, E., De Souza Lima, E. M., Thomsen, S. F., Ramón, G. D., Matos Benavides, E. E., Bauer, A., Giménez-Arnau, A. M., Kocatürk, E., Guillet, C., Larco, J. I., Zhao, Z. T., Makris, M., Ritchie, C., Xepapadaki, P., Ensina, L. F., Cherrez, S., and **Maurer, M.**: How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. *World Allergy Organ. J*. 2021: 14; e100542. IF: 5.52 |
| 432. | Ginter, K., Ahsan, D., Bizjak, M., Krause, K., **Maurer, M.**+, Altrichter, S., and Terhorst-Molawi, D.: Cryoglobulins, cryofibrinogens, and cold agglutinins in cold urticaria: literature review, retrospective patient analysis, and observational study in 49 patients. *Front. Immunol*. 2021: 12; 675451. IF: 8.79 |
| 431. | Memet, B., Vurgun, E., Barlas, F., Metz, M., **Maurer, M.**, and Kocatürk, E.+: In chronic spontaneous urticaria, comorbid depression linked to higher disease activity and substance P levels. *Front. Psychiatry* 2021: 12; 667978. IF: 5.43 |
| 430. | Puhl, V., Bonnekoh, H., Scheffel, J., Hawro, T., Weller, K., von den Driesch, P., Röwert-Huber, H.-J., Cardoso, J., Gonçalo, M., **Maurer, M.**, and Krause, K.+: A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria. *Clin. Transl. Allergy* 2021: 11; e12031. IF: 5.66 |
| 429. | Ferreira-Gomes, M.\*, Kruglov, A.\*, Durek, P.\*, Heinrich, F.\*, Tizian, C.\*, Heinz, G. A.\*, Pascual-Reguant, A., Du, W., Mothes, R., Fan, C., Frischbutter, S., Habenicht, K., Budzinski, L., Ninnemann, J., Jani, P. K., Guerra, G., Lehmann, K., Matz, M., Ostendorf, L., Heiberger, L., Chang, H.-D., Bauherr, S., **Maurer, M.**, Schönrich, G., Raftery, M., Kallinich, T., Mall, M. A., Angermair, S., Treskatsch, S., Dörner, T., Corman, V. M., Diefenbach, A., Volk, H.-D., Elezkurtaj, S., Winkler, T. H., Dong, J., Hauser, A. E., Radbruch, H.\*, Witkowski, M.\*, Melchers, F.\*, Radbruch, A.\*, and Mashreghi, M.-F.+\*: SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. *Nat. Commun.* 2021: 12; 1961. IF: 17.69 |
| 428. | Hawro, T., Prybyłowicz, K., Spindler, M., Hawro, M., Steć, M., Altrichter, S., Weller, K., Magerl, M., Reidel, U., Alarbeed, E., Alraboni, O., **Maurer, M.**+, and Metz, M.: The characteristics and impact of pruritus in adult dermatologic patients: a prospective, cross-sectional study. *J. Am. Acad. Dermatol.* 2021: 84; 691-700. IF: 15.49 |
| 427. | Skander, D., Allenova, A., **Maurer, M.**, and Kolkhir, P.+: Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria. *Eur. Ann. Allergy Clin. Immunol*. 2021: 53; 91-93*.* IF: N/A |
| 426. | Lumry, W. R.+, Weller, K., Magerl, M., Banerji, A., Longhurst, H. J., Riedl, M. A., Lewis, H. B., Lu, P., Devercelli, G., Jain, G., and **Maurer, M.**: Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. *Allergy* 2021: 76; 1188-1198. IF: 14.71 |
| 425. | Bizjak, M., Košnik, M., Terhorst-Molawi, D., Dinevski, D., and **Maurer, M.**+: Cold agglutinins and cryoglobulins associate with clinical and laboratory parameters of cold urticaria. *Front. Immunol*. 2021: 12; 665491. IF: 8.79 |
| 424. | Sauer, M., Scheffel, J., Frischbutter, S., Kolkhir, P., Xiang, Y.-K., Siebenhaar, F., Altrichter, S., **Maurer, M.**, Metz, M., and Krause, K.+: Lower IgA levels in chronic spontaneous urticaria are associated with lower IgE levels and autoimmunity. *Front. Immunol*. 2021: 12; 657211. IF: 8.79 |
| 423. | Song, X., Chen, Y.-D., Yu, M., Liu, B., Zhao, Z. T.+, and **Maurer, M.**+: Omalizumab in children and adolescents with chronic urticaria: a 16 week real-world study. *Allergy* 2021: 76; 1271-1273. IF: 14.71 |
| 422. | Agache, I.+, Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger T., Eyerich, K. Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., **Maurer, M.**, Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., and Jutel, M.: EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis. *Allergy* 2021: 76; 988-1009. IF: 14.71 |
| 421. | Yu, M., Terhorst-Molawi, D., Altrichter, S., Hawro, T., Chen, Y.-D., Liu, B., Song, X.-T., Zhao, Z.+\*, and **Maurer, M.**+\*: Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response. *Clin. Exp. Allergy* 2021: 51; 730-734*.* IF: 5.40 |
| 420. | Weller, K.+, Giménez-Arnau, A., Grattan, C., Asero, R., Mathelier-Fusade, P., Bizjak, M., Hanna, M., and **Maurer, M.**: The chronic urticaria registry: rationale, methods, and initial implementation. *J. Eur. Acad. Dermatol. Venereol.* 2021: 35; 721-729. IF: 9.23 |
| 419. | Bauer, A., Dickel, H., Jakob, T., Kleinheinz, A., Lippert, U., Metz, M., Schliemann, S., Schwichtenberg, U., Staubach, P., Valesky, E., Wagner, N., Wedi, B., and **Maurer, M.**+: Expert consensus on practical aspects in the treatment of chronic urticaria. *Allergo J. Int*. 2021. 30; 64-75*.* IF: N/A |
| 418. | Türk, M., Yilmaz, I., Hawro, T., and **Maurer, M.**+: Worsening of chronic spontaneous urticaria after intake of hot pepper. *Asian Pac. J. Allergy Immunol*. 2021: 39; 25-30*.* IF: 7.14 |
| 417. | Liao, S. L., Yu, M., Zhao, Z.\*, and **Maurer, M.**+**\***: Case Report: Omalizumab for chronic spontaneous urticaria in pregnancy. *Front. Immunol*. 2021: 12; 652973. IF: 8.79 |
| 416. | Matanis, L.\*, Eiza, N.\*, Sabag, A., Bejar, J., Giménez-Arnau, A. M., **Maurer, M.**, and Vadasz, Z.+: The expression of IL-17, in chronic spontaneous urticaria is linked to semaphorin5A. *Biomolecules* 2021: 11; 373*.* IF: 6.06 |
| 415. | Kocatürk, E.+, Salman, A., Cherrez-Ojeda, I., Criado, P. R., Peter, J., Comert-Ozer, E., Abuzakouk, M., Agondi, C. R., Al-Ahmad, M., Altrichter, S., Arnaout, R., Arruda, K. L., Asero, R., Bauer, A., Ben-Shoshan, M., Bernstein, J. A., Bizjak, M., Boccon-Gibod, I., Bonnekoh, H., Bouillet, L., Brzoza, Z., Busse, P., Campos, R. A., Carne, E., Conlon, N., Criado, R. F., de Souza Lima, E. M., Demir, S., Dissemond, J., Doğan Günaydın, S., Dorofeeva, I., Ensina, L. F., Ertaş, R., Ferrucci, M. S., Figueras-Nart, I., Fomina, D., Franken, S. M., Fukunaga, A., Giménez-Arnau, A. M., Godse, K., Gonçalo, M., Gotua, M., Grattan, C., Guillet, C., Inomata, N., Jakob, T., Karakaya, G., Kasperska-Zając, A., Katelaris, C. H., Košnik, M., Krasowska, D., Kulthanan, K., Kumaran, S. M., Lang, C., Larco-Sousa, J. I., Lazaridou, E., Leslie, T. A., Lippert, U., Llosa, O. C., Makris, M., Marsland, A., Medina, I. V., Meshkova, R., Palitot, E. B., Parisi, C. A. S., Pickert, J., Ramon, G.D., Rodríguez-Gonzalez, M., Rosario, N., Rudenko, M., Rutkowski, K., Sánchez, J., Schliemann, S., Sekerel, B. E., Serpa, F. S., Serra-Baldrich, E., Song, Z., Soria, A., Staevska, M., Staubach, P., Tagka, A., Takahagi, S., Thomsen, S. F., Treudler, R., Vadasz, Z., Valle, S. O. R., Van Doorn, M. B. A., Vestergaard, C., Wagner, N., Wang, D., Wang, L., Wedi, B., Xepapadaki, P., Yücel, E., Zalewska-Janowska, A., Zhao, Z., Zuberbier, T., and **Maurer, M.**+: The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. *Allergy* 2021: *76; 816-830*. IF: 14.71 |
| 414. | Kolkhir, P., Altrichter, S., Asero, R., Daschner, A., Ferrer, M., Giménez-Arnau, A., Hawro, T., Jakob, T., Kinaciyan, T., Kromminga, A., Konstantinou, G. N. Makris, M., Metz, M., Stahl Skov, P., Staubach, P., Sussman, G., Zhang, K., and **Maurer, M.**+: Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria. *Allergy Asthma Immunol. Res.* 2021: 13; 545-559*.* IF: 5.10 |
| 413. | Kulthanan, K., Ungprasert, P., Tapechum, S., Rujitharanawong, C., Kiratiwongwan, R., Munprom, K., Terhorst-Molawi, D., and **Maurer, M.**+: Vibratory angioedema subgroups, features and treatment: results of a systematic review. *J. Allergy Clin. Immunol. Pract.* 2021: 9; 971-984*.* IF: 11.02Kulthanan, K., Ungprasert, P., Tapechum, S., Rujitharanawong, C., Kiratiwongwan, R., Munprom, K., Terhorst-Molawi, D., and **Maurer, M.**+: The classification of vibratory angioedema, a reply to the correspondence by Maria Antonia Pastor-Nieto. *J. Allergy Clin. Immunol. Pract.* 2021: 9; 2543-2544 |
| 412. | Agache, I.+, Rocha, C., Pereira, A., Song, Y., Alonso-Coello, P., Solà, I., Beltran, J., Posso, M., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., **Maurer, M.**, Ogg, G., Ong, P., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C., Palomares, O., and Jutel, M.: Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria – a systematic review for the EAACI biologicals guidelines. *Allergy* 2021: 76; 59-70. IF: 14.71 |
| 411. | Agache, I.+, Song, Y., Posso, M., Alonso-Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., **Maurer, M.**, Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C.\*, Palomares, O.\*, and Jutel, M.\*: Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. *Allergy* 2021: 76; 45-58. IF: 14.71 |
| 410. | Chen, Y., Yu, M., Huang, X., Tu, P., Shi, P., **Maurer, M.**+\*, and Zhao, Z.+\*: Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both. *World Allergy Organ. J*. 2021:14; 100501. IF: 5.52 |
| 409. | Klimek, L.+, Pfaar, O., Worm, M., Eiwegger, T., Hagemann, J., Ollert, M., Untersmayr, E., Hoffmann-Sommergruber, K., Vultaggio, A., Agache, I., Bavbek, S., Bossios, A., Casper, I., Chan, S., Chatzipetrou, A., Vogelberg, C., Firinu, D., Kauppi, P., Kolios, A., Kothari, A., Matucci, A., Palomares, O., Szépfalusi, Z., Pohl, W., Hötzenecker, W., Rosenkranz, A. R., Bergmann, K.-C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., **Maurer, M.**, Merk, H., Mösges, R., Saloga, J., Staubach, P., Jappe, U. , Rabe, K. F., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Freudelsperger, L., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P.-V., Aberer, W., Fink-Wagner, A., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Matricardi, P. M., Spertini, F., Khaltaev, N., Michel, J.-P., Nicod, L., Schmid-Grendelmeier, P., Idzko, M., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Jensen-Jarolim, E., Korn, S., Hentges, F., Schwarze, J., O’Mahony, L., Knol, E. F., del Giacco, S., Chivato Pérez, T., Bousquet, J., Zuberbier, T., Akdis, C., and Jutel, M.: Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie. *Allergo J*. 2020: 29; 14-27. IF: N/A |
| 408. | Altrichter, S., Zampeli, V., Ellrich, A., Zhang, K., Church, M. K., and **Maurer, M.**+: IgM and IgA in addition to IgG autoantibodies against FcεRIα are frequent and associated with disease markers of chronic spontaneous urticaria. *Allergy* 2020: 75; 3208-3215. IF: 13.15 |
| 407. | **Maurer, M.**+, Weller, K., Magerl, M., Maurer, R. R., Vanegas, E., Felix, M., Cherrez, A., Mata, V. L., Kasperska-Zajac, A., Sikora, A., Fomina, D., Kovalkova, E., Godse, K., Dheeraj, N., Khoshkhui, M., Rastgoo, S., Criado, R. F. J., Abuzakouk, M., Grandon, D., van Doorn, M., Or Valle, S., De Souza Lima, E. M., Thomsen, S. F., Ramón, G. D., Benavides, E. E. M., Bauer, A., Giménez-Arnau, A. M., Kocatürk, E., Guillet, C., Larco, J. I., Zhao, Z.-T., Makris, M., Ritchie, C., Xepapadaki, P., Ensina, L. F., Cherrez, S., and Cherrez-Ojeda, I.: The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: a UCARE study. *World Allergy Organ. J.* 2020:13; 100475. IF: 4.08 |
| 406. | Lehmann, S., Deuring, E., Weller, K., Scheffel, J., Metz, M., **Maurer, M.**, and Hawro, T.+: Flare size but not intensity reflects histamine-induced itch. *Skin Pharmacol. Phys.* 2020: 33; 244-252*.* IF: 3.48 |
| 405. | **Toubi,** E., Giménez-Arnau, A. M., **Maurer, M.**, and Vadasz, Z.+: Articular angioedema in patients with chronic spontaneous urticaria is frequently misdiagnosed as arthritis. *J. Allergy Clin. Immunol. Pract.* 2020: 8; 3232-3233*.* IF: 8.86 |
| 404. | Riedl, M. A.+, **Maurer, M.**, Bernstein, J. A., Banerji, A., Longhurst, H. J., Henry Li, H., Lu, P., Hao, J., Juethner, S., and Lumry, W. R.: Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. *Allergy* 2020: 75; 2879-2887. IF: 13.15 |
| 403. | Kulthanan, K., Ungprasert, P., Tuchinda, P., Chularojanamontri, L., Rujitharanawong, C., Kiratiwongwan, R., Jantanapornchai, N., Hawro, T., and **Maurer, M.**+: Symptomatic dermographism: a systematic review of treatment options. *J. Allergy Clin. Immunol. Pract.* 2020: 8; 3141-3161*.* IF: 8.86 |
| 402. | Bonnekoh, H., Terhorst-Molawi, D., Buttgereit, T., **Maurer, M.**, and Altrichter, S.+: Treatment of severe heat urticaria with omalizumab – report of a case and review of the literature. *J. Eur. Acad. Dermatol. Venereol*. 2020: 34; 433-531. IF: 6.17 |
| 401. | **Maurer, M.**+, Giménez-Arnau, A., Ensina, L. F., Chu, C.-Y., Jaumont, X, and Tassinari, P.: Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. *World Allergy Organ. J.* 2020:13; 100460. IF: 4.08 |
| 400. | **Maurer, M.**+, Costa, C., Giménez-Arnau, A., Guillet, G., Labrador-Horrillo, M., Lapeere, H., Meshkova, R., Savic, S., and Chapman-Rothe, N.: Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. *Clin. Exp. Allergy* 2020: 50; 1166-1175 IF: 5.02 |
| 399. | Kröger, M., Scheffel, J., Nikolaev, V. V., Shirshin, E. A., Siebenhaar, F., Schleusener, J., Lademann, J., **Maurer, M.**, and Darvin, M. E.+: *In vivo* non-invasive staining-free visualization of dermal mast cells in healthy, allergy and mastocytosis humans using two-photon fluorescence lifetime imaging. *Sci. Rep.* 2020: 10; 14930. IF: 4.38 |
| 398. | Tawil, S.+, Irani, C., Kfoury, R., Salameh, P., Baiardini, I., Weller, K., **Maurer, M.**, and Ezzedine, K.: The Arabic urticaria activity score and chronic urticaria quality of life questionnaire: validation and correlations. *Int. J. Dermatol.* 2020:59; 893-901*.* IF: 2.74 |
| 397. | Chen, Y.-D., **Maurer, M.**, Liu, B., Song, X.-T., Tu, P., and Zhao, Z.-T.+: Addition of omalizumab to antihistamine treatment in chronic urticaria: a real-world study in China. *Ann. Allergy Asthma Immunol.* 2020: 125; 217-219. IF: 6.35 |
| 396. | Folkerts, J., Redegeld, F., Folkerts, G., Blokhuis, B., van den Bergen, M. P. M., de Bruijn, M. J. W., van IJcken, W. F. J., Junt, T., Tam, S.-Y., Galli, S. J., Hendriks, R. W., Stadhouders, R.+, and **Maurer, M.**+: Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling. *Allergy* 2020: 75; 1966-1978. IF: 13.15 |
| 395. | **Maurer, M.**+, Aberer, W., Agondi, R., Al-Ahmad, M., Al-Nesf, M., Ansotgui, I., Arnaout, R., Arruda, L. K., Asero, R., Aygören-Pürsün, E., Banerji, A., Bauer, A., Ben-Shoshan, M., Berardi, A., Bernstein, J., Betschel, S., Bindslev-Jensen, C., Bizjak, M., Boccon-Gibod, I., Bork, K., Bouillet, L., Boysen, H. B., Brodszki, N., Broesby-Olsen, S., Busse, P., Buttgereit, T., Bygum, A., Caballero, T., Campos, R. A., Cancian, M., Cherrez-Ojeda, I., Cohn, D. M., Costa, C., Craig, T., Criado, P. R., Criado, R., Csuka, D., Dissemond, J., Du-Thanh, A., Ensina, L. F., Ertaş, R., Fabiani, J. E., Fantini, C., Farkas, H., Ferrucci, S. M., Figueras-Nart, I., Fili, N. L., Fomina, D., Fukunaga, A., Gelincik, A., Giménez-Arnau, A., Godse, K., Gompels, M., Gonçalo, M., Gotua, M., Gower, R., Grumach, A. S., Guidos-Fogelbach, G., Hide, M., Ilina, N., Inomata, N., Jakob, T., Josviack, D. O., Kang, H.-R., Kaplan, A., Kasperska-Zając, A., Katelaris, C., Kessel, A., Kleinheinz, A., Kocatürk, E., Košnik, M., Krasowska, D., Kulthanan, K., Kumaran, M. S., Larco Sousa, J. I., Longhurst, H. I., Lumry, W., MacGinnitie, A., Magel, M., Makris, M. P., Malbrán, A., Marsland, A., Martinez-Saguer, I., Medina, I. V., Meshkova, R., Metz, M., Nasr, I., Nicolay, J., Nishigori, C., Ohsawa, I., Özyurt, K., Papadopoulos, N. G., Parisi, C. A. S., Peter, J. G., Pfützner, W., Popov, T., Prior, N., Ramon, G. D., Reich, A., Reshef, A., Riedl, M. A., Ritchie, B., Röckmann-Helmbach, H., Rudenko, M., Salman, A., Sanchez-Borges, M., Schmid-Grendelmeier, P., Serpa, F. S., Serra-Baldrich, E., Sheikh, F. R., Smith, W., Soria, A., Staubach, P., Steiner, U. C., Stobiecki, M., Sussman, G., Tagka, A., Thomsen, S. F., Treudler, R., Valle, S., van Doorn, M., Varga, L., Vázquez, D. O., Wagner, N., Wang, L., Weber-Chrysochoou, C., Ye, Y.-M., Zalewska-Janowska, A., Zanichelli, A., Zhao, Z., Zhi, Y., Zuberbier, T., Zwiener, R. D., and Castaldo, A.: Definition, aims, and implementation of GA²LEN/HAEi angioedema centers of reference and excellence. *Allergy* 2020: 75; 2115-2123. IF: 13.15 |
| 394. | Bergmann, K.-C., **Maurer, M.**, Church, M. K.+, and Zuberbier, T.: Anaphylaxis to mepolizumab and omalizumab in a single patient – is polysorbate the culprit? *J. Invest. Allergol. Clin. Immunol*. 2020: 30; 285-287*.* IF: 4.33 |
| 393. | Terhorst-Molawi, D.+, Altrichter, S., Röwert, J., Magerl, M., Zuberbier, T., **Maurer, M.**, Bergmann, K. C., and Metz, M.: Effective treatment with mepolizumab in a patient with refractory Wells syndrome. *J. Dtsch. Dermatol. Ges*. 2020: 18; 737-739. IF: 5.58 |
| 392. | Sommer, R.+, Silva, N., Langenbruch, A., **Maurer, M.**, Staubach, P., and Augustin, M.: Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria. *Eur. J. Dermatol*. 2020: 30; 259-266. IF: 3.33 |
| 391. | Klimek, L.+\*\*, Pfaar, O.\*\*, Worm, M.\*\*, Bergmann, K.-C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., **Maurer, M.**, Merk, H., Mösges, R., Saloga, J., Staubach, P., Stute, P., Rabe, K., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P.-V., Aberer, W., Fink-Wagner, A., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Akdis, C., Hoffmann-Sommergruber, K., Jutel, M., Matricardi, P., Spertini, F., Khaltaev, N., Michel, J.-P., Nicod, L., Schmid-Grendelmeier, P., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Gerstlauer, M., Vogelberg, C., Bousquet, J., and Zuberbier, T.: Allergen-Immuntherapie in der aktuellen Covid-19-Pandemie. *Allergo J*. 2020: 29; 17-25. IF: N/A  |
| 390. | Vatsiou, S., Zamanakou, M., Loules, G., Psarros, F., Parsopoulou, F., Csuka, D., Valerieva, A., Staevska, M., Porebski, G., Obtulowicz, K., Magerl, M., **Maurer, M.**, Speletas, M., Farkas, H., and Germenis, A. E.+: A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency. *Allergol. Int.* 2020: 69; 443-449. IF: 5.84 |
| 389. | Krause, K.+, Bonnekoh, H., Ellrich, A., Tsianakas, A., Wagner, N., Fischer, J., and **Maurer, M.**: Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. *J. Allergy Clin. Immunol*. 2020: 145; 1681-1686. IF: 10.79 |
| 388. | Weller, K.+, Donoso, T., Magerl, M., Aygören-Pürsün, E., Staubach, P., Martinez-Saguer, I., Hawro, T., Altrichter, S., Krause, K., Siebenhaar, F., Metz, M., Zuberbier, T., Freier, D., and **Maurer, M.**: Validation of the angioedema control test (AECT) – a patient reported outcome instrument for assessing angioedema control. *J. Allergy Clin. Immunol. Pract.* 2020: 8; 2050-2057*.* IF: 8.86 |
| 387. | Weller, K.+, Donoso, T., Magerl, M., Aygören-Pürsün, E., Staubach, P., Martinez-Saguer, I., Hawro, T., Altrichter, S., Krause, K., Siebenhaar, F., Metz, M., Zuberbier, T., Freier, D., and **Maurer, M.**: Development of the angioedema control test (AECT) – a patient reported outcome measure that assesses disease control in patients with recurrent angioedema. *Allergy* 2020: 75; 1165-1177. IF: 13.15 |
| 386. | Chen, Y.-D., Krause, K., Tu, P., Zhao, Z.+, and **Maurer, M.**+: Response of omalizumab in normocomplementemic urticarial vasculitis. *J. Allergy Clin. Immunol. Pract.* 2020: 8; 2114-2117*.* IF: 8.86 |
| 385. | Kulthanan, K., Ungprasert, P., Tuchinda, P., Chularojanamontri, L., Charoenpipatsin, N., and **Maurer, M.**+: Delayed pressure urticaria: a systematic review of treatment options. *J. Allergy Clin. Immunol. Pract.* 2020: 8; 2035-2049*.* IF: 8.86 |
| 384. | Sabag, D. A.\*, Matanes, L.\*, Bejar, J., Sheffer, H., Barzilai, A., Church, M. K., Toubi, E., **Maurer, M.**, and Vadasz, Z.+: Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. *Clin. Exp. Allergy* 2020: 50; 799-804. IF: 5.02 |
| 383. | Altrichter, S., Schumacher, P., Alraboni, O., Wang, Y., Hiragun, M., Hide, M., and **Maurer, M.**+: Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients. *Clin. Transl. Allergy* 2020: 10; 18. IF: 5.87 |
| 382. | Bertolin-Collilla, M., Garin-Boronat, O., Siebenhaar, F., **Maurer, M.**, Pujol, R. M., and Giménez-Arnau, A. M.+: Translation and cultural adaption of the German mastocytosis quality of life questionnaire (MC-QoL) into Spanish. *Actas* *Dermosifilogr*. 2020: 111; 243-248. IF: N/A |
| 381. | Dortas, S. D. Jr.+, Oliveira Rodrigues Valle, S., Weller, K., **Maurer, M.**, and Lupi, O.: Validity, reliability and interpretability of the Brazilian UCT. *Allergy Asthma Proc*. 2020: 41; e61-e66. IF: 2.59 |
| 380. | Folkerts, J., Gaudenzio, N., **Maurer, M.**, Hendriks, R. W., Stadhouders, R. Tam, S. Y., and Galli, S. J.+: Rapid identification of human mast cell degranulation regulators using functional genomics coupled to high-resolution confocal microscopy. *Nat. Protoc.* 2020: 15; 1285-1310. IF: 13.49 |
| 379. | Kolkhir, P.\*, Bonnekoh, H.\*, Kocatürk, E., Hide, M., Metz, M., Sanchez-Borges, M., Krause, K.\*, and **Maurer, M.\***+: Management of urticarial vasculitis: A worldwide physician perspective. *World Allergy Organ. J.* 2020*:* 13; 100107. IF: 4.08 |
| 378. | Fricke, J.+, Ávila, G., Keller, T., Weller, K., Lau, S., **Maurer, M.**, Zuberbier, T., and Keil, T.: Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. *Allergy* 2020: 75; 423-432. IF: 13.15 |
| 377. | Hawro, T., Hawro, M., Zalewska-Janowska, A., Weller, K., Metz, M., and **Maurer M.**+: Pruritus and sleep disturbances in patients with psoriasis. *Arch. Dermat. Res*. 2020: 312; 103-111. IF: 3.02 |
| 376. | Jiao, Q., Qian, Q., Liu, C., Luo, Y., Fang, F., Wang, M., Ji, J., Qian, H., Zhang, X.+, and **Maurer, M.**+: T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator. *Brit. J. Dermatol*. 2020: 182; 648-657. IF: 9.30 |
| 375. | Jiao, Q.\*, Luo, Y.\*, Scheffel, J., Geng, P., Wang, Y., Frischbutter, S., Li, R., **Maurer, M.**+\*, and Zhao, Z.+\*: Skin mast cells contribute to Sporothrix schenkii infection. *Front. Immunol*. 2020: 11; 469. IF: 7.56 |
| 374. | Ertaş, R., Hawro, T., Altrichter, S., Özyurt, K., Erol, K., Ketenci Ertaş, S., and **Maurer, M.**+: Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. *Allergy* 2020: 75; 468-470. IF: 13.15 |
| 373. | Ertaş, R., Erol, K., Hawro, T., Yilmaz, H., and **Maurer, M.**+: Sexual functioning is frequently and markedly impaired in female patients with chronic spontaneous urticaria. *J. Allergy Clin. Immunol. Pract.* 2020: 8; 1074-1082*.* IF: 8.86 |
| 372. | Kolkhir, P., Church, M. K., Altrichter, S., Stahl Skov, P., Hawro, T., Frischbutter, S., Metz, M., and **Maurer, M.**+: Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity and poor response to treatment. *J. Allergy Clin. Immunol. Pract.* 2020: 8; 318-325*.* IF: 8.86 |
| 371. | Hofman, Z. L. M.\*\*, Clark, C. C.\*\*, Sanrattana, W., Nosairi, A., Parr, N., Zivkovic, M., Krause, K., Mahnke, N. A., Scheffel, J., Hack, C. E., **Mauer, M.**, de Maat, S., and Maas, C.+: A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence and accelerates activation. *J. Biol. Chem.* 2020: 295; 363-374. IF: 5.16 |
| 370. | Scheffel, J., Mahnke, N. A., Hofman, Z. L. M., de Maat, S., Wu, J., Bonnekoh, H., Pengelly, R. J., Ennis, S., Holloway, J. W., Church, M. K., **Maurer, M.**+, Maas, C., and Krause, K.: Cold-induced urticarial autoinflammatory syndrome related to factor XII activation. *Nat. Commun.* 2020: 11; 179. IF: 14.92 |
| 369. | André, F., Fluhr, J. W., Hawro, T., Church, M. K., **Maurer, M.**, and Metz, M.+: Characterization of cowhage-induced pruritus in inflamed and non-inflamed skin. *J. Eur. Acad. Dermatol. Venereol*. 2020: 34; 202-206. IF: 6.17 |
| 368. | Schut, C., Magerl, M., Hawro, T., Kupfer, J., Rose, M., Gieler, U., **Maurer, M.**, and Peters, E. M. J.+: Disease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patients. *Allergy* 2020: 75; 224-226. IF: 13.15 |
| 367. | Mellerowicz, E., Weller, K., Zuberbier, T., **Maurer, M.**+, and Altrichter, S.: Real life treatment of patients with cholinergic urticaria in German speaking countries. *J. Dtsch. Dermatol. Ges*. 2019: 17; 1141-1147. IF: 3.66 |
| 366. | Bergmann, K. C., Altrichter, S., and **Maurer, M.**+: Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. *J. Eur. Acad. Dermatol. Venereol*. 2019: 33; e413-e415. IF: 5.25 |
| 365. | Kulthanan, K., Chularojanamontri, L., Rujitharanawong, C., Weerasubpong, P., Weller, K.\*, and **Maurer, M.**+\*: Angioedema activity score (AAS): a valid and reliable tool to use in Asian patients. *Biomed. Res. Int.* 2019: *9157895*. IF: 2.28 |
| 364. | Kulthanan, K., Chularojanamontri, L., Rujitharanawong, C., Weerasubpong, P., **Maurer, M.**+\*, and Weller, K.\*: Angioedema quality of life questionnaire (AE-QoL) – interpretability and sensitivity to change. *Health. Qual. Life Outcomes* 2019: 17; 160. IF: 2.34 |
| 363. | Schoepke, N., Asero, R.\*, Ellrich, A.\*, Ferrer, M.\*, Giménez-Arnau, A.\*, Gratten, C. E. H.\*, Jakob, T.\*, Konstantinou, G. N.\*, Raap, U.\*, Stahl Skov, P.\*, Staubach, P.\*, Kromminga, A.\*, Zhang, K.\*, Bindslev-Jensen, C., Daschner, A., Kinaciyan, T., Knol, E. F., Makris, M., Marrouche, N., Schmid-Grendelmeier, P., Sussman, G., Toubi, E., Church, M. K., and **Maurer, M.**+: Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study. *Allergy* 2019: 74; 2427-2436. IF: 8.71 |
| 362. | Baiardini, I.+, Fasola, S., **Maurer, M.**, Weller, K., Canonica, G. W., and Braido, F.: Minimal important difference of the chronic urticaria quality of life questionnaire (CU-Q2oL). *Allergy* 2019: 74; 2542-2544. IF: 8.71 |
| 361. | Luo, Y., Meyer, N., Jiao, Q., Scheffel, J., Zimmermann, C., Metz, M., Zenclussen, A. C., **Maurer, M.**+, and Siebenhaar, F.: Chymase-Cre; Mcl-1fl/fl mice exhibit reduced numbers of mucosal mast cells. *Front. Immunol.* 2019: 10; 2399. IF: 5.09 |
| 360. | **Maurer, M.**+, Giménez-Arnau, A. M., Sussman, G., Metz, M., Baker, D. R., Bauer, A., Bernstein, J. A., Brehler, R., Chu, C.-Y., Chung, W.-H., Danilycheva, I., Grattan, C., Hebert, J., Katelaris, C., Makris, M., Meshkova, R., Savic, S., Sinclair, R., Sitz, K., Staubach, P., Wedi, B., Löffler, J., Barve, A., Kobayashi, K., Hua, E., Severin, T., and Janocha, R.: Ligelizumab for chronic spontaneous urticaria. *New Engl. J. Med.* 2019: 381; 1321-1332*.* IF: 74.70**Maurer, M.**+, Giménez-Arnau, A. M., and Metz, M.: Reply to: Ligelizumab for chronic spontaneous urticaria. *New Engl. J. Med.* 2020: 382; 579-580 |
| 359. | Bygum, A.+, Caballero, T., Grumach, A. S., Longhurst, H. J., Bouillet, L., Aberer, W., Zanichelli, A., Botha, J., Andresen, I., **Maurer, M.** for the IOS study group: Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the icatibant outcome survey. *Clin. Transl. Allergy* 2019: 9; 37. IF: 5.13 |
| 358. | Lozza, L.\*, Moura-Alves, P.\*, Domaszewska, T., Lage Crespo, C., Streata, I., Kreuchwig, A., Bechtle, M., Klemm, M., Zedler, U., Ungureanu Bogdan, S., Guhlich-Bornhof, U., Koehler, A.-B., Stäber, M., Mollenkopf, J., Hurwitz, R., Furkert, J., Krause, G., Weiner, J., Jacinto, A., Mihai, I., Leite-de-Moraes, M., Siebenhaar, F., **Maurer, M.**, and Kaufmann, S. H. E.+: The henna pigment lawsone activates the aryl hydrocarbon receptor and impacts skin homeostasis. *Sci. Rep.* 2019: 9; 10878. IF: 4.00 |
| 357. | Almustafa, Z. Z., Weller, K., Autenrieth, J., **Maurer, M.**, and Metz, M.+: Dupilumab in treatment of chronic prurigo: a case series and literature review. *Acta Derm. Venereol.* 2019: 99; 905-906. IF: 4.02 |
| 356. | Yu, L., Buttgereit, T., Stahl Skov, P., Schmetzer, O., Scheffel, J., Kocatürk, E., Zawar, V., Magerl, M., and **Maurer, M.**+: Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria. *J. Eur. Acad. Dermatol. Venereol*. 2019: 33; 1747-1754. IF: 5.25 |
| 355. | Hawro, T., Lehmann, S., Deuring, E. Weller, K., Altrichter, S., Church, M. K., **Maurer, M.**, and Metz, M.+: Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage. *J. Eur. Acad. Dermatol. Venereol*. 2019: 33; 1755-1761. IF: 5.25 |
| 354. | Zimmermann, C., Troeltzsch, D., Giménez-Rivera, V. A., Galli, S. J., Metz, M., **Maurer, M.**, and Siebenhaar, F.+: Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. *Proc. Natl. Acad. Sci. USA* 2019: 116; 20500-20504. IF: 9.41 |
| 353. | Gorczyza, M., Curto-Barredo, L., Krause, K., Church, M. K., Hawro, T., Metz, M., Giménez-Arnau, A., and **Maurer, M.**+: H1-antihistamine inhibition of histamine and codeine-induced wheals does not predict response in chronic cold urticaria. *J. Allergy Clin. Immunol. Pract.* 2019: 7; 2043-2044*.* IF: 7.57 |
| 352. | Weller, K., Church, M. K., Metz, M., Hawro, T., Ohanyan, T., Staubach, P., and **Maurer, M.**+: The response to treatment in chronic spontaneous urticaria depends on how it is measured. *J. Allergy Clin. Immunol. Pract.* 2019: 7; 2055-2056*.* IF: 7.57 |
| 351. | **Maurer, M.\***+, Raap, U.\*, Staubach, P.\*, Richter-Huhn, G.\*, Bauer, A., Oppel, E. M., Hillen, U., Bäumer, D., Reinhardt, M., and Chapman-Rothe, N.: Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. *Clin. Exp. Allergy* 2019: 49; 655-662. IF: 4.22 |
| 350. | Mellerowicz, E. J., Asady, A., **Maurer, M.**, and Altrichter, S.+: Angioedema frequently occurs in cholinergic urticaria. *J. Allergy Clin. Immunol. Pract.* 2019: 7; 1355-1357*.* IF: 7.57 |
| 349. | Ngouateu Tateng, A., Khan Payne, V., Ngouateu, O. B., Kirstein, O. D., Warburg, A., von Stebut-Borschitz, E., **Maurer, M.**, Dondji, B.+, and Krüger, A.+: Inventory and taxonomy of phlebotomine sand flies of the Mokolo leishmaniasis focus, northern Cameroon, with description of new sergentomyia taxa (diptera: psychodidae). *Acta Trop.* 2019: 194; 172-180. IF: 2.55 |
| 348. | Bonnekoh, H., Scheffel, J., Wu, J., Hoffmann, S., **Maurer, M.**, and Krause, K.+: Skin and systemic inflammation in Schnitzler’s syndrome are associated with neutrophil extracellular trap formation. *Front. Immunol*. 2019: *10; 546*. IF: 5.08 |
| 347. | Cherrez-Ojeda, I.+, **Maurer, M.**, Bernstein, J. A., Vanegas, E., Felix, M., Ramon, G. D., Ensina, L. F., Larco Sousa, J. I., Matos Benavides, E. E., Cardona Villa, R., Latour Staffeld, P., Morfin-Maciel, B. M., Mori, J., Wilches, P. C.; Mata, V. L., and Cherrez, A.: Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. *World Allergy Organ. J.* 2019:12; 100011. IF: TBD (IF 2018: 3.68) |
| 346. | Türk, M. **Maurer, M.**+,and Yilmaz, I.: How to discontinue omalizumab in chronic spontaneous urticaria? *Allergy* 2019: 74; 821-824. IF: TBD (IF 2018: 6.77) |
| 345. | Krause, K., Sabat, R., Witte-Händel, E., Schulze, A., Puhl, V., **Maurer, M.**, and Wolk, K.+: Association of CCL2 with systematic inflammation in Schnitzler syndrome. *Br. J. Dermatol*. 2019: 180; 859-868*.* IF: TBD (IF 2018: 6.71) |
| 344. | Chuamanochan, M., Weller, K., Feist, E., Kallinich, T., **Maurer, M.**, Kümmerle-Deschner, J., and Krause, K.+: State of care for patients with systemic autoinflammatory diseases – results of a tertiary care survey. *World Allergy Organ. J.* 2019:12; 100019. IF: TBD (IF 2018: 3.68) |
| 343. | Grumach, A. S., Longhurst, H., Aberer, W., Bouillet, L., Caballero, T., Bygum, A., Zanichelli, A., Botha, J., Andresen, I., and **Maurer, M.**+: Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: icatibant outcome survey findings. *J. Allergy Clin. Immunol. Pract.* 2019: 7; 1078-1080*.* IF: TBD (IF 2018: 7.55) |
| 342. | Kolkhir, P.\*, Grakhova, M.\*, Bonnekoh, H., Krause, K.\*, and **Maurer, M.**\*+: Treatment of urticarial vasculitis: a systematic review. *J. Allergy Clin. Immunol*. 2019: 143; 458-466. IF: TBD (IF 2018: 14.11) |
| 341. | Altrichter, S.\*+, Chuamanochan, M.\*, Knoth, H., Asady, A., Ohanyan, T., Metz, M., and **Maurer, M.**: Real life treatment of cholinergic urticaria with omalizumab. *J. Allergy Clin. Immunol*. 2019: 143; 788-791. IF: TBD (IF 2018: 14.11) |
| 340. | **Maurer, M.**+, Bork, K., Martinez-Saguer, I., Aygören-Pürsün, E., Botha, J., Andresen, I., and Magerl, M.: Management of patients with hereditary angioedema in Germany: comparison to other countries in the icatibant outcome survey. *J. Eur. Acad. Dermatol. Venereol*. 2019: 33; 163-169. IF: TBD (IF 2018: 5.11) |
| 339. | Metz, M., Torene, R., Kaiser, S., Beste, M. T., Staubach, P., Bauer, A., Brehler, R., Gericke, J., Letzkus, M., Hartmann, N., Erpenbeck, V. J.\*, and **Maurer, M.\***+: Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study. *Allergy* 2019: 74; 141-151. IF: TBD (IF 2018: 6.77) |
| 338. | Lakin, E., Church, M. K., **Maurer, M.**+, and Schmetzer, O.: On the lipophilic nature of the autoreactive IgE in chronic spontaneous urticaria. *Theranostics* 2019: 9; 829-836*.* IF: TBD (IF 2018: 8.06) |
| 337. | Bork, K.+, Aygören-Pürsün, E., Bas, M., Biedermann, T., Greve, J., Hartmann, K., Magerl, M., Martinez-Saguer, I., **Maurer, M.**, Ott, H., Schauf, L., Staubach, P., and Wedi, B.: Guideline: Hereditary angioedema due to C1 inhibitor deficiency. S1-Guideline of the German Society for Angioedema (DGA), German Society for Internal Medicine (DGIM), German Society for Otorhinolaryngology (DGHNO), German Society for Allergology and Clinical Immunology (DGAKI), German Society for Child and Adolescent Medicine (DGKJ), German Dermatological Society (DDG), German Society for Pediatric Allergology and Environmental Medicine (GPA), German Association of ENT Surgeons (BVHNO) and the German HAE Patient Association (HAE-SHG). *Allergo J. Int*. 2019: 28; 16-29. IF: 2.06 |
| 336. | Kocatürk, E.+, Kiziltac, U., Can, P., Öztas Kara, R., Erdem, T., Kiziltac, K., Sahillioglu, N., Gelincik, A., **Maurer, M.**, and Weller, K.: Validation of the Turkish version of the urticaria control test: correlation with other tools and comparison between spontaneous and inducible chronic urticaria. *World Allergy Organ. J.* 2019:12; 6-13. IF: TBD (IF 2018: 3.68) |
| 335. | Grabowski, J. P.+, Sehouli, J., Glajzer, J., Worm, M., Zuberbier, T., **Maurer, M.,** and Fluhr, J. W.: Olaparib desensitization in a patient with recurrent peritoneal cancer. *New Engl. J. Med.* 2018: 379; 2176-2177*.* IF: 70.67 |
| 334. | Weller, K.+, Ohanyan, T., Hawro, T., Ellrich, A., Sussman, G., Koplowitz, J., Giménez-Arnau, A., Peveling-Oberhag, A., Staubach, P., Metz, M., and **Maurer, M.**: Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. *Allergy* 2018: 73; 2406-2408. IF: TBD (IF 2017: 6.77) |
| 333. | Zuberbier, T.+, Aberer, W., Asero, R., Latiff, A. H. A., Baker, D., Ballmer-Weber, B., Bernstein, J. A., Bindslev-Jensen, C., Brzoza, Z., Buense Bedrikow, R., Canonica, G. W., Church, M. K., Craig, T., Danilycheva, I. V., Dressler, C., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Katelaris, C. H., Kocatürk, E., Kulthanan, K., Larenas-Linnemann, D., Leslie, T. A., Magerl, M., Mathelier-Fusade, P., Meshkova, R. Y., Metz, M., Nast, A., Nettis, E., Oude-Elberink, H., Rosumeck, S., Saini, S. S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Vestergaard, C., Wedi, B., Werner, R. N., Zhao, Z., **Maurer, M.**, Brehler, R., Brockow, K., Fluhr, J., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., Merk, H., Ollert, M., Ott, H., Reese, I., Rueff, F., and Werfel, T.: EAACI/GA²LEN/EDF/WAO-Leitlinie für die Definition, Klassifikation, Diagnose und das Management der Urtikaria – konsentierte, deutschsprachige Übersetzung. *Allergo J. Int*. 2018: 27; 41-68*.* IF: 2.06 |
| 332. | Vera, C.+, Vera, J., Ball, E., Church, M. K., and **Maurer, M.**: Red and itchy bilateral supraorbital swellings. *J. Dtsch. Dermatol. Ges*. 2018: 16; 1503-1506. IF: 3.92 |
| 331. | **Maurer, M.**+, Houghton, K., Costa, C., Dabove, F., Ensina, L. F., Giménez-Arnau, A., Guillet, G., Konstantinou, G. N., Labrador-Horrillo, M., Lapeere, H., Meshkova, R., Pastorello, E. A., Velásquez-Lopera, M., Tamayo Quijano, L., M.; Vestergaard, C., and Chapman-Rothe, N.: Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. *World Allergy Organ. J.* 2018:11; 32. IF: 3.68 |
| 330. | Banerji, A.+, Riedl, M. A., Bernstein, J. A., Cicardi, M., Longhurst, H. J., Zuraw, B. L., Busse, P. J., Anderson, J., Magerl, M., Martinez-Saguer, I., Davis-Lorton, M., Zanichelli, A., Li, H., Craig, T., Jacobs, J., Johnston, D. T., Shapiro, R., Yang, W. H., Lumry, W. R., Manning,M. E., Schwartz, L. B., Shennak, M., Soteres, D., Zaragoza-Urdaz, H., Gierer, S., Smith, A. M., Tachdjian, R., Wedner, J., Hebert, J., Rehman, S. M., Staubach, P., Schranz, J., Baptista, J., Nothaft, W., and **Maurer, M.**: Effect of Lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. *JAMA* 2018: 320; 2108-2121. IF: 51.27 |
| 329. | Weller, K.+, Altrichter, S., Zuberbier, T., and **Maurer, M.**: Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: a real life study. *Allergy* 2018: 73; 2073-2075. IF: 6.77 |
| 328. | Zanichelli, A.+, Magerl, M., Longhurst, H. J., Aberer, W., Caballero, T., Bouillet, L., Bygum, A., Grumach, A. S., Botha, J., Andresen, I., and **Maurer, M.**: Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the icatibant outcome survey. *Clin. Transl. Allergy* 2018: 8; e42. IF: 4.23 |
| 327. | Ngouateu Tateng, A., Kirstein, O. D., Ngouateu, O. B., Krüger, A., von Stebut, E., **Maurer, M.**, Payne, V. K., Warburg, A., and Dondji, B.+: First detection of Leishmania donovani in sand flies from Cameroon and its epidemiological implications. *Trop. Med. Int. Health 2018*: 23; 1014-1021. IF: 2.42 |
| 326. | Riedl, M.\*+, Farkas, H.\*, Bernstein, J. A., Bouillet, L., Sheridan, W. P., and **Maurer, M.**: Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. *Allergy* 2018: 73; 1871-1880. IF: 6.77 |
| 325. | Schmetzer, O.+, Lakin, E., Topal, F. A., Preusse, P., Freier, D., Church, M. K., and **Maurer, M.**: IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. *J. Allergy Clin. Immunol*. 2018: 142; 876-882. IF: 14.11 |
| 324. | Balp, M. M.+, Weller, K., Carboni, V., Chirilov, A., Papavassilis, C., Severin, T., Tian, H., Zuberbier, T., and **Maurer, M.**: Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. *Pediatr. Allergy Immunol.* 2018: 29; 630-636*.* IF: 2.42Balp, M. M.+, Weller, K., Carboni, V., Chirilov, A., Papavassilis, C., Severin, T., Tian, H., Zuberbier, T., and **Maurer, M.**: Response to comment on: Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. *Pediatr. Allergy Immunol.* 2018: 29; 670-671 |
| 323. | Aygören-Pürsün, E.\*+, Bygum, A.\*, Grivcheva-Panovska, V., Magerl, M., Graff, J., Steiner, U., Fain, O., Huissoon, A., Kinaciyan, T., Farkas, H., Lleonart, R., Longurst, H., Rae, W., Triggiani, M., Aberer, W., Cancian, M., Zanichelli, A., Smith, W. B., Baeza, M. L., Du-Thanh, A., Gompels, M., Gonzalez-Quevedo, T., Greve, J., Guilarte, M., Katelaris, C., Dobo, S., Cornpropst, M., Clemons, D., Fang, Lei, Collis, P., Sheridan, W., **Maurer, M.**\*, Cicardi, M.\*: Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. *New Engl. J. Med.* 2018: 379; 352-362*.* IF: 70.67 |
| 322. | Hawro, T., Ohanyan, T., Schoepke, N., Metz, M., Peveling-Oberhag, A., Staubach, P., **Maurer, M.**, and Weller, K.+: The urticaria activity score – validity, reliability, and responsiveness. *J. Allergy Clin. Immunol. Pract.* 2018: 6; 1185-1190*.* IF: 7.55 |
| 321. | Anderson, E., Stavenhagen, K., Kolarich, D., Sommerhoff, C. P., **Maurer, M.**, and Metz, M.+: Human mast cell tryptase is a potential treatment for snakebite envenoming across multiple snake species. *Front. Immunol*. 2018: 9; 1532. IF: 4.72 |
| 320. | Larenas-Linnemann, D.+, Saini, S. S., Azamar-Jácome, A. A., and **Maurer, M.**: Chronic urticaria can be caused by cancer and resolves with its cure. *Allergy* 2018: 73; 1562-1566. IF: 6.77Larenas-Linnemann, D.+, Saini, S. S., Azamar-Jácome, A. A., and **Maurer, M.**: Very rarely chronic urticaria can be caused by cancer and if so, resolves with its cure. Response to comment on: Chronic urticaria can be caused by cancer and resolves with its cure. *Allergy* 2018: 1925-1926 |
| 319. | Siebenhaar, F.+, Sander, B., Ho, L. H. T., Ellrich, A., **Maurer, M.**, and Weller, K.: Development and validation of the mastocytosis activity score. *Allergy* 2018: 73; 1489-1496. IF: 6.77 |
| 318. | Sussman, G.+, Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez-Arnau, A., Grattan, C., Hollis, K., Hunter, S., Knulst, A., Lacour, J. P., Lynde, C., Marsland, A., McBride, D., **Maurer, M.**, Nakonechna, A., Ortiz de Frutos, J., Reynolds, M., Sweeney, C., Tian, H., Weller, K., Wolin, D., and Balp, M. M.: Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. *Allergy* 2018: 73; 1724-1734. IF: 6.77 |
| 317. | Altrichter, S., Hawro, T., Liedtke, M., Holtappels, G., Bachert, C., Stahl Skov, P., and **Maurer, M.**+: In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional. *Allergy* 2018: 73; 1497-1504. IF: 6.77 |
| 316. | Kulthanan, K., Tuchinda, P., Chularojanamontri, L., and **Maurer, M.**+: Food-dependent cold urticaria: a new variant of physical urticaria. *J. Allergy Clin. Immunol. Pract.* 2018: 6; 1400-1402*.* IF: 7.55 |
| 315. | Aygören-Pürsün, E.+, Magerl, M., Mätzel, A., and **Maurer, M.**: Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. *Orphanet J. Rare Dis*. 2018: 13; 73. IF: 3.69 |
| 314. | Loules, G.**\***+, Zamanakou, M.\*, Parsopoulou, F., Vatsiou, S., Psarros, F., Csuka, D., Porebski, G., Obtulowicz, K., Valerieva, A., Staevska, M., López-Lera, A., López-Trascasa, M., Moldovan, D., Magerl, M., **Maurer, M.**, Speletas, M., Farkas, H., and Germenis, A. E.: Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. *Gene* 2018: 667; 76-82. IF: 2.64 |
| 313. | **Maurer, M.**, Mathias, S. D., Crosby, R. D., Rajput, Y.+, and Zazzali, J. L.: Validity and responsiveness of the urticaria activity and impact measure: a new patient-reported tool. *Ann. Allergy Asthma Immunol.* 2018: 120;641-647. IF: 3.56 |
| 312. | Kolkhir, P.+, Pogorelov, D., Darlenski, R., Caminati, M., Tanno, L. K., Le Pham, D., Gonzalez-Estrada, A., Antolin-Amérigo, D., Dimov, V., Weller, K., Sanchez-Borges, M., Ansotegui, I., and **Maurer, M.**: Management of chronic spontaneous urticaria: a worldwide perspective. *World Allergy Organ. J.* 2018: 11; 14 eCollection. IF: 3.68 |
| 311. | Dressler, C.+, Rosumeck, S., Werner, R. N., Magerl., M., Metz, M., **Maurer, M.**, Nast, A., and Zuberbier, T.: Executive summary of the methods report for ‘The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update’. *Allergy* 2018: 73; 1145-1146. IF: 6.77 |
| 310. | Zuberbier, T.+, Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer-Weber, B., Bernstein, J. A., Bindslev-Jensen, C., Brzoza, Z., Buense Bedrikow, R., Canonica, G. W., Church, M. K., Craig, T., Danilycheva, I. V., Dressler, C., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Katelaris, C. H., Kocatürk, E., Kulthanan, K., Larenas-Linnemann, D., Leslie, T. A., Magerl, M., Mathelier-Fusade, P., Meshkova, R. Y., Metz, M., Nast, A., Nettis, E., Oude-Elberink, H., Rosumeck, S., Saini, S. S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Vestergaard, C., Wedi, B., Werner, R. N., Zhao, Z., and **Maurer, M.**: The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. *Allergy* 2018: 73; 1393-1414. IF: 6.77Zuberbier, T.+, **Maurer, M.**, and Church, M. K.: Reply to Wood et al. Response to comment on: The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update*. Allergy* 2019: 74; 418-419 |
| 309. | **Maurer, M.**\*+,Magerl, M.\*, Ansotegui, I., Aygören-Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A. S., Hide, M., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W., Martinez-Saguer, I., Moldovan, D., Nast, A., Pawankar, R., Potter, P., Riedl, M., Ritchie, B., Rosenwasser, L., Sánchez-Borges, M., Zhi, X., Zuraw, B., and Craig, T.: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. *Allergy* 2018: 73; 1575-1596. IF: 6.77 |
| 308. | **Maurer, M.**\*+,Magerl, M.\*, Ansotegui, I., Aygören-Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A., Hide, M., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W., Martinez-Saguer, I., Moldovan, D., Nast, A., Pawankar, R., Potter, P., Riedl, M., Ritchie, B., Rosenwasser, L., Sánchez-Borges, M., Zhi, X., Zuraw, B., and Craig, T.: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. *World Allergy Organ. J.* 2018: 11; 5. IF: 3.68 |
| 307. | Kolkhir, P.\*, Altrichter, S.\*, Hawro, T., and **Maurer, M.**+: C-reactive protein is linked to disease activity, impact and response to treatment in patients with chronic spontaneous urticaria. *Allergy* 2018: 73; 940-948*.* IF: 6.77 |
| 306. | Bonnekoh, H., Ohanyan, T., Lenze, D., Krause, K., **Maurer, M.**, Zuberbier, T.\*, and Siebenhaar, F.\*+: Development of tripe palms and soles in a patient with long pre-existing systemic mastocytosis and newly developed non-small cell lung cancer. *J. Eur. Acad. Dermatol. Venereol*. 2018:32; e151-e153. IF: 5.11 |
| 305. | Kikuchi, A., Inami, A., Nasir, F. B. M., Mohsen, A., Watanuki, S., Miyake, M., Matsuda, R., Koike, D., Ito, T., Sasakawa, J., Takeda, K., Hiraoka, K., **Maurer, M.**, Yanai, K., Watabe, H., and Tashiro, M.+: Effects of levocetirizine and diphenhydramine on regional glucose metabolic changes and hemodynamic responses in the human prefrontal cortex during cognitive tasks. *Hum. Psychopharmacol. Clin. Exp.* 2018: 33; e2655. IF: 2.26 |
| 304. | Magerl, M., Terhorst, D., Metz, M., Zuberbier, T., Altrichter, S., **Maurer, M.**, and Bergmann, K.-C.: Benefit from mepolizumab treatment in a patient with chronic spontaneous urticaria. *J. Dtsch. Dermatol. Ges*. 2018: 16; 477-478. IF: 3.92Magerl, M., Terhorst, D.+, Metz, M., Zuberbier, T., Altrichter, S., **Maurer, M.**, and Bergmann, K.-C.: Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. *J. Dtsch. Dermatol. Ges*. 2018: 16; 476-477 |
| 303. | Hollis, K.+, Proctor, C., McBride, D., Balp, M. M., McLeod, L., Hunter, S., Tian, H., Khalil, S., and **Maurer, M.**: Comparison of urticaria activity score over 7 days (UAS7) values obtained from once-daily and twice-daily versions: results from the ASSURE-CSU study. *Am. J. Clin. Dermatol.* 2018: 19; 267-274. IF: 3.84 |
| 302. | Caballero, T.+, Zanichelli, A., Aberer, W., **Maurer, M.**, Longhurst, H. J., Bouillet, L., and Andresen, I.: Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the icatibant outcome survey, a cohort observational study. *Clin. Transl. Allergy* 2018: 8; 11. IF: 4.23 |
| 301. | **Maurer, M.**+, Altrichter, S., Metz, M., Zuberbier, T., Church, M. K., and Bergmann, K. C.: Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. *J. Eur. Acad. Dermatol. Venereol*. 2018:32; e112-113. IF: 5.11 |
| 300. | Zänker, M.+, Becher, G., Arbach, O., **Maurer, M.**, Stuhlmüller, B., Schäfer, A., and Strohner, P.: Improved adalimumab dose decision with comprehensive diagnostics data. *Clin. Exp. Rheumatol*. 2018: 36; 136-139. IF: 3.20) |
| 299. | Bonnekoh, H., Scheffel, J., **Maurer, M.**, and Krause, K.+: Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study. *Brit. J. Dermatol*. 2018: 18; 561-562. IF: 6.71 |
| 298. | Staubach, P.\*, Metz, M.\*, Chapman-Rothe, N., Sieder, C., Bräutigam, M., **Maurer, M.**, and Weller, K.+: Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. *Allergy* 2018: 73; 576-584*.* IF: 6.77 |
| 297. | Ertaş, R., Ozyurt, K., Atasoy, M., Hawro, T., and **Maurer, M.**+: The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. *Allergy* 2018: 73; 705-712*.* IF: 6.77 |
| 296. | Ruft, J., Asady, A., Staubach, P., Casale, T., Sussman, G., Zuberbier, T., **Maurer, M.**, Weller, K., and Altrichter, S.+: Development and validation of the cholinergic urticaria quality of life questionnaire: CholU-QoL. *Clin. Exp. Allergy* 2018: 48; 433-444. IF: 4.74 |
| 295. | **Maurer, M.**+, Kaplan, A., Rosén, K., Holden, M., Iqbal, A., Trzaskoma, B. L., Yang, M., and Casale, T. B.: The XTEND-CIU study: long term use of omalizumab in chronic idiopathic urticaria. *J. Allergy Clin. Immunol*. 2018: 141; 1138-1139. IF: 14.11 |
| 294. | Kulthanan, K., Chaweekulrat, P., Komoltri, C., Hunnangkul, S., Tuchinda, P.+, Chularojanamontri, L., and **Maurer, M.**: Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. *J. Allergy Clin. Immunol. Pract.* 2018: 6; 586-599*.* IF: 7.55 |
| 293. | Terhorst, D., Koti, I., Krause, K., Metz, M., and **Maurer, M.**+: In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angioedema. *Clin. Exp. Dermatol*. 2018: 43; 131-136. IF: 1.77 |
| 292. | Ohanyan, T., Schoepke, N., Eirefelt, S., Hoey, G., Koopmann, W., Hawro, T., **Maurer, M.**, and Metz, M.+: Role of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. *Acta Derm. Venereol.* 2018: 98; 26-31. IF: 3.53 |
| 291. | Hawro, T., Ohanyan, T., Schoepke, N., Metz, M., Peveling-Oberhag, A., Staubach, P., **Maurer, M.**, and Weller, K.+: Comparison and interpretability of the available urticaria activity scores. *Allergy* 2018: 73; 251-255*.* IF: 6.77 |
| 290. | Suender, C. A., Leist, M., Abrink, M., Valentin, P., Geldmacher, A., Steinhoff, M., Metz, M., and **Maurer, M.**+: Mast cells are critical for the limitation of thrombin-induced skin inflammation. *Exp. Dermatol.* 2018: 27; 50-57*.* IF: 2.87 |
| 289. | Gianni, P., Loules, G., Zamanakou, M., Kompoti, M., Csuka, D., Psarros, F., Magerl, M., Moldovan, D., **Maurer, M.**, Speletas, M. G., Farkas, H., and Germenis, A. E.+: Genetic determinants of C1 inhibitor deficiency angioedema age of onset. *Int. Arch. Allergy Immunol.* 2017:174; 200-204. IF: 2.44 |
| 288. | Ohanyan, T., Schoepke, N., Bolukbasi, B., Metz, M., Hawro, T., Zuberbier, T., Peveling-Oberhag, A., Staubach, P., **Maurer, M.**, and Weller, K.+: Responsiveness and minimal important difference of the urticaria control test (UCT). *J. Allergy Clin. Immunol*. 2017: 140; 1710-1713. IF: 13.26 |
| 287. | Ertaş, R., Ozyurt, K., Ozlu, E., Ulas, Y., Avci, A., Atasoy, M., Hawro, T., and **Maurer, M.**+: Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. *J. Allergy Clin. Immunol*. 2017: 140; 1749-1751. IF: 13.26 |
| 286. | Irani, C., Hallit, S.+, Weller, K., **Maurer, M.**, El Haber, C., and Salameh, P.: Chronic urticaria in most patients is poorly controlled: Results of the development, validation, and real life application of the Arabic urticaria control test. *Saudi Med. J.* 2017: 38; 179-185. IF: 1.05 |
| 285. | **Maurer, M.**+, Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez-Arnau, A., Grattan, C., Hollis, K., Knulst, A., Lacour, J. P., Lynde, C., Marsland, A., McBride, D., Nakonechna, A., Ortiz de Frutos, J., Proctor, G., Sweeney, C., Tian, H., Weller, K., Wolin, D., and Balp, M. M.: The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. *Allergy* 2017: 72; 2005-2016*.* IF: 6.05 |
| 284. | Stull, D.+, McBride, D., Tian, H., Giménez-Arnau, A., **Maurer, M.**, Marsland, A., Balp, M. M., Khalil, S., and Grattan, C.: Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. *Brit. J. Dermatol*. 2017:177; 1093-1101. IF: 6.13 |
| 283. | Metz, M.+, Schütz, A., Weller, K., Gorczyza, M., Zimmer, S., Staubach, P., Merk, H. F., and **Maurer, M.**: Omalizumab is effective in cold urticaria – results of a randomized, placebo controlled trial. *J. Allergy Clin. Immunol*. 2017: 140; 864-867. IF: 13.26 |
| 282. | **Maurer, M.**+, Schütz, A., Weller, K., Schoepke, N., Peveling-Oberhag, A., Staubach, P., Müller, S., Jakob, T., and Metz, M.: Omalizumab is effective in symptomatic dermographism – results of a randomized, placebo controlled trial. *J. Allergy Clin. Immunol*. 2017: 140; 870-873. IF: 13.26 |
| 281. | Finlay, A. Y.+, Kaplan, A. P., Beck, L. A., Antonova, E. N., Balp, M. M., Zazzali, J., Khalil, S., and **Maurer, M.**: Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. *J. Eur. Acad. Dermatol. Venereol*. 2017:31; 1715-1721. IF: 4.29 |
| 280. | Asady, A., Ruft, J., Ellrich, A., Hawro, T., **Maurer, M.**+, and Altrichter, S.: Cholinergic urticaria patients of different age groups have distinct features. *Clin. Exp. Allergy* 2017: 47; 1609-1614. IF: 5.16 |
| 279. | Aberer, W.+, **Maurer, M.**, Bouillet, L., Zanichelli, A., Caballero, T., Longhurst, H. J., Perrin, A., and Andresen, I.: Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the icatibant outcome survey. *Allerg. Asthma Clin. Immunol*. 2017: 13; 31. IF: 2.05 |
| 278. | Caballero, T.+ Aberer, W., Longhurst, H. J., **Maurer, M.**, Zanichelli, A., Perrin, A., Bouillet, L., and Andresen, I.: The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. *J. Eur. Acad. Dermatol. Venereol*. 2017: 31; 1214-1222. IF: 4.29 |
| 277. | **Maurer, M.**+, Sofen, H., Ortiz, B., Kianifard, F., Gabriel, S., and Bernstein, J. A.: Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. *J. Eur. Acad. Dermatol. Venereol*. 2017: 31; 1056-1063. IF: 4.29 |
| 276. | Tabeling, C., Herbert, J., Hocke, A. C., Lamb, D., Wollin, L., Erb, K., Boiarina, E., Movassagh, H., Scheffel, J., Doehn, J. M., Hippenstiel, S., **Maurer, M.**, Gounni, A., S., Kuebler, W. M., Suttorp, N., and Witzenrath, M.: Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling. *Allergy* 2017: 72; 1061-1072*.* IF: 6.05 |
| 275. | Meyer, N., Woidacki, K., **Maurer, M.**, and Zenclussen, A. C.: Safeguarding of fetal growth by mast cells and natural killer cells: deficiency of one is counterbalanced by the other. *Front. Immunol.* 2017: 8; 711. IF: 5.51 |
| 274. | **Maurer, M.**\*, Staubach, P.\*, Raap, U.\*, Richter-Huhn, G.\*, Bauer, A., Ruëff, F., Jakob, T., Yazdi, A. S., Mahler, V., Wagner, N., Lippert, U., Hillen, U., Schwinn, A., Pawlak, M., Behnke, N., Chaouche, K., and Chapman-Rothe, N.: H1-antihistamine-refractory chronic spontaneous urticaria: It’s worse than we thought – first results of the multicenter real-life AWARE study. *Clin. Exp. Allergy* 2017: 47; 684-692. IF: 5.16 |
| 273. | Zanichelli, A., **Maurer, M.**, Aberer, W., Caballero, T., Longhurst, H., Bouillet, L., Fabien, V., and Andresen, I.: Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice. *Allergy* 2017: 72; 994-998*.* IF: 6.05 |
| 272. | Garbani, M., Xia, W., Rhyner, C., Prati, M., Scheynius, A., Malissen, B., Engqvist, H., **Maurer, M.**, Crameri, R., and Terhorst, D.: Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific immunotherapy in mice. *Allergy* 2017: 72; 570-578*.* IF: 6.05 |
| 271. | Krause, K., Tsianakas, A., Wagner, N., Fischer, J., Weller, K., Metz, M., Church, M. K., and **Maurer, M.**: Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. *J. Allergy Clin. Immunol*. 2017: 139; 1311-1320. IF: 13.26 |
| 270. | Cherrez, A., **Maurer, M.**, Weller, K., Calderon, J. C., Simancas-Racines, D., and Cherrez-Ojeda, I.+: Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. *World Allergy Organ. J.* 2017: 10; 21. IF: 5.68 |
| 269. | Metz, M., Staubach, P., Bauer, A., Brehler, R., Gericke, J., Kangas, M., Ashton-Chess, J., Jarvis, P., Georgiou, P., Canvin, J., Hillenbrand, R., Erpenbeck, V. J., and **Maurer, M.**+: Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. *Theranostics* 2017: 7; 1266-1276. IF: 8.54 |
| 268. | Hawro, M., **Maurer, M.**, Weller, K., Maleszka, R., Zalewska-Janowska, A., Kaszuba, A., Gerlicz-Kowalczuk, Z., and Hawro, T.+: Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. *J. Am. Acad. Dermatol*. 2017: 76; 648-654*.* IF: 6.90 |
| 267. | Leist, M., Sünder, C. A., Drube, S., Zimmermann, C., Geldmacher, A., Metz, M., Dudeck, A., and **Maurer, M.**+: Membrane-bound stem cell factor is the major but not only driver of fibroblast-induced murine skin mast cell differentiation. *Exp. Dermatol.* 2017: 26; 255-262*.* IF: 2.61 |
| 266. | Gericke, J.\*, Metz, M.\*, Ohanyan, T., Weller, K., Altrichter, S., Stahl Skov, P., Falkencrone, S., Brand, J., Kromminga, A., Hawro, T., Church, M. K., and **Maurer, M.**+: Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. *J. Allergy Clin. Immunol*. 2017: 139; 1059-1061. IF: 13.26 |
| 265. | Weller, K.+, **Maurer, M.**, Fridman, M., Supina, D., Schranz, J., and Magerl, M.: Health-related quality of life in hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. *Allergy Asthma Proc*. 2017: 38; 143-151*.* IF: 2.21 |
| 264. | Gorczyza, M., Schoepke, N., Krause, K., Hawro, T., and **Maurer, M.**+: Patients with chronic cold urticaria may benefit from doxycycline therapy. *Brit. J. Dermatol*. 2017:176; 259-261. IF: 6.13 |
| 263. | Longhurst, H. J.+, Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., **Maurer, M.**, Fain, O., Fabien, V., and Andresen, I.: Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey. *Clin. Exp. Immunol*. 2017: 188; 148-153. IF: 3.54 |
| 262. | Weller, K.+, Magerl, M., Peveling-Oberhag, A., Martus, P., Staubach, P., and **Maurer, M.**: The angioedema quality of life questionnaire (AE-QoL) – assessment of sensitivity to change and minimal clinically important difference. *Allergy* 2016: 71; 1203-1209*.* IF: 7.36 |
| 261. | Staubach, P., Metz, M., Chapman-Rothe, N., Sieder, C., Bräutigam, M., Canvin, J., and **Maurer, M.**+: Effect of omalizumab on angioedema in H1-antihistamine resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. *Allergy* 2016: 71; 1135-1144*.* IF: 7.36 |
| 260. | Altrichter, S., Koch, K., Church, M. K., and **Maurer, M.**+: Atopic predisposition in cholinergic urticaria patients and its implications. *J. Eur. Acad. Dermatol. Venereol*. 2016: 30; 2060-2065. IF: 3.52 |
| 259. | Hawro, T., Lehmann, S., Altrichter, S., Fluhr, J. W., Zuberbier, T., Church, M. K., **Maurer, M.**, and Metz, M.+: Skin provocation tests may help to diagnose atopic dermatitis. *Allergy* 2016: 71; 1745-1752*.* IF: 7.36 |
| 258. | **Maurer, M.**, Metz, M., Bindslev-Jensen, C., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E., Hide, M., Kocatürk, E., Magerl, M., Makris, M., Meshkova, R., Saini, S. S., Sussman, G., Toubi, E., Zhao, Z., Zuberbier, T.+, and Gimenez-Arnau, A.: Definition, aims, and implementation of GA²LEN urticaria centers of reference and excellence. *Allergy* 2016: 71; 1210-1218*.* IF: 7.36 |
| 257. | Caballero, T.+, **Maurer, M.**, Longhurst, H. J., Aberer, W., Bouillet, L., and Fabien, V.: Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. *J. Invest. Allerg. Clin. Immunol*. 2016: 26; 383-386*.* IF: 3.09 |
| 256. | Azar, R. P.+, Thomas, A. H., **Maurer, M.**, and Lindner, G.: Asymmetry of the receding hairline in men with early androgenetic alopecia. *J. Cutan. Med. Surg.* 2016: 20; 546-549. IF: 0.89 |
| 255. | Harris, J. M.+, Cabanski, C. R., Scheerens, H., Samineni, D., Bradley, M. S., Cochran, C., Staubach, P., Metz, M., Sussman, G., and **Maurer, M.**: A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. *J. Allergy Clin. Immunol*. 2016: 138; 1730-1732. IF: 13.08 |
| 254. | Gimenez-Rivera, V. A.\*, Siebenhaar, F.\*, Zimmermann, C., Siiskonen, H., Metz, M., and **Maurer, M.**+: Mast cells limit the exacerbation of chronic allergic contact dermatitis in response to repeated allergen exposure. *J. Immunol*. 2016: 197; 4240-4246*.* IF: 4.85 |
| 253. | Riedl, M. A.+, Lumry, W. R., Li, H., Banerji, A., Bernstein, J. A., Bas, M., Björkander, J., Magerl, M., **Maurer, M.**, Rockich, K., Chen, H., and Schranz, J.: Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. *Allergy Asthma Proc*. 2016: 37; 489-500*.* IF: 2.61 |
| 252. | Krull, C., Schoepke, N., Ohanyan, T., Brachaczek, M., **Maurer, M.**, Lange-Asschenfeldt, B.\*, and Metz, M.\*+: Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients. *J. Eur. Acad. Dermatol. Venereol*. 2016: 30; 1357-1361. IF: 3.52 |
| 251. | Netchiporouk, E., Moreau, L., Rahme, E., **Maurer, M.**, Lejtenyi, D., and Ben-Shoshan, M.+: Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity. *Int. Arch. Allergy Immunol*. 2016: 171; 81-88. IF: 2.72 |
| 250. | Koch, K., Weller, K., Werner, A., **Maurer, M.**+, and Altrichter, S.: Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. *J. Allergy Clin. Immunol*. 2016: 138; 1483-1485. IF: 13.08 |
| 249. | Kessel, A.+, Graif, Y., Vadasz, Z., Schichter-Konfino, V., Almog, M., Cohen, S., Teplitski, V., Stein, N., Baiardini, I. **Maurer, M.**, and Toubi, E.: Adaption and validation of the Israeli version of the chronic urticaria quality of life questionnaire (CU-Q2oL). *IMAJ* 2016: 18; 461-465. IF: 1.03 |
| 248. | Ständer, S.+, Metz, M., Ramos, M. H., **Maurer, M.**, Schoepke, N., Tsianakas, A., Zeidler, C., and Luger, T. A.: Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability. *Acta Derm. Venereol.* 2016: 96; 792-796*.* IF: 3.65 |
| 247. | Azar, R. P.+, Thomas, A. H., **Maurer, M.**, and Lindner, G.: Alterations in hair follicle morphology and hair shaft production after follicular unit transplantation. *Am. J. Dermatopathol.* 2016: 38; 732-738*.* IF: 1.09 |
| 246. | Aygören-Pürsün, E.\*, Magerl, M.\*, Graff, J., Martinez-Saguer, I., Kreuz, W., Longhurst, H., Nasr, I., Bas, M., Straßen, U., Fang, L., Cornprobst M.; Dobo, S., Collis, P., Sheridan, W. P., and **Maurer, M.**+: Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. *J. Allergy Clin. Immunol*. 2016: 138; 934-936. IF: 13.08 |
| 245. | Zazzali, J. L., Kaplan, A., **Maurer, M.**, Raimundo, K., Trzaskoma, B., Solari, P. G., Antonova, E.+, Mendelson, M., and Rosén, K.: Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. *Ann. Allergy Asthma Immunol.* 2016: 117; 370-377*.* IF: 3.72Zazzali, J. L., Kaplan, A., **Maurer, M.**, Raimundo, K., Trzaskoma, B., Antonova, E.+ N., and Rosén, K. E.: Comment on “Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria”. *Ann. Allergy Asthma Immunol.* 2017: 118; 524-526 |
| 244. | Zanichelli, A.+, Longhurst, H. J., **Maurer, M.**, Bouillet, L., Aberer, W., Fabien, V., Andresen, I., and Caballero, T.: Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. *Ann. Allergy Asthma Immunol.* 2016: 117; 394-398*.* IF: 3.72 |
| 243. | Siebenhaar, F., Melde, A., Magerl, M., Zuberbier, T., Church, M. K.+, and **Maurer, M.**: Histamine intolerance in patients with chronic spontaneous urticaria. *J. Eur. Acad. Dermatol. Venereol*. 2016: 30; 1774-1777. IF: 3.52 |
| 242. | Zhao, Z.\*, Ji, C.\*, Yu, W.\*, Meng, L., Hawro, T., Wei, J. F.+, and **Maurer, M.**: Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. *J. Allergy Clin. Immunol*. 2016: 137; 1742-1750. IF: 13.08 |
| 241. | Magerl, M., Altrichter, S., Borzova, E., Giménez-Arnau, A., Grattan, C. E. H., Lawlor, F., Mathelier-Fusade, P., Meshkova, R. Y., Zuberbier, T., Metz, M., and **Maurer, M.**+: The definition, diagnostic testing and management of chronic inducible urticarias –The EAACI/GA²LEN/EDF/UNEV 2016 consensus panel recommendations 2016 update and revision. *Allergy* 2016: 71; 780-802*.* IF: 7.36 |
| 240. | Siebenhaar, F.+, von Tschirnhaus, E., Hartmann, K., Rabenhorst, A., Staubach, P., Peveling-Oberhag, A., Wagner, N., Martus, P., Carter, M. C., Metcalfe, D. D., Church, M. K., **Maurer, M.**, and Weller, K.: Development and Validation of the Mastocytosis Quality of Life questionnaire: MC-QoL. *Allergy* 2016: 71; 869-877*.* IF: 7.36 |
| 239. | **Maurer, M.**+, Staubach, P., Raap, U., Richter-Huhn, G., Baier-Ebert, M., and Chapman-Rothe, N.: ATTENTUS, a German survey of chronic urticaria patients highlightening the burden of disease, unmet needs and real-life clinical practice. *Brit. J. Dermatol*. 2016: 174; 892-894. IF: 4.70 |
| 238. | Weller, K., Krüger, R., **Maurer, M.**, and Magerl, M.+: Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angioedema. *Clin. Exp. Dermatol.* 2016: 41; 91-93*.* IF: 1.58 |
| 237. | Altrichter, S., Hawro, T., Hänel, K., Czaja, K., Lüscher, B., **Maurer, M.**, Church, M. K.+, and Baron, J. M.: Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. *J. Eur. Acad. Dermatol. Venereol*. 2016: 30; 454-455. IF: 3.52 |
| 236. | Vadasz, Z., Kessel, A., Hershko, A. Y., **Maurer, M.**, and Toubi, E.+: Seasonal exacerbation of asthma is frequently associated with recurrent episodes of acute urticaria. *Int. Arch. Allergy Immunol*. 2016: 169; 263-266. IF: 2.72 |
| 235. | Inami, A., Matsuda, R., Grobosch, T., Komamura, H., Takeda, K., Yamada, Y., Miyake, M., Hiraoka, K., **Maurer, M.**, Yanai, K., and Tashiro, M.+: A simulated car-driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers. *Hum. Psychopharmacol. Clin. Exp.* 2016: 31; 167-177. IF: 2.21 |
| 234. | Longhurst, H. J.+, Aberer, W., Bouillet, L., Caballero, T., **Maurer, M.**, Fabien, V., Zanichelli, A.: The icatibant outcome survey: treatment of laryngeal angioedema attacks. *Eur. J. Emerg. Med.* 2016: 23; 224-227. IF: 2.02 |
| 233. | Kulthanan, K., Chularojanamontri, L.+, Tuchinda, P., Rujitharanawong, C., **Maurer, M.**, and Weller, K.: Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). *Health Qual. Life Outcomes* 2016: 14; 61-70*.* IF: 2.14 |
| 232. | Abajian, M., Curto-Barredo, L., Krause, K., Santamaria, E., Izquierdo, I., Church, M. K., **Maurer, M.**, and Giménez-Arnau, A.+: Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. *Acta Derm. Venereol.* 2016: 96; 56-59*.* IF: 3.65 |
| 231. | Potter, P., Mitha, E., Barkai, L., Gyorgyl, M., Santamaria, E., Izquierdo, I.+, and **Maurer, M.**: Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. *Pediatr. Allergy Immunol.* 2016: 27; 55-61*.* IF: 3.77 |
| 230. | Hartmann, K.+, Escribano, L., Grattan, C., Brockow, K., Carter, M. C., Alvarez-Twose, I., Matito, A., Broesby-Olsen, S., Siebenhaar, F., Lange, M., Niedoszytko, M., Castells, M., Oude Elberink, J. N. G., Bonadonna, P., Zanotti, R., Hornick, J. L., Torrelo, A., Grabbe, J., Rabenhorst, A., Nedoszytko, B., Butterfield, J. H., Gotlib, J., Reiter, A., Radia, D., Hermine, O., Sotlar, K., George, T. I., Kristensen, T. K., Kluin-Nelemans, H. C., Yavuz, S., Hägglung, H., Sperr, W. R., Schwartz, L. B., Triggiani, M., **Maurer, M.**, Nilsson, G., Horny, H. P., Arock, M., Orfao, A., Metcalfe, D. D., Akin, C., and Valent, P.: Cutaneous manifestations in mastocytosis: consensus report of the European Competence Network on Mastocytosis (ECNM), AAAAI and EAACI. *J. Allergy Clin. Immunol*. 2016: 137; p35-45*.* IF: 13.08 |
| 229. | Metz, M., Weller, K., Neumeister, C., Izquierdo, I., Bödeker, R. H., Schwantes, U.+, and **Maurer, M.**: Rupatadine in established treatment schemes improves chronic spontaneous urticaria symptoms and patients’ quality of life: a prospective, non-interventional trial. *Dermatol. Ther.* 2015: 5; 217-230*.* IF: 1.26 |
| 228. | Gericke, J., Ohanyan, T., Church, M. K., **Maurer, M.**+, and Metz, M.: Omalizumab may not inhibit mast cell and basophil activation in vitro. *J. Eur. Acad. Dermatol. Venereol.* 2015: 29; 1832-1836. IF: 2.82 |
| 227. | Hawro, T., Bogucki, A., Krupińska-Kun, M., **Maurer, M.**\*+, and Woźniacka, A.\*: Serum neuron specific enolase – a novel indicator for neuropsychiatric systemic lupus erythematosus? *Lupus* 2015: 24; 1492-1497*.* IF: 2.11 |
| 226. | Garcia-Diez, I.+, Curto-Barredo, L., Weller, K., Pujol, R. M., **Maurer, M.**, and Giménez-Arnau, A. M.: Cross-cultural adaption of the urticaria control test from German to Castilian Spanish. *Actas Dermosifiliogr*. 2015: 106; 746-752*.* IF: N/A |
| 225. | Speletas, M., Szilagyi, A., Csuka, D., Koutsostathis, N., Psarros, F., Moldovan, D., Magerl, M., Kompoti, M., Varga, L., **Maurer, M.**, Farkas, H., and Germenis, A. E.+: F12-46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema. *Allergy* 2015: 70; 1661-1664*.* IF: 6.33 |
| 224. | Altrichter, S., Wosny, K., and **Maurer, M.**+: Successful treatment of cholinergic urticaria with methantheliniumbromide. *J. Dermatol*. 2015: 42; 422-4249. IF: 1.57 |
| 223. | Kay, A. B.+, Clark, P., **Maurer, M.**, and Ying, S.: Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (“idiopathic”) urticaria. *Brit. J. Dermatol*. 2015: 172; 1294-1302. IF: 4.31 |
| 222. | Schubert, N., Dudeck, J., Liu, P., Karutz, A., Speier, S., **Maurer, M.**, Tuckermann, J., and Dudeck, A.+: Mast cell promotion of T cell-driven antigen-induced arthritis despite being dispensable for antibody-induced arthritis in which T cells are bypassed. *Arthritis Rheumatol*. 2015: 67; 903-913. IF: 6.00 |
| 221. | Craig, T., Aygören Pürsün, E. A., Bork, K., Bowen, T., Boysen, H., Farkas, H., Grumach, A. S., Katelaris, C. H., Lockey, R., Longhurst, H., Lumry, W., Magerl, M., Martinez-Saguer, I., Ritchie, B., Nast, A., Pawankar, R., Zuraw, B. L., and **Maurer, M.**+: WAO Guideline for the management of hereditary angioedema. *Arerugi* 2015: 64; 1215-1241*.* IF: N/A |
| 220. | Woidacki, K. \*, Meyer, N. \*, Schumacher, A., Goldschmidt, A., **Maurer, M.**, and Zenclussen, A. C.+: Transfer of regulatory T cells into abortion-prone mice promotes the expansion of uterine mast cells and normalizes early pregnancy angiogenesis. *Sci. Rep.* 2015: 5-13938IF: 5.22 |
| 219. | Weller, K.+, **Maurer, M.**, Grattan, C., Nakonechna, A., Abuzakouk, M., Bérard, F., Sussman, G., Giménez-Arnau, A. M., Ortiz de Frutos, J., Knulst, A., Canonica, G. W., Hollis, K., McBride, D., and Balp, M. M.: ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. *Clin. Transl. Allergy* 2015: 5; 29. IF N/A |
| 218. | Serra-Pages, M.\*, Torres, R.\*, Plaza, J., Herrerias, A., Costa-Farré, C., Jiménez, M., **Maurer, M.**, Picado, C., and de Mora, F.+: Activation of the prostaglandin E2 receptor EP2 prevents house dust mite-induced airway hyperresponsiveness and inflammation by restraining mast cells activity. *Clin. Exp. Allergy* 2015: 45; 1590-1600*.* IF: 5.58 |
| 217. | Netchiporouk, E., Nguyen, C. H., Thuraisingham, T., Jafarian, F., **Maurer, M.**, and Ben-Shoshan, M.+: Management of pediatric chronic spontaneous and physical urticaria patients with Omalizumab: case series. *Pediatr. Allergy Immunol*. 2015: 26; 585-588*.* IF: 3.94 |
| 216. | Bonner, N.+, Abetz-Webb, L., Renault, L., Caballero, T., Longhurst, H., **Maurer, M.**, Christiansen, S., and Zuraw, B.: Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies. *Health Qual. Life Outcomes* 2015: 13; 92. IF: 2.21 |
| 215. | Bousquet, J.+, Schunemann, H. J., Fonseca, J., Samolinski, B., Bachert, C., Canonica, G. W., Casale, T., Cruz, A. A., Demoly, P., Hellings, P., Valiulis, A., Wickman, M., Zuberbier, T., Bosnic-Anticevitch, S., Bedbrook, A., Bergmann, K. C., Caimmi, D., Dahl, R., Fokkens, W. J., Grisle, I., Lodrup Carlsen, K., Mullol, J., Muraro, A., Palkonen, S., Papadopoulos, N., Passalacqua, G., Ryan, D., Valovirta, E., Yorgancioglu, A., Aberer, W., Agache, I., Adachi, M., Akdis, C. A., Akdis, M., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielle, S., Arshad, H., Baiardini, I., Baigenzhin, A. K., Barbara, C., Bateman, E. D., Beghé, B., Bel, E. H., Ben Kheder, A., Bennoor, K. S., Benson, M., Bewick, M., Bieber, T., Bindslev-Jensen, C., Bjermer, L., Blain, H., Boner, A. L., Boulet, L. P., Bonini, M., Bonini, S., Bosse, I., Bourret, R., Bousquet, P. J., Braido, F., Briggs, A. H., Brightling, C. E., Brozek, J., Buhl, R., Burney, P. G., Bush, A., Caballero-Fonseca, F., Calderon, M. A., Camargos, P., Camuzat, T., Carlsen, K. H., Carr, W., Cepeda Sarabia, A. M., Chavannes, N. H., Chatzi, L., Chen, Y. Z., Chiron, R., Chkhartishvili, E., Chuchalin, A. G., Ciprandi, G., Cirule, I., Correia de Sousa, J., Cox, L., Crooks, G., Costa, D. J., Custovic, A., Dahlen, S. E., Darsow, U., De Carlo, G., De Blay, F., Dedeu, T., Deleanu, D., Denburg, J. A., Devillier, P., Didier, A., Dinh-Xuan, A. T., Dokic, D., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Dykewicz, M. S., El-Gamal, Y., Emuzyte, R., Fink Wagner, A., Fletcher, M., Fiocchi, A., Forastiere, F., Gamkrelidze, A., Gemicioğlu, B., Gereda, J. E., González Diaz, S., Gotua, M., Grouse, L., Guzmán, M. A., Haahtela, T., Hellquist-Dahl, B., Heinrich, J., Horak, F., Hourihane, J., Howarth, P., Humbert, M., Hyland, M. E., Ivancevich, J. C., Jares, E. J., Johnston, S. L., Joos, G., Jonquet, O., Jung, K. S., Just, J., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Keil, T., Keith, P. K., Khaltaev, N., Klimek, L., N'Goran, B. K., Kolek, V., Koppelman, G. H., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Lambrecht, B., Lau, S., Larenas-Linnemann, D., Laune, D., Le, L., Lieberman, P., Lipworth, B., Li, J., Louis, R., Magard, Y., Magnan, A., Mahboub, B., Majer, I., Makela, M. J., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., **Maurer, M.**, Mavale-Manuel, S., Melén, E., Melo-Gomes, E., Meltzer, E. O., Merk, H., Miculinic, N., Mihaltan, F., Milenkovic, B., Mohammad, Y., Molimard, M., Momas, I., Montilla-Santana, A., Morais-Almeida, M., Mösges, R., Namazova-Baranova, L., Naclerio, R., Neou, A., Neffen, H., Nekam, K., Niggemann, B., Nyembue, T. D., O'Hehir, R. E., Ohta, K., Okamoto, Y., Okubo, K., Ouedraogo, S., Paggiaro, P., Pali-Schöll, I., Palmer, S., Panzner, P., Papi, A., Park, H. S., Pavord, I., Pawankar, R., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Postma, D., Potter, P., Price, D., Rabe, K. F., Raciborski, F., Radier, Pontal, F., Repka-Ramirez, S., Robalo-Cordeiro, C., Rolland, C., Rosado-Pinto, J., Reitamo, S., Rodenas, F., Roman Rodriguez, M., Romano, A., Rosario, N., Rosenwasser, L., Rottem, M., Sánchez-Borges, M., Scadding, G. K., Serrano, E., Schmid-Grendelmeier, P., Sheikh, A., Simons, F., Sisul, J. C., Skrindo, I., Smit, H. A., Solé, D., Sooronbaev, T., Spranger, O., Stelmach, R., Strandberg, T., Sunyer, J., Thijs, C., Todo-Bom, A., Triggiani, M., Valenta, R., Valero, A. L., van Hage, M., Vandenplas, O., Vezzani, G., Vichyanond, P., Viegi, G., Wagenmann, M., Walker, S., Wang, D. Y., Wahn, U., Williams, D.M., Wright, J., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zar, H. J., Zernotti, M. E., Zhang, L., Zhong, N., Zidarn, M., and Mercier, J.: MACVIA-ARIA sentinel network for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation. *Allergy* 2015: 11; 1372-1392*.* IF: 6.33 |
| 214. | Longhurst, H.+, Aberer, W., Bouillet, L., Caballero, T., Fabien, V., Zanichelli, A., and **Maurer, M.**: Analysis of characteristics associated with reinjection of icatibant: results from the icatibant outcome survey. *Allergy Asthma Proc.* 2015: 36; 399-406. IF: 2.70 |
| 213. | **Maurer, M.**, Church, M. K.+, Metz, M., Starkhammar, M., Hamsten, C., and van Hage, M.: Galactose-α-1,3-galactose allergy is not a hitherto unrecognized cause of chronic spontaneous urticaria. *Int. Arch. Allergy Immunol.* 2015: 167; 250-252. IF: 2.67 |
| 212. | Hernández Fernández de Rojas, D.+, Ibáňez, E., Longhurst, H., **Maurer, M.**, Fabien, V., Aberer, W., Bouillet, L., Zanichelli, A., and Caballero, T.: Treatment of HAE attacks in the icatibant outcome survey: an analysis of icatibant self-administration versus administration by health care professionals. *Int. Arch. Allergy Immunol.* 2015: 167; 21-28. IF: 2.67 |
| 211. | Casale, T. B., Bernstein, J. A., **Maurer, M.**, Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.+: Similar efficacy with Omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. *J. Allergy Clin. Immunol. Pract.* 2015: 3; 743-750. IF: 5.42 |
| 210. | Schoepke, N., Młynek, A., Weller, K., Church, M. K.+, and **Maurer, M.**: Symptomatic dermographism: an inadequately described disease. *J. Eur. Acad. Dermatol. Venereol.* 2015: 29; 708-712. IF: 2.82 |
| 209. | Termeer, C., Staubach, P., Kurzen, H., Strömer, K., Ostendorf, R., and **Maurer, M.**+: Chronic spontaneous urticaria – a management pathway for patients with chronic spontaneous urticaria. *J. Dtsch. Dermatol. Ges*. 2015: 13; 419-428. IF: 2.51 |
| 208. | Hawro, T., Bogucki, A., Krupińska-Kun, M., **Maurer, M.**+, and Woźniacka, A.\*: Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. *PLoS ONE* 2015: 10; e0119911. IF: 3.05 |
| 207. | Ngouateu, O. B., Weller, K., Bröhl, K., Kamtchouing, P., Same-Ekobo, A., Dondji, B.\*, **Maurer, M.**\*, and Stebut, E.\*+: Impaired T cell-dependent protection against Leishmania major infection in HIV-positive patients is associated with worsened disease outcome. *Exp. Dermatol.* 2015: 24; 302-304. IF: 2.67 |
| 206. | Hawro, T., Zalewska, A., Hawro, M., Kaszuba, A., Królikowska, M., and **Maurer M.**+: Impact of psoriasis severity on family income and quality of life. *J. Eur. Acad. Dermatol. Venereol.* 2015: 29; 438-443. IF: TBD 2.82 |
| 205. | Speletas, M., Szilagyi, A., Psarros, F., Moldovan, D., Magerl, M., Kompoti, M., Gramoustianou, E., Bors, A., Mihaly, E., Tordai, A., Avramouli, A., Varga, L., **Maurer, M.**, Farkas, H., and Germenis, A. E.+: Hereditary angioedema: Molecular and clinical differences among European populations. *J. Allergy Clin. Immunol*. 2015: 135; 570-573. IF: 12.48 |
| 204. | Saini, S. S., Bindslev-Jensen, C., **Maurer, M.**, Grob, J.-J., Baskan, E. B., Bradley, M. S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., Spector, S., and Rosén, K.+: Efficacy and safety of Omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: A randomized, placebo-controlled study. *J. Invest. Dermatol.* 2015: 135; 67-75. IF: 6.91 |
| 203. | Lengweiler, S.\*, Kreim, S.\*, Barman-Aksozen, J., **Maurer, M.**, and Minder, E.+: Evaluation of the immunogenicity of the α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle 4-D-Phe 7] - α-MSH, scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies. *Skin Pharmacol. Physiol*. 2015: 28; 103-113. IF: 2.48 |
| 202. | Schmetzer, O.+, Valentin, P., Smorodchenko, A., Domenis, R., Gri, G., Siebenhaar, F., Metz, M., and **Maurer, M.**: A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs). *J. Immunol. Methods* 2014: 413; 62-68. IF: 2014: 1.82 |
| 201. | Hawro, T., Saluja, R., Weller, K., Altrichter, S., Metz, M.\*, and **Maurer, M.**\*+: Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. *Allergy* 2014: 69; 113-117. IF: 6.03 |
| 200. | Kay, A. B.+, Ying, S., Ardelean, E., Mlynek, A., Kita, H., Clark, P., and **Maurer, M.**: Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low level persistence in uninvolved skin. *Brit. J. Dermatol*. 2014: 171; 505-511. IF: 4.27 |
| 199. | Valent, P.+, Escribano, L., Broesby-Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N., Kristensen, T., Butterfield, J. H., Triggiani, M., Alvarez-Twose, I., Reiter, A., Sperr, W. R., Sotlar, K., Yavuz, S., Kluin-Nelemans, H. C., Hermine, O., Radia, D., Gotlib, J., Orfao, A., Siebenhaar, F., Schwartz, L. B., Castells, M., **Maurer, M.**, Horny, H.-P., Akin, C., Metcalfe, D. D., and Arock, M.: Proposed diagnostic algorithm for patients with suspected mastocytosis: A proposal of the European Competence Network on Mastocytosis (ECNM). *Allergy* 2014: 69; 1267-1274. IF: 6.03 |
| 198. | Metz, M.+, Krull, C., Hawro, T., Saluja, R., Groffik, A., Stanger, C., Staubach, P., and **Maurer, M.**: Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. *J. Invest. Dermatol*. 2014: 134; 2833-2836. IF: 7.22 |
| 197. | Rogala, B., Bozek, A.+, Glück, J., Rymarczyk, B., Jarzab, J., and **Maurer, M.**: Coexistence of angioedema alone with impaired glucose tolerance. *Int. Arch. Allergy Immunol.* 2014: 165; 265-269. IF: 2.67 |
| 196. | Saluja, R.+, Hawro, T., Eberle, J., Church, M. K., and **Maurer M.**: Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit independent pathways. *Int. J. Immunopathol. Pharmacol*. 2014: 28; 575-585. IF: 1.62 |
| 195. | Hawro, T., Fluhr, J. W., Mengeaud, V., Redoulès, D., Church, M. K., **Maurer, M.**, and Metz, M.+: Polidocanol inhibits cowhage - but not histamine-induced itch in humans. *Exp. Dermatol.* 2014: 23; 922-941. IF: 3.76 |
| 194. | Hiraoka, K., Tashiro, M., Grobosch, T., **Maurer, M.**, Oda, K., Toyohara, J., Ishii, K., Ishiwata, K., and Yanai, K.+: Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. *Expert Opin. Drug. Saf.* 2014: 14; 1-8. IF: 2.91 |
| 193. | Siebenhaar, F.+, Metz, M., and **Maurer, M.**: Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a Kit-dependent mouse model. *Exp. Dermatol.* 2014: 23; 159-164. IF: 3.76 |
| 192. | Darlenski, R., Kazandjieva, J., Fluhr, J. W.+, **Maurer, M.**, and Tsankov, N.: Lactic acid sting test does not differentiate between facial and generalized skin functional impairment in sensitive skin in atopic dermatitis and rosacea. *J. Dermatol. Sci.* 2014: 76; 151-153*.* IF: 3.42 |
| 191. | Hawro, T., **Maurer M.**+, Hawro, M., Kaszuba, A., Cierpiałkowska, L., Królikowska, M., and Zalewska, A.: In psoriasis, levels of hope and quality of life are linked. *Arch. Dermatol. Res.* 2014: 306; 661-666. IF: 1.90Hawro, T., Hawro, M., Zalewska, A., and **Maurer, M.**+: Reply to the letter to the editor on: “In psoriasis, levels of hope and quality of life are linked”. *Arch. Dermatol. Res.* 2016: 308; 457-458 |
| 190. | **Maurer, M.**+, Longhurst, H. J.,Fabien, V.,Li, H. H., and Lumry, W. R.: Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world setting. *Allergy Asthma Proc*. 2014: 35; 377-381. IF: 3.06 |
| 189. | Prepageran, N.+, Wang, D. Y., Nair, G., and **Maurer, M.**: The status quo and unmet needs in the management of allergic rhinitis and chronic rhinosinusitis: a Malaysian perspective. *Asia Pac. Allergy* 2014: 4; 142-148. IF: N/A |
| 188. | Kay, A. B.+, Ying, S., Ardelean, E., Młynek, A., Kita, H., Clark, P., and **Maurer, M.**: Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. *Clin. Exp. Allergy* 2014: 44; 1053-1060. IF: 4.77 |
| 187. | Weller, K., Groffik, A., Church, M. K., Hawro, T., Krause, K., Metz, M., Martus, P., Casale, T., Staubach, P., and **Maurer, M.**+: Development and validation of the urticaria control test – a patient reported outcome instrument for assessing urticaria control. *J. Allergy Clin. Immunol*. 2014: 133; 1365-1372. IF: 11.47 |
| 186. | Altrichter, S., Salow, J., Ardelean, E., Church, M. K.+, Werner, A.\*, and **Maurer, M.**\*: Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. *J. Dermatol. Sci.* 2014: 75; 88-93*.* IF: 3.42 |
| 185. | Zuberbier, T.+, Aberer, W., Asero, R., Bindslev-Jensen, C. Brzoza, Z., Canonica, G. W., Church, M. K., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Abdul Latiff, A. H., Mathelier-Fusade, P., Metz, M., Saini, S. S., Sánchez-Borges, M., Schmid-Grendelmeier P., Simons, F. E., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Wedi, B., Zhu, X. J., Nast, A.\*, and **Maurer, M.\***: [Methods report on the development of the 2013 revision and update of the EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria.](http://www.ncbi.nlm.nih.gov/pubmed/24898678) *Allergy* 2014: 69; e1-e29. IF: 6.03 |
| 184. | Zuberbier, T.+, Aberer, W., Asero, R., Bindslev-Jensen, C., Brzoza, Z., Canonica, G. W., Church, M. K., Ensina, L. F., Giménez-Arnau, A., Godse, K., Goncalo, M., Grattan, C., Hebert, J., Hide, M., Kaplan, A., Kapp, A., Abdul Latiff, A. H., Mathelier-Fusade, P., Metz, M., Nast, A., Saini, S. S., Sánches-Borges, M., Schmidt-Grendelmeier, P., Simons, F. E. R., Staubach, P., Sussman, G., Toubi, E., Vena, G. A., Wedi, B., Zhu, X. J., and **Maurer, M.**: The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update. *Allergy* 2014: 69; 868-887. IF: 6.03 |
| 183. | Metz, M., Ohanyan, T., Church, M. K., and **Maurer, M.**+: Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. *JAMA Derm*. 2014:150; 288-290. IF: 4.43 |
| 182. | Magerl, M.+, Doumoulakis, G., Kalkounou, I., Weller, K., Church, M. K., Kreuz, W., and **Maurer, M.**: Characterization of prodromal symptoms in a large population of patients with hereditary angioedema. *Clin. Exp. Dermatol.* 2014: 39; 298-303. IF: 1.09 |
| 181. | Vieira dos Santos, R., Locks Bidese, B., Rabello de Souza, J., and **Maurer, M.**+: Effects of omalizumab in a patient with three types of chronic urticaria. *Brit. J. Dermatol*. 2014: 170; 469-471. IF: 4.27 |
| 180. | Metz, M., Ohanyan, T., Church, M. K.+, and **Maurer, M.**: Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. *J. Dermatol. Sci.* 2014: 73; 57-62*.* IF: 3.42 |
| 179. | Aberer, W.+, **Maurer, M.**, Reshef, A., Longhurst, H., Kivity, S., Bygum, A., Caballero, T., Bloom, B., Nair, N., and Malbrán, A.: Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. *Allergy* 2014: 69; 305-314. IF: 6.03 |
| 178. | Vukman, K. V., Adams, P., N., Dowling, D., Metz, M., **Maurer, M.**, and O’Neill, S. M.+: The effects of *Fasciola hepatica* tegumental antigens on mast cell function. *Int. J. Parasitol.* 2013: 43; 531-539. IF: 3.64 |
| 177. | Ale, A.\*, Siebenhaar, F.\*, Kosanke, K., Aichler, M., Radrich, K., Heydrich, S., Schiemann, M., Bielicki, I., Noel, P. B., Braren, R., **Maurer, M.**, Walch, A. K., Rummeny, E. J., Nztiachristos, V., and Wildgruber, M.+: Cardioprotective C-kit+ bone marrow cells attenuate apoptosis after acute myocardial infarction in mice – *in vivo* assessment with fluorescence molecular imaging. *Theranostics* 2013: 3; 903-913. IF: 7.83 |
| 176. | Weller, K., Koti, I., Makris, M., and **Maurer, M.**+: Anxiety and depression seem less common in patients with autoreactive chronic spontaneous urticaria. *Clin. Exp. Dermatol.* 2013: 38; 870-873. IF: 1.23 |
| 175. | Nelissen, S.\*, Vangansewinkel, T.\*, Geurts, N., Geboes, L., Lemmens, E., Vidal, P. M., Lemmens, S., Willems, L., Boato, F., Dooley, D., Pehl, D., Pejler, G., **Maurer, M.**, Metz, M., and Hendrix, S.+: Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. *Neurobiol. Dis.* 2013: 62C; 260-272*.* IF: 5.20 |
| 174. | Magerl, M., Rother, M., Bieber, T., Biedermann, T., Brasch, J., Dominicus, R., Hunzelmann, N., Jakob, T., Mahler, V., Popp, G., Schäkel, K., Schlingensiepen, R., Schmitt, J., Siebenhaar, F., Simon, J. C., Staubach, P., Wedi, B., Weidner, C., and **Maurer, M.**+: Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. *J. Eur. Acad. Dermatol. Venereol.* 2013: 27; e363-e369. IF: 2.78 |
| 173. | Bas, M.+, Greve, J., Hoffmann, T., Reshef, A., Aberer, W., **Maurer, M.**, Kivity, S., Farkas, H., Floccard, B., Arcoleo, F., Martin, L., Sitkauskiene, B., Bouillet, L., Schmid-Grendelmeier, P., Li, H., and Zanichelli, A.: Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. *Allergy* 2013: 68; 1452-1459. IF: 5.99 |
| 172. | Koti, I., Weller, K., Makris, M., Tiligada, E., Psaltopoulou, T., Papageorgiou, C., Baiardini, I., Panagiotakos, D., Braido, F., and **Maurer, M.**+: Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria. *Dermatology* 2013: 226; 371-379. IF: 1.68 |
| 171. | Reiter, N., Reiter, M., Altrichter, S., Becker, S., Kristensen, T., Broesby-Olsen, S., Church, M. K., Metz, M., **Maurer, M.**, and Siebenhaar, F.+: Anaphylaxis caused by Mosquito allergy in systemic mastocytosis. *Lancet* 2013: 382; 1380*.* IF: 39.21 |
| 170. | Weller, K., Groffik, A., Magerl, M., Tohme, N., Martus, P., Krause, K., Metz, M., Staubach, P., and **Maurer, M.**+: Development, validation, and initial results of the angioedema activity score. *Allergy* 2013: 68; 1185-1192. IF: 5.99 |
| 169. | Krause, K., Mahamed, Aos, Weller, K., Metz, M., Zuberbier, T., and **Maurer, M.**+: Efficacy and safety of canakinumab in urticarial vasculitis: an open label study. *J. Allergy Clin. Immunol*. 2013: 132; 751-754. IF: 11.25 |
| 168. | Krause, K., Kessler, B., Weller, K., Veidt, J., Chen, S. C., Martus, P., Church, M. K., Metz, M.\*, and **Maurer, M.**\*+: The German version of ItchyQoL: validation and initial clinical findings. *Acta Derm. Venereol*. 2013: 93; 562-568. IF: 4.24 |
| 167. | Zanichelli, A.+, Magerl, M., Longhurst, H., Fabien, V., and **Maurer, M.**: Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. *Allergy Asthma Clin. Immunol.* 2013: 9; 29. IF: N/A |
| 166. | Siebenhaar, F.+, Förtsch, A., Krause, K., Weller, K., Metz, M., Magerl, M., Martus, P., Church, M. K., and **Maurer, M.**: Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. *Allergy* 2013: 68; 949-952. IF: 5.99 |
| 165. | Krause, K., Spohr, A., Zuberbier, T., Church. M. K.+, and **Maurer, M.**: Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. *Allergy* 2013: 68; 921-928. IF: 5.99 |
| 164. | Krause, K., Krull, C., Keßler, B., Lange-Asschenfeldt, B., **Maurer, M.**, and Metz, M.+: Effective control of recalcitrant pruritus by bevacizumab – a possible role for VEGF in chronic itch? *Acta Derm. Venereol*. 2013: 2; 175-179. IF: 4.24 |
| 163. | Kaplan, A., Ledford, D., Ashby, M., Canvin, J, Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., Stirling, R. G., Kuna, P., Berger, W., **Maurer, M.**, and Rosén, K.+: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. *J. Allergy Clin. Immunol*. 2013: 132; 101-109. IF: 11.25 |
| 162. | **Maurer, M.**+, Magerl, M., Metz, M., Siebenhaar, F., Weller, K., and Krause, K.: Practical algorithm for diagnosing patients with recurrent wheals or angioedema. *Allergy* 2013: 68; 816-819. IF: 5.99 |
| 161. | Metz, M., Krull, C., and **Maurer, M.**+: Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, Neopterin, and VEGF are not elevated in chronic spontaneous urticaria. *J. Dermatol. Sci.* 2013: 70; 222-225. IF: 3.33 |
| 160. | Schoepke, N., Church, M. K.+, and **Maurer, M.**: The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. *Acta Derm. Venereol*. 2013: 93; 286-293. IF: 4.24 |
| 159. | Nullens, S., Sabato, V., Faber, M., Leysen, J., Bridts, C. H., de Clerck, L. S., Falcone, F., **Maurer, M.**, and Ebo, D. G.+: Basophilic histamine content and release during venom immunotherapy: insights by flow cytometry. *Cytom. Part B – Clin.* CY 2013: 84; 173-178. IF: 2.28 |
| 158. | Hendrix, S.+\*, Kramer, P.\*, Pehl, D., Warnke, K., Boato, F., Nelissen, S., Lemmens, E., Pejler, G., Metz, M., Siebenhaar, F., and **Maurer, M.**: Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4. *FASEB J.* 2013: 27; 920-929. IF: 5.48 |
| 157. | Simon, A., Bouchra, A., Braun-Falco, M., De Koning, H., Fermand, J. P., Grattan, C., Krause, K., Lachmann, H., Lenormand, C., Martinez-Taboada, V., **Maurer, M.**, Peters, M., Rizzi, R., Rongioletti, F., Ruzicka, T., Schnitzler, L., Schubert, B., Sibilia, J., and Lipsker, D.+: Schnitzler's syndrome: diagnosis, treatment and follow-up. *Allergy* 2013: 68; 562-568. IF: 5.99 |
| 156. | Weller, K., Schoepke, N., Krause, K., Ardelean, E., Bräutigam, M., and **Maurer, M.**+: Selected urticaria patients benefit from a referral to tertiary care centers – results of an expert survey. *J. Eur. Acad. Dermatol. Venereol.* 2013: 27; e8-e16. IF: 2.78 |
| 155. | Młynek, A.\*, Vieira dos Santos, R.\*, Ardelean, E., Weller, K., Magerl, M., Church, M. K., and **Maurer, M.**+: A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. *Clin. Exp. Dermatol.* 2013: 38; 360-366. IF: 1.23 |
| 154. | Vukman, K. V., Adams, P. N., Dowling, D., Metz, M., **Maurer, M.**, and O’Neill, S. M.+: Fasciola hepatica tegumental coat impairs mast cells ability to drive Th1 immune responses. *J. Immunol.* 2013: 190; 2873-2879. IF: 5.36 |
| 153. | Kalogeromitros, D.+, Makris, M., Chliva, C., Sergentanis, T. N., Church, M. K., **Maurer, M.**, and Psaltopoulou, T.: An internet survey on self-reported food allergy in Greece: Clinical aspects and lack of appropriate medical consultation. *J. Eur. Acad. Dermatol. Venereol.* 2013: 27; 558-564. IF: 2.78 |
| 152. | **Maurer, M.**, Rosén, K.+, Hsie, H. J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., and Casale, T.: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *New Engl. J. Med.* 2013: 368; 924-935. IF: 54.40**Maurer, M.**, Rosén, K.+, and Hsie, H. J.: Comment on “Omalizumab for chronic urticaria”. *New Engl. J. Med.* 2013: 368; 2527-2530Rosén, K.+, **Maurer, M.**, Hsie, H. J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., and Casale, T.: Comment on Response to: “Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal”. *Brit. J. Dermatol*. 2014: 171; 15-16 |
| 151. | Weller, K.\*, Ardelean, E.\*, Scholz, E., Martus, P., Zuberbier, T., and **Maurer, M.**+: Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. *Acta Derm. Venereol*. 2013: 93; 168-174. IF: 4.24 |
| 150. | Hawro, T.+, **Maurer, M.**, Sysa-Jędrzejowska, and Woźniacka, A.: Prevalence of nonspecific cutaneous vascular lesions and association with antiphospholipid antibodies in patients with systemic lupus erythematosus. *Brit. J. Dermatol*. 2013: 168; 213-215. IF: 4.10 |
| 149. | Krause, K., Giménez-Arnau, A., Martinez-Escala, E., Farré-Albadelejo, M., Abajian, M., Church, M. K.+, and **Maurer, M.**: Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. *Allergy* 2013: 68; 256-258. IF: 5.99 |
| 148. | Woidacki, K., Popovic, M., Metz, M., Schumacher, A., Linzke, N., Teles, A., Poirier, F., Fest, S., Jensen, F., Rabinovich, G. A.\*, **Maurer, M.**\*, and Zenclussen, A. C.+\*: Mast cells rescue implantation defects caused by c-kit deficiency. *Cell Death. Dis.* 2013: 4; e462. IF: 5.18 |
| 147. | Kallinich, T.+, Gattorno, M., Grattan, C. E., de Koning, H. D., Traidl-Hoffmann, C., Feist, E., Krause, K., Lipsker, D., Navarini, A. A., **Maurer, M.**, Lachmann, H. J., and Simon, A.: Unexplained recurrent fever: when is autoinflammation the explanation? *Allergy* 2013: 68; 285-296. IF: 5.99 |
| 146. | **Maurer, M.**+, Aberer, W.\*, Bouillet, L.\*, Caballero, T.\*, Fabien, V.\*, Kanny, G.\*, Kaplan, A.\*, Longhurst, H.\*, and Zanichelli, A.\*: Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. *PLoS ONE* 2013: 8; e53773. IF: 3.53 |
| 145. | Weller, K., Viehmann, K., Bräutigam, M., Krause, K., Siebenhaar, F., Zuberbier, T., and **Maurer, M.**+: Management of chronic spontaneous urticaria in real life – in accordance with the guidelines? A cross-sectional physician-based survey study. *J. Eur. Acad. Dermatol. Venereol.* 2013: 27; 43-50. IF: 2.78 |
| 144. | Konstantinou, G. N., Asero, R., Ferrer, M., Knol, E. F., **Maurer, M.**, Raap, U., Schmid-Grendelmeier, P., Skol, P. S., and Grattan, C. E. H.+: EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. *Allergy* 2013: 68; 27-36. IF: 5.99 |
| 143. | Krause, K., Feist, E., Fiene, M., Kallinich, T., and **Maurer, M.**+: Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. *J. Allergy Clin. Immunol*. 2012: 129; 848-850. IF: 12.04 |
| 142. | Krause, K., Grattan, C. E., Bindslev-Jensen, C., Gattorno, M., Kallinich, T., de Koning, H. D., Lachmann, H. J., Lipsker, D., Navarini, A. A., Simon, A., Traidl-Hoffmann, C., and **Maurer, M.**+: How not to miss autoinflammatory diseases masquerading as urticaria. *Allergy* 2012: 67; 1465-1474. IF: 5.88 |
| 141. | Craig, T., Aygören Pürsün, E., Bork, K., Bowen, T., Boysen, H., Farkas, H., Grumach, A. S., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W. R., Magerl, M., Martinez-Saguer, I., Ritchie, B., Nast, A., Zuraw, B. L., and **Maurer, M.**+: WAO Guideline for the management of hereditary angioedema: World Allergy Organization consensus document. *World Allergy Organ. J.* 2012: 5; 182-199*.* IF: N/A |
| 140. | Weller, K., Groffik, A., Magerl, M., Tohme, N., Martus, P., Krause, K., Metz, M., Staubach, P., and **Maurer, M.**+: Development and construct validation of the angioedema Quality of Life Questionnaire (AE-QoL). *Allergy* 2012: 67; 1289-1298. IF: 5.88 |
| 139. | Ständer, S., Darsow, U., Mettang, T., Gieler, U., **Maurer, M.**, Ständer, H., Beuers, U., Niemeier, V., Gollnick, H., Vogelgsang, M., and Weisshaar, E.: S2k-Leitlinie – Chronischer Pruritus. *J. Dtsch. Dermatol. Ges*. 2012: 10; S1-S27. IF: 1.40 |
| 138. | Zuberbier, T.+, Aberer, W., Brockow, K., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., **Maurer, M.**, Merk, H. F., Ollert, M., Ruëff, F., Schmid-Grendelmeier, P., Staubach, P., Voigtmann, I., and Wedi, B.: Therapy of urticaria: German language version of the international S3-guideline. *Allergologie* 2012: 4; 187-208. IF 0.33 |
| 137. | Hepworth, M. R.+, **Maurer, M.**, and Hartmann, S.: Regulation of type 2 immunity to helminths by mast cells. *Gut Microbes* 2012: 3; 1-6. IF 2012: 4.73 |
| 136. | Kring-Tannert, L., Stahl Skov, P.+, Bjerremann Jensen, L., **Maurer, M.**, and Bindslev-Jensen, C.: Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. *Dermatology* 2012: 224; 101-105. IF: 2.02 |
| 135. | Krause, K., Weller, K., Stefaniak, R., Wittkowski, H., Altrichter, S., Siebenhaar, F., Zuberbier, T., and **Maurer, M.**+: Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: An open-label study. *Allergy* 2012: 67; 943-950. IF: 6.27 |
| 134. | Kocatürk, E.+\*, Weller, K.\*, Martus, P., Aktas, S., Kavala, M., Sarigul, S., Baiardini, I., Canonica, G. W., Brzoza, Z., Kalogeromitros, and **Maurer, M.**: Turkish version of the chronic urticaria quality of life questionnaire: cultural adaption, assessment of reliability and validity. *Acta Derm. Venereol*. 2012: 92; 419-425. IF: 3.48 |
| 133. | Hepworth, M. R.+, Danilowicz-Luebert, E., Rausch, S., Metz, M., Klotz, C., **Maurer, M.**, and Hartmann, S.: Mast cells orchestrate type 2 immunity to helminths through regulation of tissue derived cytokines. *P. Natl. Acad. Sci. USA* 2012: 109; 6644-6649. IF: 9.73 |
| 132. | Weller, K., Viehmann, K., Bräutigam, M., Krause, K., Siebenhaar, F., Zuberbier, T., and **Maurer, M.**+: Cost-intensive, time-consuming, problematical? – How physicians in private practice experience the care of urticaria patients. *J. Dtsch. Dermatol. Ges*. 2012: 10; 341-347. IF: 1.40 |
| 131. | Magerl, M.\*, Pisarevskaja, D.\*, Staubach, P., Martus, P., Church, M. K.+, and **Maurer, M.**: [Critical temperature threshold measurement for cold urticaria: a randomised controlled trial of H1-antihistamine up-dosing.](http://www.ncbi.nlm.nih.gov/pubmed/22242678) *Brit. J. Dermatol*. 2012: 166; 1095-1099. IF: 3.75 |
| 130. | Bousquet, J.+, Anto, J. M., Demoly, P., Schünemann, H. J., Togias, A., Akdis, M., Auffray, C., Bachert, C., Bieter, T., Bousquet, P. J., Carlsen, K. H., Casale, T. B., Cruz, A. A., Keil, T., Lodrup-Carlsen, K. C., **Maurer, M.**, Ohta, K., Papadopoulos, N. G., Roman Rodriguez, M., Samolinski, B., Agache, I., Andrianarisoa, A., Annesi-Maesano, I., Ballester, F., Baena-Cagnani, C. E., Basagaña, X., Bateman, E. D., Bel, E. H., Bedbrook, A., Beghue, B., Beji, M., Ben Kheder, A., Benet, M., Benoor, K. S., Bergmann, K. C., Berrissoul, F., Bindslev-Jensen, C., Bleecker, G., Bonini, S., Boner, A. L., Boulet, L. P., Brightling, C. E., Brozek, J. L., Bush, A., Busse, W. W., Camargos, P. A. M., Canonica, G. W., Carr, W., Cesario, A., Chen, Y. Z., Chin-Suorn, A., Chiriac, A., Costa, D. J., Cox, L., Custovic, A., Dahl, R., Darsow, U., Didi, T., Dolen, W. K., Douagui, H., Dubakiene, R., El-Meziane, A., Fonseca, J., Fokkens, W. J., Fthenou, E., Gamkrelidze, A., Garcia-Aymerich, J., Gerth van Wijk, R., Gimeno, E., Guerra, S., Haahtela, T., Haddad, H., Hellings, P., Hellquist-Dahl, B., Hohmann, C., Howarth, P., Hourihane, J. O., Humbert, M., Jacquemin, B., Just, J., Kalayci, O., Kaliner, M. A., Kauffmann, F., Kerkhof, M., Khayat, G., Koffi N’Goran, B., Kogevinas, M., Koppelman, G. H., Kowalski, M. L., Kull, I., Kuna, P., Larenas, D., Lavi, I., Le, L. T., Lieberman, P., Lipworth, B., Mahboub, B., Makela, M. J., Martin, F., Martinez, F. D., Marshall, G. D., Mazon, A., Melen, E., Meltzer, E. O., Mihaltan, F., Mohammad, Y., Mohammadi, A., Momas, I., Morais-Almeida, E. O., Mullol, J., Muraro, A., Naclerio, R., Nafti, S., Namazova-Baranova, L., Nawijn, M. C., Nyembue, D., Oddie, S., O’Hehir, R., Okamoto, Y., Orru, M. P., Ozdemir, C., Ouedraogo, G. S., Palkonen, S., Panzner, P., Passalacqua, G., Pawankar, C., Pigearias, B., Pin, I., Pinart, M., Pison, C., Popov, T. A., Porta, D., Postma, D. S., Price, D., Rabe, K. F., Ratomaharo, J., Reitamo, S., Rezagui, D., Ring, J., Roberts, R., Roca, J., Rogala, B., Romano, A., Rosado-Pinto, J., Ryan, D., Sánchez-Borges, M., Scadding, G. K., Sheikh, A., Simons, F. E. R., Siroux, V., Schmid-Grendelmeier, P., Smit, H. A., Sooronbaev, T., Stein, R. T., Sterk, P. J., Sunyer, J., Terreehorst, I., Toskala, E., Tremblay, Y., Valenta, R., Valeyre, D., Vandenpas, O., van Weel, C., Vassilaki, M., Varraso, R., Viegi, G., Wang, D. Y., Wickman, M., Williams, D., Wöhrl, S., Wright, J., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zernotti, M. E., Zidarn, M., Zhong, N., and Zuberbier, T.: Severe chronic allergic (and related) diseases: a uniform approach - a MeDALL-GA²LEN-ARIA position paper. *Int. Arch. Allergy Immunol*. 2012: 158; 216-231. IF: 2.24 |
| 129. | Bork, K.+, **Maurer, M.**, Bas, M., Hartmann, K., Biedermann, T., Kreuz, W., Aygören-Pürsün, E., Martinez-Saguer, I., Ott, H., and Wedi, B.: Hereditäres Angioödem durch C1-Inhibitor-Mangel. *Allergo J.* 2012: 2; 109-118. IF: N/A |
| 128. | Ngouateu, O. B., Kollo, P., Ravel, C., Derreure, J., Kamtchouing, P., Same-Ekobo, A., von Stebut, E., **Maurer, M.**, and Dondji, B.+: Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: Results of a large cross-sectional study. *T. Roy. Soc. Trop. Med. H.* 2012: 106; 137-142. IF: 1.82 |
| 127. | Vukman, K. V., Visnovitz, T., Adams, P. N., Metz, M., **Maurer, M.**, and O’Neill, S. M.+: Mast cells cultured from IL-3 treated mice show impaired responses to bacterial antigen stimulation. *Inflamm. Res.* 2012:61; 79-85. IF: 1.96 |
| 126. | **Maurer, M.** and Church, M. K.+: Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H1-antihistamines. *Exp. Dermatol.* 2012: 21; 154-155. IF: 3.57 |
| 125. | Mathias, S. D.+, Crosby, R. D., Zazzali, J. L., **Maurer, M.**, and Saini, S. S.: Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. *Ann. Allergy Asthma Immunol.* 2012: 108; 20-24. IF: 3.44 |
| 124. | Metz, M.+, Krause, K., **Maurer, M.**, and Magerl, M.: Treatment of notalgia paraesthetica with an 8% capsaicin patch. *Brit. J. Dermatol*. 2011: 165; 1359-1361. IF: 3.66 |
| 123. | Metz, M., Gilles, S., Geldmacher, A., Behrendt, H., Traidl-Hoffmann, C., and **Maurer, M.**+: Evidence for non-allergic mast cell activation in pollen-associated inflammation. *J. Invest. Dermatol*. 2011: 131; 987-990. IF: 6.31 |
| 122. | Kalogeromitros, D.+, Psaltopoulou, T., Koti, I., Chliva, C., Stefanadi, E., Makris, M., and **Maurer, M.**: Can internet surveys help us understanding allergic disorders? – Results from a large survey in urticaria in Greece. *J. Eur. Acad. Dermatol*. *Venereol.* 2011: 25; 532-537. IF: 2.98 |
| 121. | Metz, M.\*, Schäfer, B.\*, Tsai, M., **Maurer, M.**, and Galli, S. J.+: Evidence that the endothelin A receptor can enhance IgE-dependent anaphylaxis in mice. *J. Allergy Clin. Immunol*. 2011: 128; 424-426. IF: 11.00 |
| 120. | **Maurer, M.**+, Bindslev-Jensen, C., Schoepke, N., and Zuberbier, T.: Effects of a novel GA²LEN training program on urticaria on the knowledge of general practitioners in Saudi-Arabia. *World Allergy Organ. J.* 2011: 4; 45-46. IF: N/A |
| 119. | Weller, K., Church, M. K., Kalogeromitros, D., Krause, K., Magerl, M., Metz, M., Pisarevskaja, D., Siebenhaar, F., and **Maurer, M.**+: Chronic spontaneous urticaria – how to assess quality of life in patients receiving treatment. *Arch. Dermatol*. 2011: 147; 1221-1223. IF: 3.88 |
| 118. | Luckey, U.\*, **Maurer, M.**\*, Schmidt, T., Lorenz, N., Seebach, B., Metz, M., and Steinbrink, K.+: T cell killing by tolerogenic dendritic cells protects from allergy in mice. *J. Clin. Invest*. 2011: 121; 3860-3871. IF: 13.06 |
| 117. | Saini, S.+, Rosen, K. E., Hsieh, H. J., Wong, D., Conner, E., Kaplan, A., Spector, S., and **Maurer, M.**: A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. *J. Allergy Clin. Immunol*.2011: 128; 567-573.IF: 11.00 |
| 116. | Weller, K., Ziege, C., Staubach, P., Brockow, K., Siebenhaar, F., Krause, K., Altrichter, S., Church, M. K., and **Maurer, M.**+: H1-Antihistamine up-dosing in chronic spontaneous urticaria: Patients’ perspective of effectiveness and side effects – a retrospective survey study. *PLoS ONE* 2011: 6; e23931. IF: 4.09 |
| 115. | Staubach, P., Dechene, M., Metz, M., Magerl, M., Siebenhaar, F., Weller, K., Zezula, P., Eckhardt-Henn, A., and **Maurer, M.**+: High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. *Acta Derm-Venereol.* 2011: 91; 557-561. IF: 3.17 |
| 114. | **Maurer, M.**+, Altrichter, S., Bieber, T., Biedermann, T., Bräutigam, M., Seyfried, S, Brehler, R., Grabbe, J., Hunzelmann, N., Jakob, T., Jung, A., Kleine-Tebbe, J., Mempel, M., Meurer, M., Reich, K., Ruëff, F., Sengupta, K., Sieder, C., Simon, J. C., Wedi, B., Zuberbier, T., Mahler, V., and Staubach, P.: Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyreoperoxidase. *J. Allergy Clin. Immunol*.2011: 128; 202-209.IF: 11.00**Maurer, M.**: Effect of omalizumab on thyroid function and autoantibody levels in patients with chronic spontaneous urticaria. Comment on: Monitoring of thyroid function in patients who exhibit IgE against thyreoperoxidase on Omalizumab. *J. Allergy Clin. Immunol*.2012: 129; 270 |
| 113. | Zuberbier, T.+, Aberer, W., Brockow, K., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., **Maurer, M.**, Merk, H. F., Ollert, M., Ruëff, F., Schmid-Grendelmeier, P., Staubach, P., Voigtmann, I., and Wedi, B.: Therapy of urticaria: German language version of the international S3-guideline. *Allergo J*. 2011: 20; 259-276. IF: N/A |
| 112. | Zuberbier, T.+, Aberer, W., Brockow, K., Grabbe, J., Hamelmann, E., Hartmann, K., Jakob, T., Merk, H., Ollert, M., Ruëff, F., Schmid-Grendelmeier, P., Staubach, P., Voigtmann, I., Wedi, B., and **Maurer, M.**: Classification and diagnosis of urticaria: German language version of the international S3-guideline. *Allergo J*. 2011: 20; 249-258. IF: N/A |
| 111. | Baiardini, I.\*, Braido, F.\*, Bindslev-Jensen, C., Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., Gerth van Wijk, R. Giménez-Arnau, A., Godse, K., Grattan, C., Grob, J. J., La Grutta, S., Kalogeromitros, D., Kocatürk, E., Lombardi, C., Pinto, A. M., Ridolo, E., Saini, S. S., Sánchez-Borges, M., Senna, G. E., Terreehorst, I., Todo Bom, A., Toubi, E., Bousquet, J., Zuberbier, T., and **Maurer, M.**+: Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: A GA²LEN taskforce position paper. *Allergy* 2011: 66; 840-844. IF: 6.27 |
| 110. | Dudeck, A.+, Sünder, C., Lopez Kostka, S., von Stebut, E.\*, and **Maurer, M.**\*: Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. *Eur. J. Immunol.* 2011: 41; 1883-1893.IF: 2.52 |
| 109. | Eller, K., Wolf, D., Huber, J. M., Metz, M., Mayer, G., McKenzie A. N. J., **Maurer, M.**, Rosenkranz, A. R.+, and Wolf, A. M.: IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune-suppression. *J. Immunol.* 2011: 186; 83-91. IF: 5.78 |
| 108. | Franzke, N.+, Schäfer, I., Jost, K., Blome, C., Rustenbach, S. J., Reich, K., Reusch, M., **Maurer, M.**, and Augustin, M.: A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. *Allergy* 2011: 66; 665-670. IF: 6.27 |
| 107. | Altrichter, S.\*, Peter, H.-J.\*, Pisarevskaja, D., Metz, M., Martus, P., and **Maurer, M.**+: IgE mediated autoallergy against thyroid peroxidase – a novel pathomechanism of chronic spontaneous urticaria? *PLoS ONE* 2011: 6; e14794. IF: 4.09 |
| 106. | Brzoza, Z.+, Badura-Brzoza, K., Młynek, A., Magerl, M., Baiardini, I., Canonica, G. W., Weller, K., Kocatürk, E., Kalogeromitros, D., Zalewska-Janowska, A., Zuberbier, T., and **Maurer, M.**: Adaptation and initial results of the polish version of the GA²LEN chronic urticaria quality of life questionnaire (CU-Q2oL). *J. Dermatol. Sci.* 2011: 62; 36-41. IF: 3.71 |
| 105. | Metz, M., Doyle, E., Bindslev-Jensen, C, Watanabe, T., Zuberbier, T., and **Maurer, M.**+: Effects of antihistamines on innate immune responses to severe bacterial infection in mice. *Int. Arch. Allergy Immunol.* 2011: 155; 355-360. IF: 2.40 |
| 104. | Metz, M., Altrichter, S., Ardelean, E., Keßler, B., Krause, K., Magerl, M., Siebenhaar, F., Weller, K., Zuberbier, T., and **Maurer, M.**+: Anti-immunglobulin E treatment of patients with recalcitrant physical urticaria. *Int. Arch. Allergy Immunol.* 2011: 154; 177-180. IF: 2.40 |
| 103. | Groffik, A., Mitzel-Kaoukhov, H., Magerl, M., **Maurer, M.**, and Staubach, P.+: Omalizumab – an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. *Allergy* 2011: 66; 303-305. IF: 6.27 |
| 102. | Weller, K., Magerl, M., and **Maurer, M.**+: Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. *J. Eur. Acad. Dermatol.* 2011: 25; 119-120. IF: 2.98 |
| 101. | Krause, K., Ardelean, E., Keßler, B., Magerl, M., Metz, M., Siebenhaar, F., Weller, K., Worm, M., Zuberbier, T., and **Maurer, M.**+: Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. *Allergy* 2011: 65; 1494-1495. IF: 6.27 |
| 100. | Dölle, S., Hoser, D., Rasche, C., Loddenkemper, C., **Maurer, M**., Zuberbier, T., and Worm, M.+: Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. *Allergy* 2010: 65; 1158-1165. IF: 6.29 |
| 99. | Braido, F.+, Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., Gerth van Wijk, R., La Grutta, S., Lombardi, C., **Maurer, M.**, Pinto, A. M., Ridolo, E., Senna, G. E., Terreehorst, I., Todo Bom, A., Bousquet, J., Zuberbier, T., and Baiardini, I.: Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA2LEN taskforce position paper. *Allergy* 2010: 65; 959-968. IF: 6.29 |
| 98. | Magerl, M., Staubach, P., Altrichter, S., Ardelean, E., Krause, K., Metz, M., Weller, K., and **Maurer, M.**+: Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. *J. Allergy Clin. Immun*.2010: 126; 665-666.IF: 9.27 |
| 97. | Cicardi, M.+\*, Banerji, A.\*, Bracho, F., Malbrán, A., Rosenkranz, B., Riedl, M., Bork, K., Lumry, W., Aberer, W., Bier, H., Bas, M., Greve, J., Hoffmann, T. K., Farkas, H., Reshef, A., Ritchie, B., Yang, W., Grabbe, J., Kivity, S., Kreuz, W., Levy, R. J., Luger, T., Obtulowicz, K., Schmidt-Grendelmeier, P., Bull, C., Sitkauskiene, B., Smith, W. B., Toubi, E., Werner, S., Anné, S., Björkander, J., Bouillet, L., Cillari, E., Hurewitz, D., Jacobson, K. W., Katelaris, C. H., **Maurer, M.**, Merk, H., Bernstein, J. A., Feighery, C., Floccard, B., Gleich, G., Hébert, J., Kaatz, M., Keith, P., Kirkpatrick, C. H., Langton, D., Martin, L., Pichler, C., Resnick, D., Wombolt, D., Fernández Romero, D. S., Zanichelli, A., Arcoleo, F., Knolle, J., Kravec, I., Dong, L., Zimmermann, J., Rosen, K., and Fan, W.-T.: Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. *New Engl. J. Med.* 2010: 363; 532-541*.* IF: 53.48 |
| 96. | Zuberbier, T.+, Balke, M., Worm, M., Edenharter, G., and **Maurer, M.**: Epidemiology of urticaria: a representative cross-sectional population survey. *Clin. Exp. Dermatol.* 2010: 35; 869-873. IF: 1.26 |
| 95. | Hartmann, K.+\*, Siebenhaar, F.\*, Belloni, B., Brockow, K., Eben, R., Hartmann, B., Ruëff, F., Schoepke, N., Staubach, P., Weber, A., and **Maurer, M.**: Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized double-blind, placebo-controlled trial. *Brit. J. Dermatol.* 2010: 162; 185-190. IF: 4.35 |
| 94. | Vieira dos Santos, R., Magerl, M., Martus, P., Zuberbier, T., Church, M. K., Escribano, L., and **Maurer, M.**+: Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. *Brit. J. Dermatol.* 2010: 162; 674-676. IF: 4.35 |
| 93. | Krause, K., Metz, M., Zuberbier, T., **Maurer, M.**, and Magerl, M.+: Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. *J. Dtsch. Dermatol. Ges.* 2010: 8; 272-274*.* IF: 1.48 |
| 92. | Dudeck, A.+, Leist, M., Rubant, S., Zimmermann, A., Dudeck, J., Boehncke, W. H. and **Maurer, M.**: Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E- and P-selectin, VCAM-1 and PECAM-1. *Exp. Dermatol.* 2010: 19; 424-434. IF: 4.15 |
| 91. | Młynek, A., Magerl, M., Siebenhaar,F., Weller, K.,Vieira dos Santos, R., Zuberbier, T.,Zalewska-Janowska, A., and **Maurer, M.**+: Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. *Brit. J. Dermatol.* 2010: 162; 198-200*.* IF: 4.35 |
| 90. | Baiardini, I.+, Bousquet, P. J., Brzoza, Z., Canonica, G. W., Compalati, E., Fiocchi, A., Fokkens, W., van Wijk, G. R., La Grutta, S., Lombardi, C., **Maurer, M.**, Pinto, A. M., Ridolo, E., Senna, G. E., Terreehorst, I., Bom, A. T., Bousquet, J., Zuberbier, T., and Braido, F.: Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: A GA2LEN taskforce position paper. *Allergy* 2010: 65; 290-295. IF: 6.29 |
| 89. | Metz, M., Scholz, E., Ferrán, M., Izquierdo, I., Giménez-Arnau, A., and **Maurer, M.**+: Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. *Ann. Allergy Asthma Immunol.* 2010: 104; 86-92. IF: 2.80 |
| 88. | Bachert, C.+ and **Maurer, M.**: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria. Results of four postmarketing surveillance studies. *Clin. Drug Invest.* 2010: 30; 109-122. IF: 1.62 |
| 87. | Magerl, M., Pisarevskaja, D., Scheufele, R., Zuberbier, T., and **Maurer, M.**+: Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: A prospective trial. *Allergy* 2010: 65;78-83. IF: 6.29 |
| 86. | Hartmann, K.+, Biedermann, T., Brockow, K., Grabbe, J., Horny, H.-P., Lippert, U., **Maurer, M.**, Raithel, M., Rietschel, E., Ruëff, F., and Sotlar, K. für das Kompetenznetzwerk Mastozytose e. V.: Leitlinie Mastozytose. *Allergol*. 2009: 32; 199-213. IF: 2009: 0.12 |
| 85. | Magerl, M., Borzova, E., Giménez-Arnau, A., Grattan, C. E. H., Lawlor, F., Mathelier-Fusade, P., Metz, M., Młynek, A., and **Maurer, M.**+: The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. *Allergy* 2009: 64; 1715-1721. IF: 6.38 |
| 84. | Konstantinou, G. N., Asero, R., **Maurer, M.**, Sabroe, R. A., Schmid-Grendelmeier, P., and Grattan, C. E. H.+: EAACI/GA2LEN task force consensus report: the autologous serum skin test in urticaria. *Allergy* 2009: 64; 1256-1268. IF: 6.38 |
| 83. | Schulz, S., Metz, M., Siepmann, D., Luger, T. A., **Maurer, M.**, and Ständer, S.+: Antipruritic efficacy of a high-dosage antihistamine therapy: Results of a retrospectively analysed case series. *Hautarzt* 2009: 60; 564-568*.* IF: 0.43 |
| 82. | Weller, K.\*, Artuc, M.\*, Jennings, G., Friedrichson, T., Guhl, S., Vieira dos Santos, R., Sünder, C., Zuberbier, T., and **Maurer, M.**+: Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. *J. Invest. Dermatol.* 2009: 129; 496-498. IF: 5.54 |
| 81. | Weller, K. and **Maurer, M.**+: Desloratadine inhibits human skin mast cell activation and histamine release*. J. Invest. Dermatol.* 2009: 129; 2723-2726*.* IF: 5.54 |
| 80. | Zuberbier, T.+, Asero, R., Bindslev-Jensen, C., Canonica, G. W., Church, M. K., Giménez-Arnau, A. M., Grattan, C. E. H., Kapp, A., Merk, H. F., Rogala, B., Saini, S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Schünemann, H., Staubach, P., Vena, G. A., Wedi, B., and **Maurer, M.**: EAACI/GA2LEN/EDF/WAO Guideline: Definition, classification and diagnosis of urticaria. *Allergy* 2009: 64; 1417-1426. IF: 6.38 |
| 79. | Zuberbier, T.+, Asero, R., Bindslev-Jensen, C., Canonica, G. W., Church, M. K., Giménez-Arnau, A. M., Grattan, C. E. H., Kapp, A., **Maurer, M.**, Merk, H. F., Rogala, B., Saini, S., Sánchez-Borges, M., Schmid-Grendelmeier, P., Schünemann, H., Staubach, P., Vena, G. A., and Wedi, B.: EAACI/GA2LEN/EDF/WAO Guideline: Management of urticaria. *Allergy* 2009: 64; 1427-1443. IF: 6.38 |
| 78. | Giménez-Arnau, A., Izquierdo, I.+, and **Maurer, M.**: The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. *J. Eur. Acad. Dermatol. Venereol.* 2009: 23; 1088-1091. IF: 2.79 |
| 77. | **Maurer, M.**+, Ortonne, J.-P., and Zuberbier, T.: Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation. *Allergy* 2009: 64; 581-588.IF: 6.38 |
| 76. | Młynek, A.\*, Magerl, M.\*, Hanna, M., Lhachimi, S., Baiardini, I., Canonica, G. W., Brzoza, Z., Kasperska-Zajac, A., Rogala, B., Zalewska-Janowska, A., Zuberbier, T., and **Maurer, M.**+: The German version of the chronic urticaria quality-of-life questionnaire (CU-Q2oL): Factor analysis, validation and initial clinical findings. *Allergy* 2009: 64; 927-936. IF: 6.38 |
| 75. | Metz, M.\*, Magerl, M.\*, Kühl, N. F., Valeva, A., Bhakdi, S., and **Maurer, M.**+: Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. *Exp. Dermatol.* 2009: 18; 160-166*.* IF: 3.24 |
| 74. | Mrabet-Dahbi, S.\*, Metz, M.\*, Dudeck, A., Zuberbier, T., and **Maurer, M.**+: Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. *Exp. Dermatol.* 2009: 18; 437-444.IF: 3.24 |
| 73. | Potter, P. C.+, Kapp, A., **Maurer, M.**, Guillet, G., Jian, A. M., Hauptmann, P., and Finlay, A. Y.: Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients*. Allergy* 2009: 64; 596-604*.* IF: 6.38 |
| 72. | Metz, M., Gimenez-Arnau, A., Borzova, E., Grattan, C. E. H., Magerl, M., and **Maurer, M.**+: Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. *J. Allergy Clin. Immunol*.2009: 123; 705-706*.* IF: 9.16 Metz, M., Gimenez-Arnau, A., Borzova, E., Grattan, C. E. H., Magerl, M., and **Maurer, M.**+: Comment on “Is the autologous plasma skin test in patients with chronic urticaria really useless? *J. Allergy Clin. Immunol*.2009: 123; 1417 |
| 71. | Altrichter, S., Boodstein, N., and **Maurer, M.**+: Matrix metalloproteinase-9: A novel biomarker for monitoring disease activity in patients with chronic urticaria? *Allergy* 2009: 64; 652-656*.* IF: 6.38 |
| 70. | Siebenhaar, F., Degener, F., Zuberbier, T., Martus, P., and **Maurer, M.**+: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. *J. Allergy Clin. Immunol.* 2009: 123; 672-679*.* IF: 9.16 |
| 69. | Magerl, M., Schmolke, J., Metz, M., Zuberbier, T., Siebenhaar, F., and **Maurer, M.**+: Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. *Clin. Exp. Dermatol.* 2009: 34; e137-e140.IF: 1.55 |
| 68. | **Maurer, M.**+**,** Ortonne, J.-P., and Zuberbier, T.: Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. *Brit. J. Dermatol.* 2009: 160; 633-641*.* IF: 4.26 |
| 67. | Vieira dos Santos, R., Metz, M., Lima, H. C., Martus, P., and **Maurer, M.**+: Differential effects of skin nerves on allergic skin inflammation. *Allergy* 2009: 64; 496-498*.* IF: 6.38 |
| 66. | Staubach, P., Vonend, A., Burow, G., Metz, M., Magerl, M., and **Maurer, M.**+: Patients with chronic urticaria exhibit increased rates of sensitisation to Candida albicans, but not to common moulds. *Mycoses* 2008: 52; 334-338.IF: 1.53 |
| 65. | Zuberbier, T.+, **Maurer**, **M.**,andAugustin, M.: Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. *Allergy* 2008: 63; 1560-1561*.* IF: 6.20 |
| 64. | Güzelbey, O., Ardelean, E., Magerl, M., Zuberbier, T., **Maurer, M.**, and Metz, M.+: Successful treatment of solar urticaria with anti-immunoglobulin E therapy. *Allergy* 2008: 63; 1563-1565.IF: 6.20 |
| 63. | Vieira dos Santos, R., Młynek, A., Lima, H. C., Martus, P., and **Maurer, M.**+: Beyond flat weals: validation of a three-dimensional imaging technology that will improve skin allergy research. *Clin. Exp. Dermatol.* 2008: 33; 772-775.IF: 1.78 |
| 62. | Caucig, P., Lescau, S., Knop, J., **Maurer, M.**, and von Stebut, E.+: Interleukin-2 immediate type hypersensitivity? *J. Dtsch. Dermatol. Ges.* 2008: 6; 956-956.IF: N/A |
| 61. | Siebenhaar, F., Magerl, M., Peters, E. M. J., Hendrix, S., Metz, M., and **Maurer, M.**+: Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. *J. Allergy Clin. Immunol*. 2008: 121; 955-961*.* IF: 9.77 |
| 60. | Młynek, A., Zalewska-Janowska, A., Martus, P., Staubach, P., Zuberbier, T., and **Maurer, M.**+: How to assess disease activity in patients with chronic urticaria? *Allergy* 2008: 63; 777-780*.* IF: 6.20 |
| 59. | Magerl, M.\*, Lammel, V.\*, Siebenhaar, F., Zuberbier, T., Metz, M., and **Maurer, M.**+: Non-pathogenic commensal Escherichia coli bacteria can inhibit degranulation of mast cells. *Exp. Dermatol.* 2008: 17; 427-435*.* IF: 3.26 |
| 58. | Metz, M., Bergmann, P., Zuberbier, T., and **Maurer, M.**+: Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. *Allergy* 2008: 63; 247-249. IF: 6.20 |
| 57. | Magerl, M., Schmolke, J, Siebenhaar, F., Zuberbier, T., Metz, M., and **Maurer, M.**+: Acquired cold urticaria symptoms can be safely prevented by Ebastine. *Allergy* 2007: 62; 1465-1468. IF: 5.01 |
| 56. | Orinska, Z.\*, **Maurer, M.**\*, Mirghomizadeh, F.\*, Bulanova, E., Metz, M., Nashkevich, N., Schiemann, F., Schulmistrat, J., Budagian, V., Giron-Michel, J., Brandt, E., Paus, R., and Bulfone-Paus, S.+: IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. *Nature Medicine* 2007: 13; 927-934. IF: 26.38 |
| 55. | **Maurer, M.**+and Zuberbier, T.: Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. *Allergy* 2007: 62; 1057-1063. IF: 5.01 |
| 54. | Staubach-Renz, P.+, von Stebut, E., Bräuninger, W., **Maurer, M.**,and Steinbrink, K.: Hypocomplementemic urticarial vasculitis syndrome. Successful therapy with intravenous immunoglobulins. *Hautarzt* 2007: 58; 693-697. IF: 0.33 |
| 53. | Siebenhaar, F., Kühn, W., Zuberbier, T., and **Maurer, M.**+: Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. *J. Allergy Clin. Immunol*. 2007: 120; 213-215. IF: 8.12 |
| 52. | Siebenhaar, F., Syska, W., Weller, K., Magerl, M., Zuberbier T., Metz, M., and **Maurer, M.**+: Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. *Am. J. Pathol.* 2007: 170; 1910-1916. IF: 5.49 |
| 51. | Magerl, M., Philipp, S., Manasterski, M., Friedrich, M., and **Maurer, M.**+: Successful treatment of delayed pressure urticaria with anti-TNF-alpha. *J. Allergy Clin. Immunol.* 2007: 119; 752-754. IF: 8.12 |
| 50. | Siebenhaar, F., Sharov, A. A., Peters, E. M. J., Sharova, T. Y., Syska, W., Mardaryev, A. N., Freyschmidt-Paul, P., Sundberg, J. P., **Maurer, M.**, and Botchkarev, V. A.+:Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (Alopecia Areata). *J. Invest. Dermatol.* 2007: 127; 1489-1497. IF: 4.83 |
| 49. | Metz, M.+, Lammel, V., Gibbs, B.F., and **Maurer, M.**: Inflammatory murine skin responses to UV-B light are partially dependent on Endothelin-1 and mast cells. *Am. J. Pathol.* 2006: 169; 815-822. IF: 5.92 |
| 48. | Zuberbier, T.+, Bindslev-Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A., **Maurer, M.**, Merk, H. F., Schäfer, T., Simon, D., Vena, G. A., and Wedi, B.: EAACI/GA²LEN/EDF guideline: definition, classification and diagnosis of urticaria. *Allergy* 2006: 61; 316-320. IF: 5.33 |
| 47. | Zuberbier, T.+, Bindslev-Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A., **Maurer, M.**, Merk, H. F., Schäfer, T., Simon, D., Vena, G. A., and Wedi, B.: EAACI/GA²LEN/EDF guideline: management of urticaria. *Allergy* 2006: 61; 321-331. IF: 5.33 |
| 46. | **Maurer, M.**, Lopez Kostka, S., Siebenhaar, F., Moelle, K., Metz, M., Knop, J., and von Stebut, E.+: Skin mast cells control T cell-dependent host defence in *Leishmania major* infections. *FASEB J.* 2006: 20; 2460-2467. IF: 6.72 |
| 45. | Weller, K., Foitzik, F., Paus, R., Syska, W., and **Maurer, M.**+: Mast cells are required for normal healing of skin wounds in mice. *FASEB J.* 2006: 20; 2366-2368. IF: 6.72 |
| 44. | Staubach, P., Onnen, K., Vonend, A., Metz, M., Siebenhaar, F., Tschentscher, I., Opper, B., Magerl, M., Lüdtke, R., Kromminga, A., and **Maurer, M.**+: Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: A placebo-controlled trial.*Dermatology* 2006: 212; 150-159. IF: 1.85 |
| 43. | Staubach, P., Eckhardt-Henn, A., Dechene, M., Hanau, A., Metz, M., Magerl, M., Breuer, P., and **Maurer, M.**+: Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. *Brit. J. Dermatol.* 2006: 154; 294-298. IF: 3.33 |
| 42. | Hendrix, S.+\*, Warnke, K.\*, Siebenhaar, F., Peters, E. M. J., Nitsch, R., and **Maurer, M.**: The majority of brain mast cells in B10.PL mice is present in the hippocampal formation. *Neurosci. Lett.* 2006: 392; 174-177. IF: 2.09 |
| 41. | Weber, A., and **Maurer, M.**+: Skin site mast cell numbers correlate with rates of nodular growth, but not incidence, of basal cell carcinoma. *Dermatology* 2005: 211; 298-299. IF: 1.83 |
| 40. | Hochegger, K., Siebenhaar, F., Vielhauer, V., Heininger, D., Mayadas, T. N., Mayer, G., **Maurer, M.**, and Rosenkranz, A. R.+: Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. *Eur. J. Immunol.* 2005: 35; 3074-3082. IF: 4.87Hochegger, K., Rosenkranz, A.R., Siebenhaar, F., and **Maurer, M.**: Comment on „Mast cell-mediated remodelling and fibrinolytic activity protect against fatal glomerulonephritis”. *J. Immunol.* 2006: 177; 1377 |
| 39. | Orinska, Z., Bulanova, E., Budagian, V., Metz, M., **Maurer, M.**, and Bulfone-Paus, S.+: TLR3-induced activation of mast cells modulates CD8+ T cell-recruitment. *Blood* 2005: 106; 978-987. IF: 10.13 |
| 38. | **Maurer, M.** and Galli, S. J.+: Lack of significant skin inflammation during elimination by apoptosis of large numbers of mouse cutaneous mast cells after cessation of treatment with SCF. *Lab. Invest.* 2004: 84; 1593-1602. IF: 3.7 |
| 37. | **Maurer, M.**\*, Wedemeyer, J.\*, Metz, M., Chatterjea, D., Clouthier, D. E., Yanagisawa, M., Tsai, M., and Galli, S. J.+: Mast cells promote homeostasis by limiting endothelin-1 induced toxicity. *Nature* 2004: 432; 512-516. IF: 32.18 |
| 36. | Siebenhaar, F., Staubach, P., Metz, M., Magerl, M., Jung, J., and **Maurer, M.**+: Peltier effect-based temperature challenge – an improved method for diagnosing cold urticaria. *J. Allergy Clin. Immunol.* 2004: 114; 1224-1225. IF: 7.2 |
| 35. | Giménez-Arnau, A. M.+, Ferrer-Puga, M., Peter, H.-J., **Maurer, M.**, and Pujol-Vallverdú, R. M.: Chronic urticaria: Prospective ethiologic study and autoimmune syndrome significance. *Acta Dermo-Sifiliográfica* 2004: 95; 560-566*.* IF: N/A |
| 34. | Metz, M., Botchkarev, V. A., Botchkareva, N. V., Welker, P., Tobin, D., Knop, J., **Maurer, M.**+, and Paus, R.:Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. *Exp. Dermatol.* 2004: 13; 273-281. IF: 1.7 |
| 33. | Peters, E. M., **Maurer, M.**, Botchkarev, V. A., deMasey Jensen, K., Welker, P., Scott, G. A., and Paus, R.+: Kit is expressed by epithelial cells *in vivo*. *J. Invest. Dermatol.* 2003: 121; 976-984. IF: 4.19 |
| 32. | **Maurer, M.**\*, Seidel-Guyenot, W.\*, Metz, M., Knop, J., and Steinbrink, K.+: Critical role of IL-10 in the induction of low zone tolerance to contact allergens. *J. Clin. Invest.* 2003: 112; 432-439. IF: 14.3 |
| 31. | Weber, A., Knop, J., and **Maurer, M.**+: Pattern analysis of human cutaneous mast cell populations by total body surface mapping. *Brit. J. Dermatol.* 2003: 148; 224-228. IF: 2.69 |
| 30. | Stebut, E. von, Metz, M., Milon, G., Knop, J., and **Maurer, M.**+: Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1 α/β released from neutrophils recruited by mast cell-derived TNFα. *Blood* 2003: 101; 210-215. IF: 10.12 |
| 29. | Peters, E. M., Tobin, D. J., Botchkareva, N., **Maurer, M.**, and Paus, R.+: Migration of melanoblasts into the developing murine hair follicle is accompanied by transient c-Kit expression. *J. Histochem. Cytochem.* 2002: 50; 751-766. IF: 1.15 |
| 28. | Botchkarev, V. A.+, Komarova, E. A, Siebenhaar, F., Botchkareva, N. V., Sharov, A. A., Komarov, P. G., **Maurer. M.**, Gudkov, A. V., and Gilchrest, B. A.: p53 involvement in the control of murine hair follicle regression. *Am. J. Pathol.* 2001: 158; 1913-1919. IF: 7.1 |
| 27. | Botchkarev, V. A., Komarova, E. A., Siebenhaar, F., Botchkareva, N. V., Komarov, P. G., **Maurer, M.**, Gilchrest, B. A., and Gudkov, A. V.+: p53 is essential for chemotherapy-induced hair loss. *Cancer Res.* 2000: 60; 5002-5006. IF: 8.46 |
| 26. | Gommerman, J. L.\*, Oh, D. Y.\*, Zhou, X., Tedder, T. F., **Maurer, M.**, Galli, S. J., and Carroll, M. C.+: A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. *J. Immunol.* 2000: 165; 6915-6921. IF: 6.83 |
| 25. | Cindik, E. D.+, **Maurer, M.**, Hannan, M. K., Müller, R., Hayes, W. C., Hovy, L., and Kurth, A.: Phenotypical characterization of c-kit receptor deficient mouse femurs using non-destructive high-resolution imaging techniques and biomechanical testing. *Technol. Health Care* 2000: 8; 267-275. IF: N/A |
| 24. | Foitzik, K., Lindner, G., Mueller-Roever, S., **Maurer, M.**, Botchkareva, N., Botchkarev, V., Handjiski, B., Metz, M., Hibino, T., Soma, T., Dotto, G. P., and Paus, R.+: Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. *FASEB J.* 2000: 14; 752-760. IF: 9.25 |
| 23. | **Maurer, M.**, Tsai, M., Metz, M., Fish, S., Korsmeyer, S. J., and Galli, S. J.+:A role for Bax in the regulation of apoptosis in mouse mast cells. *J. Invest. Dermatol.* 2000: 114; 1205-1206. IF: 4.54 |
| 22. | Paus, R.+, Müller-Röver, S., Van Der Veen, C., **Maurer. M.**, Eichmüller, S., Ling, G., Hofmann, U., Foitzik, K., Mecklenburg, L., and Handjiski, B.: A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis*. J. Invest. Dermatol.* 1999: 113; 523-532. IF: 4.9 |
| 21. | Peters, E. M., **Maurer, M.**, Botchkarev, V. A., Gordon, D. S., and Paus, R.+: Hair growth-modulation by adrenergic drugs. *Exp. Dermatol.* 1999: 8; 274-281. IF: 2.1 |
| 20. | Botchkarev, V. A., Peters, E. M., Botchkareva, N. V., **Maurer, M.**, and Paus, R.+: Hair cycle-dependent changes in adrenergic skin innervation and hair growth modulation by adrenergic drugs. *J. Invest. Dermatol*. 1999: 113; 878-887. IF: 4.9 |
| 19. | Rosenkranz, A. R., Coxon, A.\*, **Maurer, M.**\*, Gurish, M. F., Austen, K. F., Friend, D. S., Galli, S. J., and Mayadas, T. N.+: Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. *J. Immunol.* 1998: 161; 6463-6467. IF: 7.16 |
| 18. | **Maurer, M.**, Echtenacher, B.\*, Hültner, L.\*, Kollias, G., Männel, D. N., Langley, K. E., and Galli, S. J.+: The c-kit ligand, stem cell factor, can enhance immunity through effects on mast cells. *J. Exp. Med.* 1998: 188; 1-6. IF: 15.88 |
| 17. | Boesiger, J., Tsai, M., **Maurer, M.**, Yamaguchi, M., Brown, L. F., Claffey, K. P., Dvorak, H. F., and Galli, S. J.+: Mast cells can secret VPF/VEGF and exhibit enhanced release after IgE-dependent upregulation of FceRI expression. *J. Exp. Med.* 1998: 188; 1135-1145. IF: 15.88 |
| 16. | **Maurer, M.**+, Peters, E. M. J., Botchkarev, V. A., and Paus, R.: Intact hair follicle innervation is not essential for anagen induction and development. *Arch. Dermatol. Res.* 1998: 290; 574-578. IF: 1.42 |
| 15. | Biró, T., **Maurer, M.**, Modarres, S., Lewin, N. E., Brodie, C., Acs, G., Acs, P., Paus, R., and Blumberg, P.+:Characterization of functional vanilloid receptors – expressed by mast cells. *Blood* 1998: 91; 1332-1340. IF: 8.3 |
| 14. | Stebut, E. von+, **Maurer, M.**, and Zuberbier, T.: Intoleranzreaktion auf systemische Kortikosteroide. *Allergologie* 1997: 7; 336-339. IF: 0.56 |
| 13. | Prodeus, A., Zhou, X., **Maurer, M.**, Galli, S. J., and Carroll, M. C.+: Impaired mast cell-dependent natural immunity in complement C3-deficient mice. *Nature* 1997: 390; 172-175. IF: 27.36 |
| 12. | **Maurer, M.**, Fischer, E., Handjiski, B., Stebut, E. von, Algermissen, B., Bavandi, A., and Paus, R.+: Activated skin mast cells are involved in murine hair follicle regression (catagen). *Lab. Invest.* 1997: 77; 319-332. IF: 4.65 |
| 11. | Botchkarev, V. A., Eichmüller, S., Peters, E., Pietsch, P., Johansson, O., **Maurer, M.**, and Paus, R.+: A simple immunofluorescent technique for simultaneous visualisation of mast cells and nerve fibers reveals selectivity and hair cycle-dependent changes in mast cell-nerve fibre contacts in murine skin. *Arch. Dermatol. Res.* 1997: 289; 292-302. IF: 1.23 |
| 10. | **Maurer, M.**, Opitz, M., Henz, B. M., and Paus, R.+: The mast cell products histamine and serotonin stimulate and TNF-alpha inhibits the proliferation of murine epidermal keratinocytes in situ*. J. Dermatol. Sci.*1997: 16; 79-84. IF: 0.57 |
| 9. | Slominski, A.+, Goodman-Snitkoff, G., **Maurer, M.**, and Paus, R.: Hair cycle-associated changes in splenocyte proliferation. *In Vivo*1997: 11; 101-102. IF: 0.44 |
| 8. | **Maurer, M.**, Handjiski, B., and Paus, R.+:Hair growth modulation by topical immunophilin ligands: Induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. *Am. J. Pathol.* 1997: 150; 1433-1441. IF: 6.5 |
| 7. | Slominski, A.+, Paus, R., Plonka, P., Handjiski, B., **Maurer, M.**, Chakraborty, A., and Mihm, M.: Pharmacological disruption of hair follicle pigmentation by cyclophosphamid as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ. *J. Invest. Dermatol.* 1996: 106; 1203-1211. IF: 4.7 |
| 6. | Paus, R.+, Böttge, J. A., Czarnetzki, B. M., and **Maurer, M.**: Hair growth control by immunosuppression. *Arch. Dermatol. Res.* 1996: 288; 408-410. IF: 1.47 |
| 5. | **Maurer, M.**, Paus, R.+, and Czarnetzki, B. M.: Mast cells as modulators of hair follicle cycling. *Exp. Dermatol.* 1995: 4; 266-271. IF: N/A |
| 4. | Paus, R.+, Heinzelmann, T., Robiscek, S., Czarnetzki, B. M., and **Maurer, M.**: Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. *Arch. Dermatol. Res.* 1995: 287; 500-502. IF: 1.33 |
| 3. | Slominski, A.+, Chassalevris, N., Mazurkiewicz, J., **Maurer, M.**,and Paus, R.: Murine skin as a target for melatonin bioregulation. *Exp. Dermatol.* 1994: 3; 45-50. IF: N/A |
| 2. | Slominski, A.+, Paus, R., Plonka, P., Chakraborty, A., **Maurer, M.**, Pruski, D., and Lukiewicz, S.: Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. *J. Invest. Dermatol.* 1994: 102; 862-869. IF: 3.6 |
| 1. | Paus, R.+, **Maurer, M.**, Slominski, A., and Czarnetzki, B. M.: Mast cell involvement in murine hair growth. *Dev. Biol.* 1994: 163; 230-240. IF: 4.7 |

|  |  |
| --- | --- |
| Number of original publications in peer-reviewed journals: | 580 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |

**Reviews in Peer-reviewed Journals**

|  |  |
| --- | --- |
|  | Hu, M., Scheffel, J., Elieh-Ali-Komi, D., **Maurer, M.**, Hawro, T.+, and Metz, M.+: An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma. *Clin. Exp. Med*. 2023: *in press*. IF: TBD (IF 2022: 4.60) |
|  | Kocatürk, E.+, Abrams, E. M., **Maurer, M.**, Mitri, J., Oppenheimer, J., Vestergaard, C., and Zein, J.: COVID-19 and its impact on common diseases in the allergy clinics. *J. Allergy Clin. Immunol. Pract*. 2023: *in press*. IF: TBD (IF 2022: 9.40) |
|  | Metz, M., Kolkhir, P., Altrichter, S., Siebenhaar, F., Levi-Schaffer, F., Youngblood, B. A., Church, M. K., and **Maurer, M.**+: Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell-mediated diseases. *Allergy* 2023: *in press.* IF: TBD (IF 2022: 12.40) |
|  | Zuberbier, T.+, Stevanovic, K., Ansotegui, I. J., Anto, J. M., Bergmann, K.-C., D’Amato, G., Grüntuch-Ernst, A., Haahtela, T., **Maurer, M.**, Pietikäinen, S., Christou, D., and Bousquet, J.: Green roof gardens – selecting allergy friendly vegetation: a GA²LEN position paper. *J. Allergy Clin. Immunol. Pract*. 2023: *in press*. IF: TBD (IF 2022: 9.40) |
| 206. | Casale, T. B.+, Giménez-Arnau, A. M., Bernstein, J. A., Holden, M., Zuberbier, T., and **Maurer, M.**: Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status. *Dermatol. Ther*. 2023: 13; 2573-2588. IF: TBD (IF 2022: 3.40) |
| 205. | Charles, N.+, Kortekaas Krohn, I., Kocatürk, E., Scheffel, J., Altrichter, S., Steinert, C., Xiang, Y.-K., Gutermuth, J., Reber, L., and **Maurer, M.**\*: Autoreactive IgE: pathogenic role and therapeutic target in autoimmune diseases. *Allergy* 2023: 78; 3118-3135. IF: TBD (IF 2022: 12.40) |
| 204. | Asero, R.+\*, Ferrer, M.\*, Kocatürk, E.\*, and **Maurer, M.**\*: Chronic spontaneous urticaria: the role and relevance of autoreactivity, autoimmunity and autoallergy. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 2302-2308. IF: TBD (IF 2022: 9.40) |
| 203. | Kolkhir, P.+, Akdis, C., Akdis, M., Bachert, C., Bieber, T., Canonica, G., Guttman-Yassky, E., Metz, M., Mullol, J., Palomares, O., Renz, H., Ständer, S., Zuberbier, T., and **Maurer, M.**+: Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. *Nat. Rev. Drug Discov*. 2023: 22; 743-767. IF: TBD (IF 2022: 120.10) |
| 202. | Neisinger, S.+, Ramanauskaite, A., Kocatürk, E., Britz, R., Lingnau, A., Cherrez-Ojeda, I., and **Maurer, M.**: Embracing digital health solutions: the pivotal role of the CRUSE app in chronic spontaneous urticaria management. *Asthma Allergy Immunol*. 2023: 21; 79-81. IF: TBD (IF 2022: 0.2) |
| 201. | Bousquet, J.+, Samolinski, B., Kaidashev, I., **Maurer, M.**, Roche, N., Sousa-Pinto, B., Kurchenko, A., Stepanenko, R., Tsaryk, V., Klimek, L., Ventura, M. T., Bedbrook, A., Czarlewski, W., Lysanets, Y., Kupczyk, M., Skolimowski, Ł., Kulus, M., Del Giacco, S., Ollert, M., Garcia-Aymerich, J., Robalo Cordeiro, C., Yorgancioglu, A., Schlapbach, C., Amaral, R., Bonaglia, C., Bossé, I., Buquicchio, R., Christou, D., Fedoruk, G., Fontanesi, P., Gemicioglu, B., Giuliano, A. F. M., Lepore, P., Nakonechna, A., Neisinger, S., Pereira, A. M., Ramanauskaite, A., Raciborski, F., Sitkauskiene, B., Sokhatska, O., Stepanenko, V., Stevanovic, K., Syzon, O., Kvedariene, V., de Vries, G., van Eerd, M., Valiulis, A., Fonseca, J. A., Anto, J. M., Haahtela, T., Schünemann, H., and Zuberbier, T.: UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan. *Allergy* 2023: 78; 2581-2595. IF: TBD (IF 2022: 12.40) |
| 200. | **Maurer, M.**+, Buttgereit, T., Magerl, M., Schön, K., Balla, Z., and Farkas, H.: Patient-physician interactions in hereditary angioedema – key learnings from the coronavirus disease 2019 pandemic. *Clin. Transl. Allergy* 2023:13; e12300. IF: TBD (IF 2022: 4.40) |
| 199. | **Maurer, M.**, Kolkhir, P., Moñino-Romero, S., and Metz, M.: The crucial role of IgE as a predictor of treatment response to omalizumab in chronic spontaneous urticaria. *J. Allergy Clin. Immunol. Pract*. 2023: *11; 2390-2391*. IF: TBD (IF 2022: 9.40) |
| 198. | Kolkhir, P., Ali, H., Babina, M., Ebo, D., Sabato, V., Elst, J., Frischbutter, S., Pyatilova, P., and **Maurer, M.**+: MRGPRX2 in drug allergy: What we know and what we do not know. *J. Allergy Clin. Immunol*. 2023: 15; 410-412. IF: TBD (IF 2022: 14.20) |
| 197. | Bousquet, J.+, Melén, E., Haahtela, T., Koppelman, G. H., Togias, A., Valenta, R., Akdis, C. A., Czarlewski, W., Rothenberg, M., Valiulis, A., Wickmann, M., Aguilar, D., Akdis, M., Ansotegui, I. J., Barbara, C., Bedbrook, A., Bindslev Jensen, C., Bosnic-Anticevich, S., Boulet, L. P., Brightling, C. E., Brussino, L., Burte, E., Bustamante, M., Canonica, G. W., Cecchi, L., Celedon, J. C., Chaves-Loureiro, C., Costa, E., Cruz, A. A., Erhola, M., Gemicioglu, B., Fokkens, W. J., Garcia Aymerich, J., Guerra, S., Heinrich, J., Ivancevich, J. C., Keil, T., Klimek, L., Kuna, P., Kupczyk, M., Kvedariene, V., Larenas-Linnemann, D. E., Lemonnier, N., Lodrup Carlsen, K. C., Louis, R., Makris, M., **Maurer, M.**, Momas, I., Morais-Almeida, M., Mullol, J., Naclerio, R. N., Nadeau, K., Nadif, R., Niedoszytko, M., Okamoto, Y., Ollert, M., Papadopoulos, N. G., Passalacqua, G., Patella, V., Pawankar, R., Pham-Thi, N., Pfaar, O., Regateiro, F. S., Ring, J., Rouadi, P. W., Samolinski, B., Sastre, J., Savouré, M., Scichilone, N., Shamji, M. H., Sheikh, A., Siroux, V., Sousa-Pinto, B., Standl, M., Sunyer, J., Taborda-Barata, L., Toppila-Salmi, S., Torres, M. J., Tsiligianni, I., Valovirta, E., Vandenplas, O., Ventura, M. T., Weiss, S., Yorgancioglu, A., Zhang, L., Abdul Latiff, A. H., Aberer, W., Agache, I., Al-Ahmad, M., Alobid, I., Arshad, H. S., Asayag, E., Baharudin, A., Battur, L., Bennoor, K. S., Berghea, E. C., Bergmann, K. C., Bernstein, D., Bewick, M., Blain, H., Bonini, M., Braido, F., Buhl, R., Bumbacea, R., Bush, A., Calderon, M., Calvo, G., Camargos, P., Caraballo, L., Cardona, V., Carr, W., Carreiro-Martins, P., Casale, T., Cepeda Sarabia, A. M., Chandrasekharan, R., Charpin, D., Chen, Y. Z., Cherrez-Ojeda, I., Chivato, T., Chkhartishvili, E., Christoff, G., Chu, D. K., Cingi, C., Correia da Sousa, J., Corrigan, C., Custovic, A., D'Amato, G., Del Giacco, S., De Blay, F., Devillier, P., Didier, A., do Ceu Teixeira, M., Dokic, D., Douagui, H., Doulaptsi, M., Durham, S., Dykewicz, M., Eiwegger, T., El-Sayed, Z.A., Emuzyte, R., Emuzyte, R., Fiocchi, A., Fyhrquist, N., Gomez, R. M., Gotua, M., Guzman, M. A., Hagemann, J., Hamamah, S., Halken, S., Halpin, D. M. G., Hofmann, M., Hossny, E., Hrubiško, M., Irani, C., Ispayeva, Z., Jares, E., Jartti, T., Jassem, E., Julge, K., Just, J., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, O., Kardas, P., Kirenga, B., Kraxner, H., Kull, I., Kulus, M., La Gruta, S., Lau, S., Le Tuyet Thi, L., Levin, M., Lipworth, B., Lourenço, O., Mahboub, B., Mäkelä, M. J., Martinez-Infante, E., Matricardi, P., Miculinic, N., Migueres, N., Mihaltan, F., Mohamad, Y., Moniusko, M., Montefort, S., Neffen, H., Nekam, K., Nunes, E., Nyembue Tshipukane, D., O'Hehir, R. E., Ogulur, I., Ohta, K., Okubo, K., Ouedraogo, S., Olze, H., Pali-Schöll, I., Palomares, O., Palosuo, K., Panaitescu, C., Panzner, P., Park, H. S., Pitsios, C., Plavec, D., Popov, T. A., Puggioni, F., Quirce, S., Recto, M., Repka-Ramirez, R., Roballo-Cordeiro, C., Roche, N., Rodriguez-Gonzales, M., Romantowski, J., Rosario Filho, N., Rottem, M., Sagara, H., Sarquis-Serpa, F., Sayah, Z., Scheire, S., Schmid-Grendelmeier, P., Sisul, J. C., Sole, D., Soto-Martinez, M., Sova, M., Sperl, A., Spranger, O., Stelmach, R., Suppli Ulrik, C., Thomas, M., To, T., Todo-Bom, A., Tomazic, P. V., Urrutia-Pereira, M., Valentin-Rostan, M., van Ganse, E., Van Hage, M., Vasankari, T., Vichyanond, P., Viegi, G., Wallace, D., Wang, D. Y., Williams, S., Worm, M., Yiallouros, P., Yiallouros, P., Yusuf, O., Zaitoun, F., Zernotti, M., Zidarn, M., Zuberbier, J., Fonseca, J. A., Zuberbier, T., and Anto, J. M.: Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis. *Allergy* 2023: 78; 1169-1203. IF: TBD (IF 2022: 12.40) |
| 196. | Elieh-Ali-Komi, D., Metz, M., Kolkhir, P., Kocatürk, E., Scheffel, J., Frischbutter, S., Terhorst-Molawi, D., Fox, L., and **Maurer, M.**+: Chronic urticaria and the pathogenic role of mast cells. *Allergol. Int*. 2023: 72; 359-368. IF: TBD (IF 2022: 6.80) |
| 195. | Kolkhir, P.+, Grad, D. A., Charalampous, P., Cruz Oliveira, C., Mechili, E. A., Unim, B., Pearce, D. A., **Maurer, M.**, Devleesschauwer, B., and Haagsma, J.: An EU task force to assess the burden of rare diseases. *Nat. Medicine* 2023: 29; 516-517. IF: TBD (IF 2022: 82.90) |
| 194. | McSweeney, S. M.+, Christou, E. A. A., **Maurer, M.**, Grattan, C. E., Tziotzios, C., and McGrath, J. A.: Physical urticaria: clinical features, pathogenesis, diagnostic work-up, and management. *J. Am. Acad. Dermatol*. 2023: 89; 324-337. IF: TBD (IF 2022: 13.80) |
| 193. | Terhorst-Molawi, D., Fox, L., Siebenhaar, F., Metz, M., and **Maurer, M.**+: Stepping down treatment in chronic spontaneous urticaria – what we know and what we don‘t know. *Am. J. Clin. Dermatol*. 2023: 24; 397-404. IF: TBD (IF 2022: 7.30) |
| 192. | Kocatürk, E., Muñoz, M., Elieh-Ali-Komi, D., Criado, P. R., Peter, J., Kolkhir, P., Can, P., Wedi, B., Rudenko, M., Gotua, M., Ensina, L. F., Grattan, C., and **Maurer, M.**+: How infection and vaccination are linked to acute and chronic urticaria: a special focus on COVID-19. *Viruses* 2023: 15; 1585. IF: TBD (IF 2022: 4.70) |
| 191. | Kaplan, A. P., Lebwohl, M., Giménez-Arnau, A. M., Hide, M., Armstrong, A. W., and **Maurer, M.**+: Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. *Allergy* 2023:78; 389-401*.* IF: TBD (IF 2022: 12.40) |
| 190. | Zuraw, B. L.+, **Maurer, M.**, Sexton, D. J., and Cicardi, M.: Therapeutic monoclonal antibodies with a focus on hereditary angioedema. *Allergol. Int*. 2023: 72; 54-62. IF: TBD (IF 2022: 6.80) |
| 189. | Konstantinou, G. N.+, Riedl, M. A., Valent, P., Podder, I., and **Maurer, M.**: Urticaria and angioedema: understanding complex pathomechanisms to facilitate patient communication, disease management, and future treatment. *J. Allergy Clin. Immunol. Pract*. 2023: 11; 94-106. IF: TBD (IF 2022: 9.40) |
| 188. | Pyatilova, P., Akin, C., Alvarez-Twose, I., Arock, M., Bonadonna, P., Brockow, K., Butterfield, J. H., Broesby-Olsen, S., Carter, M. C., Castells, M., George, T. I., Gotlib, J., Greiner, G., Gülen, T., Hartmann, K., Hermine, O., Homy, H.-P., Jawhar, M., Lange, M., Lyons, J. J., **Maurer, M.**, Metcalfe, D. D., Nedoszytko, B., Niedoszytko, M., Orfao, A., Reiter, A., Schwaab, J., Sotlar, K., Sperr, W. R., Triggiani, M., Valent, P., and Siebenhaar, F.+: Refined treatment response criteria for indolent systemic mastocytosis proposed by the ECNM-AIM consortium. *J. Allergy Clin. Immunol. Pract*. 2022: 10; 2015-2024. IF: 9.40 |
| 187. | Zuberbier, T.+, Bernstein, J. A., and **Maurer, M.**: Chronic spontaneous urticaria guidelines: what is new? *J. Allergy Clin. Immunol.* 2022: 150; 1249-1255. IF: 14.20 |
| 186. | Greve, J., Kinaciyan, T.+, **Maurer, M.**, Dillenburger, B., Recke, A., and Schöffl, C.: Expert consensus on prophylactic treatment of hereditary angioedema. *Allergo J*. 2022: 31; 233-242. IF: N/A |
| 185. | Kolkhir, P.+, Giménez-Arnau, A. M., Kulthanan, K., Peter, J., Metz, M., and **Maurer, M.**: Urticaria. *Nat. Rev. Dis. Primers* 2022: 8; 61. IF: 81.50 |
| 184. | Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., **Maurer, M.**, Thaci, D., Schmidt, E., Cole, C., Amber, K. T., Didona, D., Hertl, M., Recke, A., Graßhoff, H., Hackel, A., Schumann, A., Riemekasten, G., Bieber, K., Sprow, G., Dan, J., Zillikens, D., Sezin, T., Christiano, A. M., Wolk, K., Sabat, R., Kridin, K., Werth, V. P., and Ludwig, R. J.+: Unmet medical needs in chronic, non-communicable inflammatory skin diseases. *Front. Med*. 2022: 9; 899857. IF: 8.10  |
| 183. | Gómez, R. M.+, Bernstein, J. A., Ansotegui, I., and **Maurer, M.**: Chronic urticaria: the need for improved definition. *Front. Allergy* 2022: 3; 905677. IF: N/A |
| 182. | Kocatürk, E.+, Podder, I., Zenclussen, A. C., Kasperska-Zajac, A., Komi, D. E. A., D., Church, M. K., and **Maurer, M.**: Urticaria in pregnancy and lactation. *Front. Allergy* 2022: 3; 892673. IF: N/A |
| 181. | Ryan, D.+, Tanno, L. K., Angier, E., Clark, E., Price, D., Zuberbier, T., and **Maurer M.**: Clinical review: The suggested management pathway for urticaria in primary care. *Clin. Transl.* *Allergy* 2022: 12; e12195. IF: 4.40 |
| 180. | Mendes-Bastos, P.+, Brasileiro, A., Kolkhir, P., Frischbutter, S., Scheffel, J., Moñino-Romero, S., and **Maurer, M.**: Bruton’s tyrosine kinase inhibition – an emerging therapeutic strategy in immune-mediated dermatological conditions. *Allergy* 2022:77; 2355-2366*.* IF: 12.40 |
| 179. | Kolkhir, P., Komi, D. E. A., Metz, M., Siebenhaar, F., and **Maurer, M.**+: Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. *Nat. Rev. Immunol.* 2022:22; 294-308*.* IF: 100.30 |
| 178. | Zuberbier, T.+, Dörr, T., Aberer, W., Alvaro, M., Angier, E., Arasi, S., Arshad, H., Ballmer-Weber, B., Bartra, J., Beck, L., Bégin, P., Bindslev-Jensen, C., Bislimovska, J., Bousquet, J., Brockow, K., Bush, A., Cianferoni, A., Cork, M. J., Custovic, A., Darsow, U., de Jong, N., Deleanu, D., del Giacco, S., Deschildre, A., Dunn Galvin, A., Ebisawa, M., Fernández-Rivas, M., Ferrer, M., Fiocchi, A., Gerth van Wijk, R., Gotua, M., Grimshaw, K., Grünhagen, J., Heffler, E., Hide, M., Hoffmann-Sommergruber, K., Incorvaia, C., Janson, C., Malte John, S., Jones, C., Jutel, M., Katoh, N., Kendziora, B., Kinaciyan, T., Knol, E., Kurbacheva, O., Lau, S., Loh, R., Lombardi, C., Mäkelä, M., Marchisotto, M. J., Makris, M., **Maurer, M.**, Meyer, R., Mijakoski, D., Minov, J., Mullol, J., Nilsson, C., Nowak-Wegrzyn, A., Nwaru, B. I., Odemyr, M., Pajno, G. B., Paudel, S., Papadopoulos, N. G., Renz, H., Ricci, G., Ring, J., Rogala, B., Sampson, H., Senna, G., Sitkauskiene, B., Smith, P. K., Stevanovic, K., Stoleski, S., Szajewska, H., Tanaka, A., Todo-Bom, A., Topal, F. A., Valovirta, E., Van Ree, R., Venter, C., Wöhrl, S., Wong, G. W. K., Zhao, Z., and Worm, M.: Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper. *Allergy* 2022:77; 1736-1750*.* IF: 12.40 |
| 177. | **Maurer, M.**+, Aberer, W., Caballero, T., Bouillet, L., Grumach, A. S., Botha, J., Andresen, I., and Longhurst, H. J. for the IOS study group: the icatibant outcome survey: 10 years of experience with icatibant for patients with hereditary angioedema. *Clin. Exp. Allergy* 2022: 52; 1048-1058. IF: 6.10 |
| 176. | Levi-Schaffer, F.+, Gibbs, B. F., Hallgren, J., Pucillo, C., Redegeld, F., Siebenhaar, F., Vitte, J., Mezouar, S., Michel, M., Puzzovio, P. G., and **Maurer, M.**+: Selected recent advances in understanding the role of of human mast cells in health and disease. *J. Allergy Clin. Immunol*. 2022: 149; 1833-1844. IF: 14.20 |
| 175. | Kolkhir, P.\*, Muñoz, M.\*, Asero, R., Ferrer, M., Kocatürk, E., Metz, M., Xiang, Y., and **Maurer, M.**+: Autoimmune chronic spontaneous urticaria. *J. Allergy Clin. Immunol.* 2022: 149; 1819-1831. IF: TBD 14.20 |
| 174. | Dahlin, J. S., **Maurer, M.**, Metcalfe, D. D., Pejler, G., Sagi-Eisenberg, R., and Nilsson, G.+: The ingenious mast cell: contemporary insights into mast cell behavior and function. *Allergy* 2022: 77; 83-99. IF: 12.40 |
| 173. | Zhao, Z.+, Cai, T., Chen, H., Chen, L., Chen, Y., Gao, X., Gao, X., Geng, S., Guo, Y., Hao, F., Hao, G., Hu, Y., Jin, H., Jin, Z., Li, C., Li, H., Li, J., Li, Y., Liang, Y., Liu, G., Liu, Q., Long, H., Ma, L., Shang, Y., Song, Y., Song, Z., Su, X., Sui, H., Sun, Q., Sun, Y., Tang, J., Tong, X., Wang, H., Wang, G., Wang, L., Wang, S., Xiang, L., Xiao, T., Xie, Z., Ye, L., Yu, Y., Zhang, C., Zhang, L., Zhang, S., Zheng, R., Zhi, L., Zhou, W., Zou, Y., and **Maurer, M.**+: Expert consensus on the use of omalizumab in chronic urticaria in China. *World Allergy Organ. J*. 2021: 14; e100610. IF: 5.52 |
| 172. | Fok, J. S.\*, Kolkhir, P.\*, Church, M. K., and **Maurer, M.**+: Predictors of treatment response in chronic spontaneous urticaria. *Allergy* 2021: 76; 2965-2981. IF: 14.71 |
| 171. | Bachert, C.+, **Maurer, M.**, Palomares, O., and Busse, W. W.: What is the contribution of IgE to nasal polyposis? *J. Allergy Clin. Immunol*. 2021: 147; 1997-2008. IF: 14.29 |
| 170. | Riedl, M. and **Maurer, M.**+: The road to better urticaria and angioedema management. *J. Allergy Clin. Immunol. Pract.* 2021: 9; 2243-2244*.* IF: 11.02 |
| 169. | **Maurer, M.**+\*, Khan, D. A.\*, Komi, D. E. A., and Kaplan, A. P.\*: Biologics for the use in chronic spontaneous urticaria: when and which? *J. Allergy Clin. Immunol. Pract.* 2021: 9; 1067-1078*.* IF: 11.02 |
| 168. | Metz, M.+ and **Maurer, M.**: Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy? *Allergol. Select.* 2021: 5; 89-95. IF: N/A |
| 167. | Maltseva, N.\*, Borzova, E.\*, Fomina, D.\*, Bizjak, M.\*, Terhorst-Molawi, D.\*, Košnik, M.\*, Kulthanan, K.\*, Meshkova, R.\*, Thomsen, S. F.\*, and **Maurer, M.**+\*: Cold urticaria – what we know and what we do not know. *Allergy* 2021: 76; 1077-1094. IF: 14.71 |
| 166. | **Maurer, M.**+ and Magerl, M.: Differences and similarities in the mechanisms and clinical expression of bradykinin-mediated vs. mast cell-mediated angioedema. *Clin. Rev. Allerg. Immunol.* 2021: 9; 1067-1078. IF: 10.82 |
| 165. | Gonçalo, M.+, Giménez-Arnau, A., Al-Ahmad, M., Ben-Shoshan, M., Bernstein, J., Ensina, L. F., Fomina, D., Galvàn, C. A., Godse, K., Grattan, C., Hide, M., Katelaris, C. H., Khoshkhui, M., Kocatürk, E., Kulthanan, K., Medina, I., Nasr, I., Peter, J., Staubach, P., Wang, L., Weller, K., and **Maurer, M.**: The global burden of chronic urticaria for the patient and society. *Brit. J. Dermatol*. 2021: 184; 226-236. IF: 11.11 |
| 164. | Kühn, H.\*, Kolkhir, P.\*, Babina, M., Düll, M., Frischbutter, S., Fok, J. S., Jiao, Q., Metz, M., Scheffel, J., Wolf, K., Kremer, A. E., and **Maurer, M.**+: Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. *J. Allergy Clin. Immunol*. 2021: 147; 456-469. IF: 14.29 |
| 163. | Bousquet, J.+, Anto, J., Bachert, C., Haahtela, T., Zuberbier, T., Carlewski, W., Bedbrook, A., Bosnic-Anticevich, S., Canonica, W., Cardona, V., Costa, E., Cruz, A. A., Erhola, M., Fokkens, W. J., Fonseca, J. A., Illario, M., Ivencevich, J. C., Jutel, M., Klimek, L., Kuna, P., Kvedariene, V., Le, L. T. T., Larenas-Linnemann, D., Laune, D., Laurenço, O. M., Melén, E., Mullol, J., Niedoszytko, M., Odemyr, M., Okamoto, Y., Papadopoulos, N. G., Patella, V., Pfaar, O., Pham-Thi, N., Rolland, C., Samolinski, B., Sheikh, A., Sofiev, M., Suppli Ulrik C., Todo-Bom, A., Tomazic, P. V., Toppila-Salmi, S., Tsiligianni, I., Valiulis, A., Valovirta, E., Ventura, E., Walker, S., Williams, S., Yorgancioglu, A., Agache, I., Akdis, C. A., Almeida, R., Ansotegui, I. J., Annesi-Maesano, I., Arnavielhe, S., Basagana, X., Bateman, E., Bédard, A., Bedolla-Barajas, M., Becker, S., Bennoor, K. S., Benveniste, S., Bergmann, K. C., Bewick, M., Bialek, S., Billo, N., Bindslev-Jensen, C., Bjermer, L., Blain, H., Bonini, M., Bonniaud, P., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Boussery, K., Braido, F., Briedis, V., Briggs, A., Brightling, C. E., Brozek, J., Brusselle, G., Brussino, L., Buhl, R., Buanaiuto, R., Calderon, M. A., Camargos, P., Camuzat, T., Caraballo, L., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Cecchi, L., Cepeda Sarabia, A. M., Chavannes, N., Chkhartishvili, E., Chu, D. K., Cingi, C., Correia de Sousa, J., Costa, D. J., Courbis, A. L., Custovic, A., Cvetkosvki, B., D’Amato, G., da Silva, J., Dantas, C., Dokic, D., Dauvilliers, Y., De Feo, G., De Vries, G., Devillier, P., Di Capua, S., Dray, G., Dubakiene, R., Durham, S. R., Dykewicz, M., Ebisawa, M., Gaga, M., El-Gamal, Y., Heffler, E., Emuzyte, R., Farrell, J., Fauquert, J.-L., Fiocchi, A., Fink-Wagner, A., Fontaine, J.-F., Fuentes Perrez, J. M., Gemicioğlu, B., Gamkrelidze, A., Garcia-Aymerich, J., Gevaert, P., Gomez, M., González Diaz, S., Gotua, M., Guldemond, N. A., Guzmán, M.-A., Hajjam, J., Huerta Villalobos, Y. R., Humbert, M., Iaccarino, G., Ierodiakonou, D., Iinuma, T., Jassem, E., Joos, G., Jung, K.-S., Kaidashev, I., Kalayci, O., Kardas, P., Keil, T., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kouznetsov, R., Kowalski, M. L., Kritikos, V., Kull, I., La Grutta, S., Leonardini, L., Ljungberg, H., Lieberman, P., Lipworth, B., Lodrup Carlsen, K. C., Lopes-Pereira, C., Loureiro, C. C., Louis, R., Mair, A., Mahboub, B., Makris, M., Malva, J., Manning, P., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Carreiro-Martins, P., Makela, M., Mathieu-Dupas, E., **Maurer, M.**, De Manuel Keenoy, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Micheli, Y., Miculinic, N., Mihaltan, F., Milenkovic, B., Mitsias, D. I., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Montefort, S., Monti, R., Morais-Almeida, M., Mösges, R., Münter, L., Muraro, A., Murray, R., Naclerio, R., Napoli, L., Namazova-Baranova, L., Neffen, H., Nekam, K., Neou, A., Nordlund, B., Novellino, E., Nyembue, D., O’Hehir, R., Ohta, K., Okubo, K., Onorato, G. L., Ouedraogo, S., Palamarchuk, J., Pali-Schöll, I., Panzner, P., Park, H.-S., Passalacqua, G., Pépin, J.-L., Paulino, E., Phillips, J., Picard, R., Pinnock, H., Plavec, D., Popov, T. A., Portejoie, F., Price, D., Prokapakis, E., Psarros, F., Pugin, B., Puggioni, F., Quinones-Delgado, P., Raciborski, F., Rajabian-Söderlund, R., Regateiro, F. S., Reitsma, S., Rivero-Yeverino, D., Roberts, G., Roche, N., Rodriguez-Zagal, E., Rolland, C., Roller-Wirnsberger, R. E., Rosario, N., Romano, A., Rottem, M., Ryan, D., Salimäki, J., Sanchez-Borges, M. M., Sastre, J., Scadding, G. K., Scheire, S., Schmid-Grendelmeier, P., Schünemann, H. J., Sarquis Serpa, F., Shamji, M., Sisul, J.-C., Sofiev, M., Solé, D., Somekh, D., Sooronbaev, T., Sova, M., Spertini, F., Spranger, O., Stellato, C., Stelmach, R., Thibaudon, M., To, T., Toumi, M., Usmani, O., Valero, A. A., Valenta, R., Valentin-Rostan, M., Van der Kleij, R., Van Eerd, M., Vandenplas, O., Vasankari, T., Vaz Carneiro, A., Vezzani, G., Viart, F., Viegi, G., Wallace, D., Wagenmann, M., Wang, D. Y., Waserman, S., Wickman, M., Williams, D. M., Wong, G., Wroczynski, P., Yiallouros, P. K., Yusuf, O. M., Zar, H. J., Zeng, S., Zernotti, M. E., Zhang, L., Zhong, N. S., and Zidarn, M.: ARIA digital anamorphosis: digital transformation of health and care in airway diseases from research to practice. *Allergy* 2021: 76; 168-190. IF: 14.71 |
| 162. | Altrichter, S., Fok, J. S., Jiao, Q., Kolkhir, P., Pyatilova, P., Moñino-Romero, S., Scheffel, J., Siebenhaar, F., Steinert, C., Terhorst-Molawi, D., Xiang, Y.-K., Church, M. K., and **Maurer, M.**+: Total IgE as marker in chronic spontaneous urticaria. *Allergy Asthma Immunol. Res.* 2021: 13; 206-218. IF: 5.1 |
| 161. | Klimek, L.+, Pfaar, O., Worm, M., Eiwegger, T., Hagemann, J., Ollert, M., Untersmayr, E., Hoffmann-Sommergruber, K., Vultaggio, A., Agache, I., Bavbek, S., Bossios, A., Casper, I., Chan, S., Chatzipetrou, A., Vogelberg, C., Firinu, D., Kauppi, P., Kolios, A., Kothari, A., Matucci, A., Palomares, O., Szépfalusi, Z., Pohl, W., Hötzenecker, W., Rosenkranz, A. R., Bergmann, K. C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., **Maurer, M.**, Merk, H., Mösges, R., Saloga, J., Staubach, P., Jappe, U., Rabe, K. F., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Freudelsperger, L., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P. V., Aberer, W., Fink-Wagner, A. H., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Matricardi, P. M., Spertini, F., Khaltaev, N., Michel, J. P., Nicod, L., Schmid-Grendelmeier, P., Idzko, M., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Jensen-Jarolim, E., Korn, S., Hentges, F., Schwarze, J., O Mahony, L., Knol, E. F., Del Giacco, S., Chivato Pérez, T., Bousquet, J., Bedbrook, A., Zuberbier, T., Akdis, C., Jutel, M.: Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI), Österreichische Gesellschaft für Pneumologie (ÖGP) in co-operation with the German, Austrian, and Swiss ARIA groups, and the European Academy of Allergy and Clinical Immunology (EAACI). *Allergol. Select.* 2020: 4; 53-68. IF: N/A |
| 160. | Rongisch, R., Schmidt, E., Deresz, N., Deresz, K., Schöfer, H., Just-Nübling, G., Schäkel, K., Jakob, T., **Maurer, M.**, Sticherling, M., Sunderkötter, C., Babilas, P., Spornraft-Ragaller, P., Traidl-Hoffmann, C., Gläser, R., Hartmann, K., Kolb-Mäurer, A., Wenzel, J., Biedermann, T., Homey, B., Pfützner, W., Weid, F., Fischer, M., Linder, R., and von Stebut, E.+: Travel-associated infectious skin diseases. *J. Dtsch. Dermatol. Ges*. 2020:18; 730-733. IF: 5.58 |
| 159. | Saini, S., Shams, M., Bernstein, J. A., and **Maurer, M.**+: Urticaria and Angioedema across the ages. *J. Allergy Clin. Immunol. Pract.* 2020: 6; 1866-1874*.* IF: 8.86 |
| 158. | Maurer, M.+, Eyerich, K., Eyerich, S., Ferrer, M., Gutermuth, J., Hartmann, K., Jakob, T., Kapp, A., Kolkhir, P., Larenas-Linnemann, D., Park, H.-S., Pejler, G., Sanchez-Borges, M., Schäkel, K., Simon, D., Simon, H.-U., Weller, K., Zuberbier, T., and Metz, M.: Urticaria: Collegium Internationale Allergologicum (CIA) update 2020. *Int. Arch. Allergy Immunol*. 2020: 181; 321-333. IF: 2.75 |
| 157. | Altrichter, S., Frischbutter, S., Fok, J. S., Kolkhir, P., Jiao, Q., Stahl Skov, P., Metz, M., Church, M. K., and **Maurer, M.**+: The role of eosinophils in chronic spontaneous urticaria. *J. Allergy Clin. Immunol*. 2020: 145; 1510-1516. IF: 10.79 |
| 156. | Hallgren, J., Hellman, L., **Maurer, M.**, Nilsson, G. P., Wernersson, S., Abrink, M., and Pejler, G.+: Novel aspects of mast cell and basophil function: highlights from the 9th meeting of the European Mast Cell and Basophil Research Network (EMBRN) – a Marcus Wallenberg Symposium. *Allergy* 2020: 75; 707-709. IF: 13.15 |
| 155. | Cai, Y., Folkerts, J., Folkerts, G., **Maurer, M.**, and Braber, S.+: Microbiota-dependent and –independent effects of dietary fiber on human health. *Brit. J. Pharmacol.* 2020:177; 1363-1381. IF: 8.74 |
| 154. | Kolkhir, P., Altrichter, S., Muñoz, M., Hawro, T., and **Maurer, M.**+: New treatments for chronic urticaria. *Ann. Allergy Asthma Immunol*. 2020: 124; 2-12. IF: 6.35 |
| 153. | **Maurer, M.**+, Magerl, M.: How to control recurrent angioedema using monoclonal antibody therapies? *Expert Opin. Biol. Ther*. 2020: 20; 1-4. IF: 4.39 |
| 152. | Türk, M., Carneiro-Leão, L., Kolkhir, P., Bonnekoh, H., Buttgereit, T., and **Maurer, M.**+: How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. *J. Allergy Clin. Immunol. Pract.* 2020: 8; 115-124*.* IF: 8.86 |
| 151. | Cataldi, M., **Maurer, M.**, Taglialatela, M., and Church, M. K.+: Cardiac safety of second-generation H1-antihistamines when updosed in chronic spontaneous urticaria. *Clin. Exp. Allergy* 2019: 49; 1615-1623*.* IF: 4.22 |
| 150. | **Maurer, M.**+, Hawro, T., Krause, K., Magerl, M., Metz, M., Siebenhaar, F., Terhorst-Molawi, D., Weller, K., Zuberbier, T., and Altrichter, S.: Diagnosis and treatment of chronic inducible urticaria. *Allergy* 2019: 74; 2550-2553. IF: 8.71 |
| 149. | De la Caba, K., Guerrero, P., Si Trung, T., Cruz-Romero, M., Kerry, J. P., Fluhr, J., **Maurer, M.**, Kruijssen, F., Albalat, A., Bunting, S., Burt, S., Little, D., and Newton, R.: From seafood waste to active seafood packaging: an emerging opportunity of the circular economy. *J. Clean. Prod.* 2019:208; 86-98*.* IF: 7.25 |
| 148. | Popov, T. A., Church, M. K., Christoff, G., and **Maurer, M.**+: Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources. *World Allergy Organ. Journal* 2019*: 12; 100079.* IF: 3.68 |
| 147. | **Maurer, M.**+, Köberle, M., Metz, M., and Biedermann, T.: Mast cells – promotors of health and modulators of disease. *J. Allergy Clin. Immunol*. 2019: 4; S1-3. IF: 10.23 |
| 146. | **Maurer, M.**+, Taube, C., Schröder, N. W. J., Ebmeyer, J., Siebenhaar, F., Geldmacher, A., Schubert, N., and Roers, A.+: Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions. *J. Allergy Clin. Immunol*. 2019: 4; S19-30. IF: 10.23 |
| 145. | Jiao, Q.\*, Luo, Y.\*, Scheffel, J., Zhao, Z., and **Maurer, M.**+: The complex role of mast cells in fungal infections. *Exp. Dermatol.* 2019: 28; 749-755*.* IF: 3.37 |
| 144. | Baumann, K. Y., Church, M. K., Clough, G. F., Quist, S., R., Schmelz, M., Stahl Skov, P., Anderson, C. D., Kring Tannert, L., Giménez-Arnau, A. M., Frischbutter, S., Scheffel, J., and **Maurer, M.**+: Skin microdialysis: methods, applications and future opportunities - an EAACI position paper. *Clin. Transl. Allergy* 2019: 9; 24. IF: 5.13 |
| 143. | Kulthanan, K., Hunnangkul, S.+, Tuchinda, P., Chularojanamontri, L., Weerasubpong, P., Subchookul, C., and **Maurer, M.**+: Treatments of cold urticaria: a systematic review. *J. Allergy Clin. Immunol*. 2019: 143; 1311-1331. IF: 10.23 |
| 142. | Buttgereit, T.+ and **Maurer, M.**: Classification and pathophysiology of angioedema. *Hautarzt* 2019: 70; 84-91. IF: 0.68 |
| 141. | Kolkhir, P.\*, Bonnekoh, H.\*, Kocatürk, E., Hide, M., Metz, M., Sanchez-Borges, M., Krause, K.\*, and **Maurer, M.**+\*: Management of urticarial vasculitis: a worldwide physician perspective. *World Allergy Organ. J.* 2018*:* 11; 14. IF: 3.68 |
| 140. | **Maurer, M.**+, Metz, M., and Magerl, M.: Neues zur Pathogenese der chronischen spontanen Urtikaria. *Ärztliches Journal Dermatologie* 2018: 2; 20-22. IF: N/A |
| 139. | Kolkhir, P.\*, Pereverzina, N., Olisova, O., and **Maurer, M.**+: Comorbidity of viral hepatitis and chronic spontaneous urticaria: a systematic review. *Allergy* 2018: 73; 1946-1953. IF: 6.77 |
| 138. | **Maurer, M.**+, Fluhr, J., and Khan, D. A.: How to approach chronic inducible urticaria. *J. Allergy Clin. Immunol. Pract.* 2018: 6; 1119-1130*.* IF: 7.55 |
| 137. | Folkerts, J., Stadhouders, R., Redegeld, F. A., Tam, S. Y., Hendriks, R. W., Galli, S., and **Maurer, M.**+: Effect of dietary fiber and metabolites on mast cell activation and mast cell-associated diseases. *Front. Immunol*. 2018: 9; 1067. IF: 4.72 |
| 136. | **Maurer, M.**+, Zuberbier, T., Siebenhaar, F., and Krause, K.: Chronic urticaria – what does the new guideline tell us? *J. Dtsch. Dermatol. Ges*. 2018: 16; 584-595. IF: 3.92 |
| 135. | Dressler, C., Werner, R. N., Eisert, L., Zuberbier, T., Nast, A., and **Maurer, M.**+: Chronic inducible urticaria: a systematic review of treatment options. *J. Allergy Clin. Immunol*. 2018: 141; 1726-1734. IF: 14.11 |
| 134. | **Maurer, M.**, Altrichter, S., Schmetzer, O., Scheffel, J., Church, M. K.+, and Metz, M.: Immunoglobulin E-mediated autoimmunity. *Front. Immunol*. 2018: 9; 689. IF: 4.72 |
| 133. | Siiskonen, H.+, Smorodchenko, A., Krause, K., and **Mauer, M.**: Ultraviolet radiation and skin mast cells: effects, mechanisms, and relevance for skin diseases. *Exp. Dermatol.* 2018: 27; 3-8*.* IF: 2.87 |
| 132. | Siebenhaar, F., Redegeld, F. A., Bischoff, S. C., Gibbs, B. F., and **Maurer, M.**+: Mast cells drivers of disease and therapeutic targets. *Trends Immunol.* 2018: 39; 151-162. IF: 13.00 |
| 131. | Church, M. K., Kolkhir, P., Metz, M., and **Maurer, M.**+: The role and relevance of mast cells in urticaria. *Immunol. Rev.* 2018: 282; 232-247. IF: 11.29 |
| 130. | **Maurer, M.**+ and Pucillo, C.: What we know (and don’t know) about the biology and functions of mast cells and basophils. *Immunol. Rev.* 2018: 282;5-7. IF: 11.29 |
| 129. | **Maurer, M.**+, Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V., Pföhler, C., Staubach, P., Treudler, R., Wedi, B., and Magerl, M.: Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. *J. Allergy Clin. Immunol*. 2018: 141; 638-649. IF: 14.11 |
| 128. | Bygum, A., Busse, P., Caballero, T., and **Maurer, M.**+: Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema. *Front. Med.* 2017: 4; 212. IF: 2.03 |
| 127. | **Maurer, M.**+, Church, M. K., and Weller, K.: Chronic urticaria in children – still itching for insight. *JAMA Derm*. 2017: 153; 1221-1222. IF: 8.11 |
| 126. | Kolkhir, P., Metz, M., Altrichter, S., and **Maurer, M.**+: Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review. *Allergy* 2017: 72; 1440-1460. IF: 6.05 |
| 125. | Kolkhir, P., Borzova, E., Grattan, C., Asero, R., Pogorelov, D., and **Maurer, M.**+: Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. *Autoimmun. Rev.* 2017: 16; 1196-1208. IF: 8.74 |
| 124. | Sánchez-Borges, M.+, Caballero-Fonseca, F., Capriles-Hulett, A., González-Aveledo, L., and **Maurer, M.**: Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. *J. Eur. Acad. Dermatol. Venereol*. 2017: 31; 964-971. IF: 4.29 |
| 123. | Vena, G. A.+, **Maurer, M.**, Cassano, N., and Zuberbier, T.: Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm. *Curr. Opin. Allergy Clin. Immunol*. 2017: 17; 278-285. IF: 3.54 |
| 122. | Magerl, M.+, Germenis, A. E., Maas, C., and **Maurer, M.**: Hereditary angioedema with normal C1 inhibitor: Update on evaluation and treatment. *Immunol. Allergy Clin. North Am*. 2017: 3; 571-584. IF: 3.69 |
| 121. | Kolkhir, P., Church, M. K., Weller, K., Metz, M., Schmetzer, O., and **Maurer, M.**+: Autoimmune chronic spontaneous urticaria: what we know and what we don‘t know. *J. Allergy Clin. Immunol*. 2017: 139; 1772-1781. IF: 13.26Kolkhir, P., Church, M. K., Weller, K., Metz, M., Schmetzer, O., and **Maurer, M.**+: Defining the role of autoimmunity in chronic spontaneous urticaria. Reply to C. E. Grattan’s letter on “Autoimmune chronic spontaneous urticaria: what we know and what we don‘t know”. *J. Allergy Clin. Immunol*. 2018: 141; 1166-1167 |
| 120. | Kolkhir, P., André, F., Church, M. K., **Maurer, M.**, and Metz, M.+: Potential blood biomarkers in chronic spontaneous urticaria. *Clin. Exp. Allergy* 2017: 47; 19-36*.* IF: 5.16 |
| 119. | Vestergaard, C., Toubi, E., **Maurer, M.**, Triggiani, M., Ballmer-Weber, B., Marsland, A., Ferrer, M., Knulst, A., and Giménez-Arnau, A.+: Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. *Eur. J. Dermatol*. 2017: 27; 10-19. IF: 1.94 |
| 118. | Beck, L. A.+, Bernstein, J. A., and **Maurer, M.**: A review of international recommendations for the diagnosis and management of chronic urticaria. *Acta Derm. Venereol*. 2017: 97; 149-158. IF: 3.13 |
| 117. | Kocatürk, E.+, **Maurer, M.**, Metz, M., and Grattan, C.: Looking forward to new targeted treatments for chronic spontaneous urticaria. *Clin. Transl. Allergy* 2017: 7; 1-10. IF: 3.54Kocatürk, E.+, **Maurer, M.**, Metz, M., and Grattan, C.: Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria. *Clin. Transl. Allergy* 2017: 7; 11 |
| 116. | Weller, K.+, Siebenhaar, F., Hawro, T., Altrichter, S., Schoepke, N., and **Maurer, M.**: Clinical measures of chronic urticaria. *Immunol. Allergy Clin. North Am*. 2017: 37; 35-49. IF: 3.69 |
| 115. | Bousquet, J.+, Hellings, P. W., Agache, I., Bedbrook, A., Bachert, C., Bergmann, K. C., Bewick, M., Bindslev-Jensen, C., Bosnic-Anticevitch, S., Bucca, C., Caimmi, D. P., Camargos, P. A., Canonica, G. W., Casale, T., Chavannes, N. H., Cruz, A. A., De Carlo, G., Dahl, R., Demoly, P., Devillier, P., Fonseca, J., Fokkens, W. J., Guldemond, N. A., Haahtela, T., Illario, M., Just, J., Keil, T., Klimek, L., Kuna, P., Larenas-Linnemann, D., Morais-Almeida, M., Mullol, J., Murray, R., Naclerio, R., O'Hehir, R. E., Papadopoulos, N. G., Pawankar, R., Potter, P., Ryan, D., Samolinski, B., Schunemann, H. J., Sheikh, A.,Simons, F. E., Stellato, C., Todo-Bom, A., Tomazic, P. V., Valiulis, A., Valovirta, E., Ventura, M. T., Wickman, M., Young, I., Yorgancioglu, A., Zuberbier, T., Aberer, W., Akdis, C. A., Akdis, M., Annesi-Maesano, I., Ankri, J., Ansotegui, I. J., Anto, J. M., Arnavielhe, S., Asarnoj, A., Arshad, H., Avolio, F., Baiardini, I., Barbara, C., Barbagallo, M., Bateman, E. D., Beghé, B., Bel, EH., Bennoor, K. S., Benson, M., Białoszewski, A. Z., Bieber, T., Bjermer, L., Blain, H., Blasi, F., Boner, A. L., Bonini, M., Bonini, S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, PJ., Braido, F., Briggs, A. H., Brightling, C. E., Brozek, J., Buhl, R., Bunu, C., Burte, E., Bush, A., Caballero-Fonseca, F., Calderon, M. A., Camuzat, T., Cardona, V., Carreiro-Martins, P., Carriazo, A. M., Carlsen, K. H., Carr, W., Cepeda Sarabia, A. M., Cesari, M., Chatzi, L., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciprandi, G., de Sousa, J. C., Cox, L., Crooks, G., Custovic, A., Dahlen, S. E., Darsow, U., Dedeu, T., Deleanu, D., Denburg, J. A., De Vries, G., Didier, A., Dinh-Xuan, A. T., Dokic, D., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., Eklund, P., El-Gamal, Y., Ellers, E., Emuzyte, R., Farrell, J., Fink Wagner, A., Fiocchi, A., Fletcher, M., Forastiere, F., Gaga, M., Gamkrelidze, A., Gemicioğlu, B., Gereda, J. E., van Wick, R. G., González Diaz, S., Grisle, I., Grouse, L., Gutter, Z., Guzmán, M. A., Hellquist-Dahl, B., Heinrich, J., Horak, F., Hourihane, J. O., Humbert, M., Hyland, M., Iaccarino, G., Jares, E. J., Jeandel, C., Johnston, S. L., Joos, G., Jonquet, O., Jung, K. S., Jutel, M., Kaidashev, I., Khaitov, M., Kalayci, O., Kalyoncu, AF., Kardas, P., Keith, P. K., Kerkhof, M., Kerstjens, H. A., Khaltaev, N., Kogevinas, M., Kolek, V., Koppelman, G. H., Kowalski, M. L., Kuitunen, M., Kull, I., Kvedariene, V., Lambrecht, B., Lau, S., Laune, D., Le, L. T., Lieberman, P., Lipworth, B., Li, J., Lodrup Carlsen, K. C., Louis, R., Lupinek, C., MacNee, W., Magar, Y., Magnan, A., Mahboub, B., Maier, D., Majer, I., Malva, J., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Mathieu-Dupas, E., **Maurer, M.**, Mavale-Manuel, S., Melén, E., Melo-Gomes, E., Meltzer, E. O., Mercier, J., Merk, H., Miculinic, N., Mihaltan, F., Milenkovic, B., Millot-Keurinck, J., Mohammad, Y., Momas, I., Mösges, R., Muraro, A., Namazova-Baranova, L., Nadif, R., Neffen, H., Nekam, K., Nieto, A., Niggemann, B., Nogueira-Silva, L., Nogues, M., Nyembue, T. D., Ohta, K., Okamoto, Y., Okubo, K., Olive-Elias, M., Ouedraogo, S., Paggiaro, P., Pali-Schöll, I., Palkonen, S., Panzner, P., Papi, A., Park, H. S., Passalacqua, G., Pedersen, S., Pereira, A. M., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Postma, D., Poulsen, L. K., Price, D., Rabe, K. F., Raciborski, F., Roberts, G., Robalo-Cordeiro, C., Rodenas, F., Rodriguez-Mañas, L., Rolland, C., Roman Rodriguez, M., Romano, A., Rosado-Pinto, J., Rosario, N., Rottem, M., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Scichilone, N., Schmid-Grendelmeier, P., Serrano, E., Shields, M., Siroux, V., Sisul, J. C., Skrindo, I., Smit, H. A., Solé, D., Sooronbaev, T., Spranger, O., Stelmach, R., Sterk, P. J., Strandberg, T., Sunyer, J., Thijs, C., Triggiani, M., Valenta, R., Valero, A., van Eerd, M., van Ganse, E., van Hague, M., Vandenplas, O., Varona, L. L., Vellas, B., Vezzani, G., Vazankari, T., Viegi, G., Vontetsianos, T., Wagenmann, M., Walker, S., Wang, D. Y., Wahn, U., Werfel, T., Whalley, B., Williams, D. M., Williams, S., Wilson, N., Wright, J., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zaidi, A., Zar, H. J., Zernotti, M. E., Zhang, L., Zhong, N., and Zidarn, M.: ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. *Clin. Transl. Allergy*. 2016: 6; 47. IF: 3.2 |
| 114. | Bousquet, J.+, Crooks, G., Farrell, J., Rosado-Pinto, J., Robalo-Cordeiro, C., Malva, J., Bel, E. H., Bewick, M., Chavannes, N. H., Hellings, P., De Manuel Keenoy, E., Muraro, A., Palkonen, S., Papadopoulos, N., Samolinski, B., Standberg, T., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Dedeu, T., Henderson, D., Bedbrook, A., Ansotegui, I. J., Agusti, A., C Bachert, C., Bindslev-Jensen, C., Bosnic-Anticevitch, S., Calderon, M. A., Canonica, G. W., Casale, T., Carriazo, A., Cruz, A. A., Demoly, P., Dahl, R., Fabbri, L., Fonseca, J., Fink Wagner, A., Fokkens, W. J., Haahtela, T., Illario, M., Khaltaev, N., Lodrup Carlsen, K., Morais-Almeida, M., Mullol, J., Nogues, M., Passalacqua, G., Pengelly, R., Postma, D., Price, D., Reddel, H., Rodenas, F., Rodriguez Mañas, L., Rolland, C., Ryan, D., Sánchez-Borges, M., Schunemann, H. J., Sheikh, A., Sterk, P., Triggiani, M., Valovirta, E., Viegi, G., Wickman, M., Aberer, W., Agache, I., Adachi, M., Akdis, C. A., Akdis, M., Alonso, A., Annesi-Maesano, I., Anto, J. M., Arnavielle, S., Arshad, H., Bai, C., Baiardini, I., Baigenzhin, A. K., Barbara, C., Bateman, E. D., Beghé, B., Ben Kheder, A., Bennoor, K. S., Benson, M., Bergmann, K. C., Bieber, T., Bjermer, L., Blain, H., Blasi, F., Boner, A. L., Boulet, L. P., Bonini, M., Bonini, S., Bourret, R., Bousquet, P. J., Braido, F., Briggs, A. H., Brightling, C. E., Brozek, J., Buhl, R., Burney, P. G., Bush, A., Caballero-Fonseca, F., Caimmi, D., Calverley, P., Camargos, P. A. M., Camuzat, T., Carlsen, K. H., Carr, W., Cepeda Sarabia, A. M., Chatzi, L., Chen, Y. Z., Chiron, R., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F.,, Ciprandi, G., Cirule, I., Correia de Sousa, J., Cox, L., Costa, D. J., Custovic, A., Dahlen, S. E., Darsow, U., De Carlo, G., De Blay, F., Deleanu, D., Denburg, J. A., Devillier, P., Didier, A., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Dykewicz, M. S., El-Gamal, Y., Emuzyte, R., Fletcher, M., Fiocchi, A., Forastiere, F., Frith, P., Gaga, M., Gamkrelidze, A., Garces, J., Garcia-Aymerich, J., Gemicioğlu, B., Gereda, J. E., González Diaz, S., Gotua, M., Grisle, I., Grouse, L., Gutter, Z., Guzmán, M. A., Heaney, L. G. , Hellquist-Dahl, B., Hendry, A., Heinrich, J., Heve, D., Horak, F., Hourihane, J., Howarth, P., Humbert, M., Hyland, M. E., Ivancevich, J. C., Jardim, J. R., Jares, E. J., Jeandel, C., Jenkins, C., Johnston, S. L., Joos, G., Jonquet, O., Julge, K., Jung, K. S., Just, J., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Keil, T., Keith, P. K., Klimek, L., Koffi N’Goran, B., Kolek, V., Koppelman, G. H., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Lambrecht, B., Lau, S., Larenas-Linnemann, D., Laune, D., Le, L. T. T., Lieberman, P., Lipworth, B., Li, J., Louis, R., MacNee, W., Magard, Y., Magnan, A., Mahboub, B., Mair, A., Majer, I., Makela, M. J., Manning, P., Mara, S., Marshall, G. D., Masjedi, M. R., Matignon, P., **Maurer, M.**, Mavale-Manuel, S., Melén, E., Melo-Gomes, E., Meltzer, E. O., Menzies-Gow, A., Merk, H., Michel, J. P., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mohammad, Y., Molimard, M., Momas, I., Montilla-Santana, A., Morgan, M., Mösges, R., Nafti, S. , Namazova-Baranova, L., Naclerio, R., Neou, A., Neffen, H., Nekam, K., Niggemann, B., Nyembue, T. D., O’Hehir, R. E., Ohta, K., Okamoto, Y., Okubo, K., Ouedraogo, S., Paggiaro, P., Pali-Schöll, I., Palmer, S., Panzner, P., Papi, A., Park, H. S., Pavord, I., Pawankar, R., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Poethig, D., Pohl, W., Popov, T. A. , Portejoie, F., Potter, P., Rabe, K. F., Raciborski, F., Radier Pontal, F., Repka-Ramirez, S., Reitamo, S., Rennard, S. , Roberts, J., Roca, J., Roman Rodriguez, M., Romano, A., Rosario, N., Rosenwasser, L., Rottem, M., Scadding, G. K., Serrano, E., Schmid-Grendelmeier, P., Schulz, H., Shields, M., Siafakas, N. , Sibille, Y., Similowski, T., Simons, F. E. R., Sisul, J. C., Skrindo, I., Smit, H. A., Solé, D., Sooronbaev, T., Spranger, O., Stelmach, R., Sunyer, J., Thijs, C., To, T., Todo-Bom, A., Valenta, R., Valero, A. L., Valia, E., Van Ganse, E. , van Hage, M., Vandenplas, O., Vasankari, T., Vellas, B., Vestbo, J , Vezzani, G., Vichyanond, P., Vogelmeier, C., Vontetsianos, T., Wagenmann, M., Wallaert, B., Walker, S., Wang, D. Y., Wahn, U., Williams, D. M., Wright, J., Vogelmeier, C., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zaidi, A., Zar, H. J., Zernotti, M. E., Zhang, L., Zhong, N., Zidarn, M., and Merci, J.: Scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (action plan B3: Area 5). *Clin. Transl. Allergy* 2016: 6; 29-47. IF: 3.23 |
| 113. | **Maurer, M.**, Giménez-Arnau, A. M.+, and Zuberbier, T.: What is new and upcoming in the world of chronic urticaria? *J. Eur. Acad. Dermatol. Venereol*. 2016: 30, Suppl. 5; 5-6. IF: 3.52 |
| 112. | Weller, K.+ and **Maurer, M.**: Antihistamine updosing in chronic urticaria – is there enough evidence? *Brit. J. Dermatol*. 2016: 175; 1134-1135. IF: 4.70 |
| 111. | **Maurer, M.**, Church, M. K., Marsland, A. M., Sussman, G., Siebenhaar, F., Vestergaard, C., and Broom, B.: Questions and answers in chronic urticaria: where do we stand and where do we go? *J. Eur. Acad. Dermatol. Venereol*. 2016: 30, Suppl. 5; 7-15. IF: 3.52 |
| 110. | Giménez-Arnau, A. M.+, Toubi, E., Marsland, A. M., and **Maurer, M.**: Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. *J. Eur. Acad. Dermatol. Venereol*. 2016: 30, Suppl. 5; 25-32. IF: 3.52 |
| 109. | Klein, O., Ngo-Nyekel, F., Stefanache, T., Torres, R., Salomonsson, M.+, Hallgren, J., Rådinger, M., Bambouskova, M., Campbell, M., Cohen-Mor, S., Dema, B., Rose, C. G., Abrink, M., Charles, N., Ainooson, G., Paivandy, A., Pavlova, V. G., Serrano-Candelas, E., Yu, Y., Hellman, L., Jensen, B. M., Van Anrooij, B., Grootens, J., Gura, H. K., Stylianou, M., Tobio, A., Blank, U.+, Öhrvik, H., and **Maurer, M.**: Identification of biological and pharmaceutical mast cell and basophil related targets. *Scand. J. Immunol*. 2016: 83; 465-472. IF: 2.25 |
| 108. | Rietzler, M.+, **Maurer, M.**, Siebenhaar, F., Angelino, S, Handt, J., Burghardt, R., and Smetana, H.: Innovative approaches to avoid electric shaving-induced skin irritation. *Int. J. Cosmet. Sci.* 2016: 38; Suppl. 1; 10-16. IF: 1.58 |
| 107. | **Maurer, M.**, Rietzler, M.+, Burghardt, R., and Siebenhaar, F.: The male beard hair and facial skin – challenges for shaving. *Int. J. Cosmet. Sci.* 2016: 38; Suppl. 1; 3-9. IF: 1.58 |
| 106. | Schmetzer, O., Valentin, P., Church, M. K., **Maurer, M.**, and Siebenhaar, F.+: Murine and human mast cell progenitors. *Eur. J. Pharmacol.* 2016: 778; 2-10. IF: 2.89 |
| 105. | **Maurer, M.**, Vena, G. A.+, Cassano, N., and Zuberbier, T.: Current and future therapies for treating chronic spontaneous urticaria. *Expert Opin. Pharmacother.* 2016: 17; 1131-1139. IF: 3.89 |
| 104. | Weller, K.+, Peveling-Oberhag, A., Altrichter, S., Schoepke, N., Abajian, M., Zuberbier, T., Staubach, P.\*, and **Maurer, M.**\*: Instrumente zur Erfassung von Krankheitsaktivität, Krankheitskontrolle und Lebensqualitätsbeeinträchtigung bei Patienten mit chronischer Urtikaria und Angioödemen. *Allergologie* 2016: 39; 6-15. IF: 0.31 |
| 103. | Kolkhir, P., Balakirski, G., Merk, H. F., Olisova, O., and **Maurer, M.**+: Chronic spontaneous urticaria and internal parasites – a systematic review. *Allergy* 2016: 71; 308-322*.* IF: 7.36 |
| 102. | Kolkhir, P., Pogorelow, D., Olisova, O., and **Maurer, M.**+: Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus – a systemic review. *Clin. Exp. Allergy* 2016: 46; 275-287*.* IF: 5.26 |
| 101. | Mitchell, S.+, Balp, M. M., Samuel, M., McBride, D., and **Maurer, M.**: Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments. *Int. J. Dermatol.* 2015: 54; 1088-1104. IF: 1.41 |
| 100. | Church, M. K. and **Maurer, M.**+: H1-Antihistamines and itch in atopic dermatitis. *Exp. Dermatol.* 2015: 24; 332-333. IF: 2.67 |
| 99. | Weller, K.+, Zuberbier, T., and **Maurer, M.**: Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. *Curr. Opin. Allergy Clin. Immunol.* 2015: 15; 220-226. IF: 2.77 |
| 98. | Saluja, R.+, Khan, M., Church, M. K., and **Maurer, M.**: The role of IL-33 and mast cells in allergy and inflammation. *Clin. Transl. Allergy* 2015: 5; 33. IF N/A |
| 97. | **Maurer, M.**+and Giménez-Arnau, A. M.: What is urticaria? Expert opinion from the 1st Global Urticaria Forum. *J. Eur. Acad. Dermatol. Venereol*. 2015: S3; 38-44. IF: 2.82 |
| 96. | **Maurer, M.**+, Church, M. K., Gonçalo, M., Sussman, G., and Sánchez-Borges, M.: Management and treatment of chronic urticaria (CU). *J. Eur. Acad. Dermatol. Venereol*. 2015: S3; 16-32. IF: 2.82 |
| 95. | Weller, K., Zuberbier, T.+, and **Maurer, M.**+: Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. *J. Eur. Acad. Dermatol. Venereol*. 2015: S3; 38-44. IF: 2.82 |
| 94. | Zuberbier, T.+ and **Maurer, M.**: Omalizumab for the treatment of chronic urticaria. *Expert Rev. Clin. Immunol*. 2015: 11; 171-180. IF: 2.59 |
| 93. | Wieder, S., **Maurer, M.**, and Lebwohl, M.+: Treatment of severely recalcitrant chronic spontaneous urticaria: A discussion of relevant issues. *J. Am. Acad. Dermatol.* 2015: 16; 19-26. IF: 5.62 |
| 92. | Chang, T. S., Chen, C., Lin, C.-J., Metz, M., Church, M. K.+, and **Maurer, M.**: The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. *J. Allergy Clin. Immunol*. 2015: 135; 337-342. IF: 12.48 |
| 91. | Siebenhaar, F., Falcone, F. H., Tiligada, E., Hammel, I., **Maurer, M.**, Sagi-Eisenberg, R., and Levi-Schaffer, F.: The search for mast cell and basophil models – are we getting closer to pathophysiological relevance? *Allergy* 2015: 70; 1-5. IF: 6.33 |
| 90. | Mullol, J., Bousquet, J., Bachert, C., Canonica, G. W., Giménez-Arnau, A., Kowalski, M. L., Simons, F. E. R., **Maurer, M.**, Ryan, D., and Scadding, G.: Update on rupatadine in the management of allergic disorders. *Allergy* 2015: 70: 1-24. IF: 6.33 |
| 89. | Harvima, I. T., Levi-Schaffer, F., Draber, P., Friedman, S., Polakovicova, I., Gibbs, B. F., Blank, U., Nilsson, G., and **Maurer, M.**: Molecular targets on mast cells and basophils for novel therapies. *J. Allergy Clin. Immunol*. 2014: 134; 530-544. IF: 11.47 |
| 88. | Saluja, R., Ketelaar, M. E., Hawro, T., Church, M. K., **Maurer, M.** \*, and Nawijn, M. C. \*: The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. *Mol. Immunol.* 2014: 63; 80-85. IF: 2.97 |
| 87. | Magerl, M., Bader, M., Gompel, A., Kusumam, J., Kaplan, A. P., Kojda, G., Renné, T., Wirth, M., **Maurer, M.**, and Church, M. K.: Bradykinin in health and disease: proceedings of the Bradykinin Symposium 2012, Berlin 23-24 August 2012. *Inflamm. Res.* 2014:63; 173-178. IF: 2.35 |
| 86. | Church, M. K. and **Maurer, M.**: Antihistamines. *Chem. Immunol. Allergy* 2014: 100, 302-310. IF: N/A |
| 85. | **Maurer, M.** Urticaria and angioedema. *History of allergy. Chem. Immunol. Allergy* 2014: 100, 101-104. IF N/A |
| 84. | Siebenhaar, F., Akin, C., Bindslev-Jensen, C., **Maurer, M.**, and Broesby-Olsen, S.: Treatment strategies in mastocytosis. *Immunol. Allergy Clin. North. Am.* 2014: 34; 433-447. IF: 1.82 |
| 83. | Zuberbier, T. and **Maurer, M.**: Urticaria vasculitis and Schnitzler syndrome. *Immunol. Allergy Clin. North. Am.* 2014: 34; 141-147. IF 2014: 1.82 |
| 82. | Abajian, M., Schoepke, N., Altricher, S., Zuberbier, T., and **Maurer, M.**: Physical urticarias and cholinergic urticaria. *Immunol. Allergy Clin. North. Am.* 2014: 34; 73-88. IF: 1.82 |
| 81. | **Maurer, M.**, Magerl, M., Metz, M., and Zuberbier, T.: Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. *J. Dtsch. Dermatol. Ges.* 2013: 11; 971-978. IF: 1.81**Maurer, M.**, Magerl, M., Metz, M., and Zuberbier, T.: Neues von der internationalen Leitlinie für Diagnostik und Therapie der chronischen Urtikaria. *J. Dtsch. Dermatol. Ges.* 2013: 11; 971-978**Maurer, M.**: Authors reply. *J. Dtsch. Dermatol. Ges.* 2014: 12; 365 |
| 80. | Makris, M., **Maurer, M.**, and Zuberbier, T.: Pharmacotherapy of chronic spontaneous urticaria. *Expert Opin. Pharmacother.* 2013: 14; 2511-2519. IF: 3.08 |
| 79. | Abajian, M., **Maurer, M.**, and Schoepke, N.: Chronic spontaneous urticaria – An autoimmune disease? *Hautarzt* 2013: 64; 675-684. IF: 0.54 |
| 78. | **Maurer, M.**, Magerl, M., Metz, M., and Zuberbier, T.: Diagnostik und Therapie der chronischen Urtikaria – Was wird von Revision und Aktualisierung der internationalen Leitlinie erwartet? Ein Report der öffentlichen Konsensuskonferenz „URTICARIA 2012“. *Hautarzt* 2013: 64; 638-643. IF: 0.54 |
| 77. | **Maurer, M.**, Magerl, M., Metz, M., and Zuberbier, T.: Diagnostik und Therapie der chronischen Urtikaria – was wird von Revision und Aktualisierung der internationalen Leitlinie erwartet? Ein Report der öffentlichen Konsensuskonferenz "URTICARIA 2012". *Allergo J.* 2013: 22; 324-329. IF: N/A |
| 76. | **Maurer, M.**, Magerl, M., Metz, M., Weller, K., and Siebenhaar, F.: Miltefosine: A novel treatment option for mast cell-mediated diseases. *J. Dermatol. Treat.* 2013: 24; 244-249. IF: 1.76 |
| 75. | Nelissen, S., Lemmens, E., Geurts, N., Kramer, P., **Maurer, M.**, Hendriks, J., and Hendrix, S.: The role of mast cells in neuroinflammation. *Acta Neuropathol.* 2013: 125; 637-650. IF: 9.78 |
| 74. | Schoepke, N., Doumoulakis, G., and **Maurer, M.**: Diagnosis of urticaria. *Ind.* *J. Dermatology* 2013: 58; 211-218. IF: N/A |
| 73. | **Maurer, M.** and Parish, L. C.: The dermatology view of hereditary angioedema: Practical diagnostic and management considerations. *J. Eur. Acad. Dermatol. Venereol.* 2013: 27; 133-141. IF: 2.78 |
| 72. | **Maurer, M.**, Bindslev-Jensen, C., Gimenez-Arnau, A., Godse, K., Grattan, C. E. M., Hide, M., Kaplan, A. P., Makris, M., Simons, F. E. R., Zhao, Z., Zuberbier, T., and Church, M. K.: Chronic idiopathic urticaria (CIU) is no longer idiopathic: time for an update! *Brit. J. Dermatol*. 2013: 168; 455-456. IF: 4.10 |
| 71. | Bousquet, J., Schünemann, H. J., Samolinski, B., Demoly, P., Baena-Cagnani, C. E., Bachert, C., Bonini, S., Boulet, L.P., Bousquet, P. J., Brozek, J. L., Canonica, G.W., Casale, T. B., Cruz A. A., Fokkens, W. J., Fonseca, J. A., Gerth van Wijk, R., Grouse, L., Haahtela, T., Khaltaev, N., Kuna, P., Lockey, R. F., Lodrup Carlsen, K. C., Mullol, J., Naclerio, R., O’Hehir, R. E., Ohta, K., Palkonen, S., Papadopoulos, N. G., Passalacqua, G., Pawankar, R., Price, D., Ryan, D., Simons, F. E. R., Togias, A., Williams, D., Yorgancioglu, A., Yusuf, O. M., Aberer, W., Adachi, M., Agache, I., Aϊt-Khaled, N., Akdis, C. A., Andrianarisoa, A., Annesi-Maesano, I., Ansotegui, I. J., Baiardini, I., Bateman, E. D., Bedbrook, A., Beghé, B., Beji, M., Bel, E. H., Ben Kheder, A., Bennoor, K. S., Bergmann, K. C., Berrissoul, F., Bieber, T., Bindslev-Jensen, C., Blaiss, M. S., Boner, A. L., Bouchard, J., Braido, F., Brightling, C. E., Bush, A., Caballero, F., Calderon, M. A., Calvo, M. A., Camargos, P. A. M., Caraballo, L. R., Carlsen, K. H., Carr, W., Cepeda, A. M., Cesario, A., Chavannes, N. H., Chen, Y. Z., Chiriac, A. M., Chivato Pérez, T., Chkhartishvili, E., Ciprandi, G., Costa, D. J., Cox, L., Custovic, A., Dahl, R., Darsow, U., De Blay, F., Deleanu, D., Denburg, J. A., Devillier, P., Didi, T., Dokic, D., Dolen, W. K., Douagui, H., Dubakiene, R., Durham, S. R., Dykewicz, M. S., El-Gamal, Y., El-Meziane, A., Emuzyte, R., Fiocchi, A., Fletcher, M., Fukuda, T., Gamkrelidze, A., Gereda, J. E., González Diaz S., Gotua, M., Guzmán, M. A., Hellings, P. W., Hellquist-Dahl, B., Horak, F., Hourihane, J. O’B., Howarth, P., Humbert, M., Ivancevich, J. C., Jackson, C., Just, J., Kalayci, O., Kaliner, M. A., Kalyoncu, A. F., Keil, T., Keith, P. K., Khayat, G., Kim, Y. Y., Koffi N’Goran, B., Koppelman, G. H., Kowalski, M. L., Kull, I., Kvedariene, V., Larenas-Linnemann, D., Le, L. T., Lemière, C., Li, J., Lieberman, P., Lipworth, B., Mahboub, B., Makela, M. J., Martin, F., Marshall, G. D., Martinez, F. D., Masjedi, M. R., **Maurer, M.**, Mavale-Manuel, S., Mazon, A., Melen, E., Melter, E. O., Mendez, N. H., Merk, H., Mihaltan, F., Mohammad, Y., Morais-Almeida, M., Muraro, A., Nafti, S., Namazova-Baranova, L., Nekam, K., Neou, A., Niggemann, B., Nizankowska-Mogilnicka, E., Nyembue, T. D., Okamoto, Y., Okubo, K., Orru, M. P., Ouedraogo, S., Olzdemir, C., Panzner, P., Pali-Schöll, I., Park, S., Pigearias, B., Pohl, W., Popov, T. A., Postma, D. S., Potter, P., Rabe, K. F., Ratomaharo, J., Reitamo, S., Ring, J., Roberts, R., Rogala, B., Romano, A., Roman Rodriguez, M., Rosado-Pinto, J., Rosenwasser, L., Rottem, M., Sánchez-Borges, M., Scadding, G. K., Schmid-Grendelmeier, P., Sheikh, A., Sisul, J. C., Solé, D., Sooronbaev, T., Spicak, V., Spranger, O., Stein, R. T., Stoloff, S. W., Sunyer, J., Szczeklik, A., Todo-Bom, A., Toskala, E., Tremblay, Y., Valena, R., Valero, A. L., Valeyre, D., Valiulis, A., Valovirta, E., Van Cauwenberge, P., Vandenplas, O., van Weel, C. Vichyanond, P., Viegi, G., Wang, D. Y., Wickman, M., Wöhrl, S., Wright, J., Yawn, B. P., Yiallouros, P. K., Zar, H. J., Zernotti, M. E., Zhong, N., Zidarn, M., and Zuberbier, T.: ARIA (Allergic Rhinitis and its Impact on Asthma) – Achievements in 10 years and future needs. *J. Allergy Clin. Immunol*. 2012: 130; 1049-1062. IF: 12.04 |
| 70. | Saluja, R., Metz, M., and **Maurer, M.**: Role and relevance of mast cells in fungal infections. *Front. Immunol.* 2012: 3; 1-11. IF: N/A |
| 69. | Valent, P., Arock, M., Bonadonna, P., Brockow, K., Broesby-Olsen, S., Escribano, L., von Gleixner, K., Grattan, C., Hadzijusufovic, E., Hägglund, H., Hermine, O., Horny, H. P., Kluin-Nelemans, H. C., **Maurer, M.**, Niedoszytko, M., Nedoszyotko, B., Nilsson, G., Oude Elberink, H. N. G., Orfao, Radia, D., A., Reiter, A., Siebenhaar, F., Sotlar, K., Sperr, W. R., Triggiani, M., VanDormaal, J. J., Várkonyi, J., Yavuz, S., and Hartmann, K.: European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. *Wien. Klin. Wochenschr.* 2012: 124; 807-814. IF: 0.81 |
| 68. | Lang, D. M., Aberer, W., Bernstein, J. A., Chng, H. H., Sevciovic Grumach, A., Hide, M., **Maurer, M.**, Weber, R., and Zuraw, B.: International consensus on hereditary and acquired angioedema. *Ann. Allergy Asthma Immunol.* 2012: 109; 395-402. IF: 3.44 |
| 67. | Sánchez-Borges, M., Asero, R., Ansotegui, I. J., Baiardini, I., Bernstein, J. A., Canonica, G. W., Gower, R., Kahn, D. A., Kaplan, A. P., Katelaris, C., **Maurer, M.**, Sim Park, H., Potter, P., Saini, S., Tassinari, P., Tedeschi, A., Min Ye, Y., Zuberbier, T., and the WAO Scientific and Clinical Issues Council: Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. *World Allergy Organ. J.* 2012: 5; 125-147. IF: N/A |
| 66. | Zielinski, C., Zuberbier, T., and **Maurer, M.**: Immunoregulation in cutaneous allergy – prevention and control. *Curr. Opin.* *Allergy Clin. Immunol*. 2012: 12; 498-503.IF: 3.39 |
| 65. | Church, M. K. and **Maurer, M.**: H1-antihistamines and urticaria: how can we predict the best drug for our patient? *Clin. Exp. Allergy* 2012: 42; 1423-1429. IF: 4.78 |
| 64. | Krause, K., Metz, M., Makris, M., Zuberbier, T., and **Maurer, M.**: The role of Interleukin-1 in allergy-related disorders. *Curr. Opin.* *Allergy Clin. Immunol*. 2012: 12; 477-484.IF: 3.39 |
| 63. | Siebenhaar, F., Weller, K., Blume-Peytavi, and **Maurer, M.**: Mastozytosen im Kindesalter. *Hautarzt* 2012: 63; 104-111. IF: 0.50 |
| 62. | Abajian, M., Młynek, A., and **Maurer, M.**: Physical urticaria. *Curr. Allergy Asthma Rep.* 2012: 12; 281-287*.* IF: 2.74 |
| 61. | Metz, M. and **Maurer, M.**: Omalizumab in chronic urticaria. *Curr. Opin.* *Allergy Clin. Immunol*. 2012: 12; 406-411.IF: 3.39 |
| 60. | Magerl, M., Brasch, J., Förster, U., Hauswald, B., Mohr, B., Präßler, J., Treudler, R., Vetter, R., Wahn, V., Zampelli, V., Ziemer, M., and **Maurer, M.**: Diagnostik und Ausschluss des hereditären Angioödems – Ein standardisierter Ansatz für die Praxis. *Hautarzt* 2012:63; 567-572*.* IF: 0.50 |
| 59. | Kirchhoff, D., Kaulfuss, S., **Maurer, M.**, and Zollner, T. M.: Mast cells in endometriosis: Guilty or innocent bystanders? *Expert Opin. Ther. Targets* 2012: 16; 237-241. IF: 4.13 |
| 58. | Weller, K., Soost, S., Worm, M., **Maurer**, **M.**, and Zuberbier, T.: Atopic dermatitis and allergic rhinitis – do co-effects in therapy exist? *J. Dtsch. Dermatol. Ges.* 2012: 10; 221-239*.* IF: 1.40 |
| 57. | Krause, K., Feist, E., **Maurer, M.**, and Kallinich, T.: Cryopyrin-assoziierte periodische Syndrome (CAPS) – Prototypen autoinflammatorischer Erkrankungen. *ZfKuJM* 2011: 6; 349-357. IF: N/A |
| 56. | **Maurer, M.**, Bader, M., Bas, M., Bossi, F., Cicardi, M., Cugno, M., Howarth, P., Kaplan, A., Kojda, G., Leeb-Lundberg, F., Lötvall, J., and Magerl, M.: New topics in bradykinin research. *Allergy* 2011: 66;1397-1406. IF: 6.27 |
| 55. | Buddenkotte, J., **Maurer, M.**, and Steinhoff, M.: Histamine and antihistamines in atopic dermatitis. *Adv. Exp. Med. Biol.* 2011: 709; 73-80. IF: 1.37 |
| 54. | Zuberbier, T. and **Maurer, M.**: Antihistamines in the treatment of urticaria. *Adv. Exp. Med. Biol.* 2011: 709; 67-72. IF: 1.37 |
| 53. | Gower, R. G., Busse, P. J., Aygören-Pürsün, E., Barakat, A. J., Caballero, T., Davis-Lorton, M., Farkas, H., Hurewitz, D. S., Jacobs, J. S., Johnston, D. T., Lumry, W., and **Maurer, M.**: Hereditary angioedema caused by C1-Esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. *World Allergy Organ. J.* 2011: 4; S9-S21. IF: N/A |
| 52. | **Maurer, M.**\*, Weller, K.\*, Bindslev-Jensen, C., Giménez-Arnau, A., Bousquet, P., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E. J., Greaves, M. W., Hide, M., Kalogeromitros, D., Kaplan, A. P., Saini, S. S., Zhu, X. J., and Zuberbier, T.: Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. *Allergy* 2011: 66; 317-330. IF:6.27 |
| 51. | **Maurer, M.** and Magerl, M.: Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. *J. Dtsch. Dermatol. Ges.* 2011: 9; 99-107*.* IF: 1.47 |
| 50. | Church, M. K., Weller, K., Stock, P., and **Maurer, M.**: Chronic spontaneous urticaria in children: itching for insight. *Pediatr. Allergy Immunol.* 2011: 22; 1-8. IF: 2.45 |
| 49. | Metz, M. and **Maurer, M.**: Rupatadine for the treatment of allergic rhinitis and urticaria. *Expert Rev. Clin. Immunol.* 2011:7; 15-20.IF: 2.07 |
| 48. | Krause, K., Ardelean, E., Keßler, B., Magerl, M., Metz, M., Siebenhaar, F., Weller, K., Zuberbier, T. and **Maurer, M.**: Causes, triggers and mechanisms of physical urticarias – insights from cold-contact urticaria. *Adv. Psor. Inflamm. Skin Dis.* 2010: 1; 99-104. IF: N/A |
| 47. | Church, M. K., **Maurer, M.**, Simons, F. E., Bindslev-Jensen, C., van Cauwenberge, P., Bousquet, J., Holgate, S. T., and Zuberbier, T.: Risk of first-generation H1-antihistamines: A GA²LEN position paper. *Allergy* 2010: 65; 459-466. IF: 6.29 |
| 46. | Mrabet-Dahbi, S. and **Maurer, M.**: Does allergy impair innate immunity? Leads and lessons from atopic dermatitis. *Allergy* 2010: 65; 1351-1356. IF: 6.29 |
| 45. | **Maurer, M.** and Magerl, M.: Hereditary angioedema: an update on available therapeutic options. *J. Dtsch. Dermatol. Ges.* 2010: 8; 663-672*.* IF: 1.48 |
| 44. | Weller, K., Altrichter, S., Ardelean, E., Krause, K., Magerl, M., Metz, M., Siebenhaar, F., and **Maurer, M.**: Chronische Urtikaria – Prävalenz, Verlauf, Prognosefaktoren und Folgen. *Hautarzt* 2010:61; 750-757.IF: 0.45 |
| 43. | Krause, K., Degener, F., Altrichter, S., Ardelean, E., Kalogeromitros, D., Magerl, M., Metz, M., Siebenhaar, F., Weller, K., and **Maurer, M.**: Kälteinduzierte Quaddeln und Angioödeme – Klassifikation, Diagnostik und Therapie. *Hautarzt* 2010:61; 743-749.IF: 0.45 |
| 42. | Church, M. K., Máspero, J. F., **Maurer, M.**, and Ryan, D.: The scope of pharmacological and clinical effects of modern antihistamines, with a special focus on Rupatadine. *World Allergy Organ. J.* 2010: 3; S1-S16*.* IF: N/A |
| 41. | **Maurer, M.**, Altrichter, S., Ardelean, E., Krause, K., Magerl, M., Metz, M., Siebenhaar, F., Weller, K., and Zuberbier, T.: Therapeutic alternatives for antihistamine-refractory urticaria. *Hautarzt* 2010:61; 765-769.IF:0.45 |
| 40. | Gimenez-Arnau, A., **Maurer, M.**, de la Cuadra, J., and Maibach, H.: Immediate contact skin reactions, an update of contact urticaria, contact urticaria syndrome and protein contact dermatitis – “A never ending story”. *Eur. J. Dermatol.* 2010: 20; 552-562. IF: 2.42 |
| 39. | Kröpfl, L., **Maurer, M.**,andZuberbier, T.:Treatment strategies in urticaria. *Expert Opin. Pharmacother.* 2010: 11; 1445-1450*.* IF: 2.40 |
| 38. | Krause, K., Zuberbier, T. and **Maurer, M.**: Modern approaches to the diagnosis and treatment of cold contact urticaria. *Curr. Allergy Asthm.* 2010: 10; 243-249*.* IF: 2.34 |
| 37. | Magerl, M., Keßler, B., and **Maurer, M.**: Treatment of acute attacks of hereditary angioedema (HAE) with the bradykinin B2 receptor antagonist icatibant. *Rev*. *Port. Imunoalergologia* 2010: 18; 207-214. IF: N/A |
| 36. | Metz, M., **Maurer, M.**, Zuberbier, T., and Magerl, M.: Was ändert sich mit den neuen EAACI/GA2LEN/EDF/WAO Leitlinien für die Betreuung von Patienten mit Urtikaria? *Der Deutsche Dermatologe* 2009: 11; 1-5. IF: N/A |
| 35. | Magerl, M, Keßler, B., **Maurer, M.**, and Musch, A.: Icatibant Behandlung akuter Schwellungsanfälle des hereditären Angioödems (HAE). *Arzneimitteltherapie* 2009: 27; 109-113. IF: N/A |
| 34. | Krause, K., Metz, M., Magerl, M., and **Maurer, M.**: Prevalence and relevance of skin autoreactivity in chronic urticaria. *Expert Rev. Dermatol.* 2009: 4; 655-663*.* IF: N/A |
| 33. | **Maurer, M.**: Cold urticaria: a management model for difficult-to-treat chronic urticaria. *Ann. Dermatol. Vener.* 2009: 136; 15-18. IF: 0.39 |
| 32. | Metz, M. and **Maurer, M.**: Innate immunity and allergy in the skin. *Curr. Opin. Immunol.* 2009: 21; 687-693. IF: 10.88 |
| 31. | Hakim-Rad, K., Metz, M., and **Maurer, M.:** Mast Cells: Makers and Breakers of allergic inflammation. *Curr. Opin.* *Allergy Clin. Immunol*. 2009: 9; 427-430.IF: 3.15 |
| 30. | **Maurer, M.**\*, Dondji, B.\*, and von Stebut, E.\*: What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis. *Med. Microbiol. Immunol.* 2009: 198; 137-146. IF: 3.77 |
| 29. | Kirchhoff, D., Bischoff, S. C., **Maurer, M.**, and Zollner, T. M.: Mast cells in health and disease: from basic science to clinical application. *Expert Opin. Ther. Tar.* 2008: 12; 1591-1594. IF: 4.04 |
| 28. | Mullol, J., **Maurer, M.**, and Bousquet, J.: Sleep and allergic rhinitis. *J. Investig. Allergol. Clin. Immunol.* 2008: 18; 415-419*.* IF: 1.25 |
| 27. | Młynek, A., **Maurer, M.**, and Zalewska, A.: Update on chronic urticaria: focusing on mechanisms. *Curr. Opin. Allergy Clin. Immunol.* 2008: 8;433-437. IF: 3.50 |
| 26. | Metz, M., Siebenhaar, F. and **Maurer, M.**: Mast cell functions in the innate skin immune system. *Immunobiology* 2008: 213; 251-260*.* IF: 3.46 |
| 25. | **Maurer, M.** and Grabbe, J.: Urtikaria – gezielte Anamnese und ursachenorientierte Therapie. *Dtsch. Ärztebl.* 2008: 105; 458-466*.* IF: N/A |
| 24. | Magerl, M., Altrichter, S., Boodstein, N., Güzelbey, O., Keßler, B., Krause, K., Metz, M., Weller, K., Zuberbier, T., and **Maurer, M.**: Urticaria – classification and strategies for diagnosis and treatment. *CME Dermatol.* 2008: 3; 2-18*.* IF: N/A |
| 23. | Taube, C. and **Maurer, M.**: Role of mast cells in the development of allergic asthma. *Allergo J*. 2008: 17; 297-300. IF: N/A |
| 22. | Mullol, J., Bousquet, J., Bachert, C., Canonica, W. G., Gimenez-Arnau, A., Kowalski, M. L., Marti-Guadano, E., **Maurer, M.**, Picado, C., Scadding, G., and van Cauwenberge, P.: Rupatadine in allergic rhinitis and chronic urticaria. *Allergy* 2008: 63; 5–28. IF: 6.20 |
| 21. | Weller, K. and **Maurer, M.**: Aktuelle wissenschaftliche Erkenntnisse zur Mastzelle: Bedeutung für die Praxis. *Allergologie* 2007: 6; 206-210. IF: 0.16 |
| 20. | Schröder, N. W. J. and **Maurer, M.**: The role of innate immunity in asthma: leads and lessons from mouse models. *Allergy* 2007: 62; 579-590. IF: 5.01 |
| 19. | **Maurer, M.** and Staubach, P.: Praktische Tipps für die Betreuung von Patienten mit Urtikaria. *Allergologie* 2007: 6; 211-215.IF: 0.16 |
| 18. | Siebenhaar, F., Weller, K., Młynek, A., Magerl, M., Altrichter, S., Vieira dos Santos, R., **Maurer, M.**, and Zuberbier, T.: Acquired cold urticaria: clinical picture and update on diagnosis and treatment. *Clin. Exp. Dermatol.* 2007: 32; 241-245. IF: 1.52 |
| 17. | Metz, M. and **Maurer, M.**: Mast cells - key effector cells in immune responses. *Trends Immunol.* 2007: 28; 234-241. IF: 9.48 |
| 16. | Zuberbier, T. and **Maurer, M.**: Urticaria: Current opinions about etiology, diagnosis and therapy. *Acta Derm. Venereol*. 2007: 87; 196-205. IF: 1.93 |
| 15. | Magerl, M. and **Maurer, M.**: Urtikaria - from bench to bedside. *Hautarzt* 2007: 58; 308-313. IF: 0.33 |
| 14. | Schröder, J. M., Reich, K., Kabashima, K., Liu, F. T., Romani, N., Metz, M., Kerstan, A., Lee, P. H. A., Loser, K., Schön, M. P., **Maurer, M.**, Stoitzner, P., Beissert, S., Tokura, Y., and Gallo, R. L.: Who is really in control of skin immunity under physiologicalcircumstances – lymphocytes, dendritic cells or keratinocytes? *Exp. Dermatol.* 2006: 15; 913-929. IF: 2.45 |
| 13. | Bousquet, J., Anto, J. M., Bachert, C., Bousquet, P. J., Colombo, P., Crameri, R., Daeron, M., Fokkens, W., Leynaert, B., Lahoz, C., **Maurer**, **M.,** Passalacqua, G., Valenta, R., van Hage, M., and van Ree, R.: Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. *Allergy* 2006: 61; 671-680. IF 5.33 |
| 12. | Steinhoff, M., Bienenstock, J., Schmelz, M., **Maurer, M.**, Wei, E., and Bíró, T.: Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. *J. Invest. Dermatol.* 2006: 126; 1705-1718. IF: 4.54 |
| 11. | **Maurer, M.**, Siebenhaar, F., Syska, W., and Magerl, M.: Ätiopathogenese der akuten und der chronischen Urtikaria. *Allergo J.* 2006: 15; 199-204. IF: N/A |
| 10. | **Maurer, M.**, and Metz, M.: The *status quo* and *quo vadis* of mast cells. *Exp. Dermatol.* 2005: 14; 923-929. IF: 2.09  |
| 9. | Biró, T., Ko, M. C., Bromm, B., Wei, E. T., Bigliardi, P., Siebenhaar, F., Hashizume, H., Misery, L., Baserga, N., Kamei, C., Schouenborg, J., Roostermann, D., Szabó, T., **Maurer, M.**, Bigliardi-Qi, M., Meingassner, J. G., Hossen, M. A., Schmelz, M., and Steinhoff, M.: How best to fight that nasty itch – from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. *Exp. Dermatol.* 2005: 14; 225-240. IF: 2.09 |
| 8. | **Maurer, M.** and von Stebut, E.: Macrophage inflammatory protein-1. *Int. J. Biochem. Cell. Biol*. 2004: 36; 1882-1886. IF: 3.58 |
| 7. | **Maurer, M.** and Zuberbier, T.: Immer wieder Urtikaria. Leitlinien zur Diagnostik der chronischen Urtikaria. *Dermatologe* 2004: 7; 471-474. IF: N/A |
| 6. | **Maurer, M.**, Metz, M., Magerl, M., Siebenhaar, F., and Staubach, P.: Autoreactive urticaria and autoimmune urticaria. *Hautarzt* 2004: 55; 350-356. IF: 0.46 |
| 5. | **Maurer, M.**, Theoharides, T., Granstein, R., Kovanen, P. T., Bischoff, S. C., Befus, D., Vliagoftis, H., Forsythe, P., Kambe, N., Miyachi, Y., Henz, B. M., Piliponsky, A. M., Levi-Schaffer, F., Kitamura, Y., Bienenstock, J., and Galli, S. J.: What is the physiological function of mast cells? *Exp. Dermatol.* 2003: 12; 886-910. IF: 2.04 |
| 4. | **Maurer, M.,** Hanau, A., Metz, M., Magerl, M., and Staubach, P.: Relevanz von Nahrungsmittelallergien und –intoleranzreaktionen als Ursachen von Urtikaria. *Hautarzt* 2003: 54; 138-143. IF: 0.52 |
| 3. | Tokura, Y., Röcken, M., Clark, R. A. F., **Maurer, M.**, Grabbe, S., Haliasos, E., Takigawa M., and Sinha, A. A.: What are the most promising strategies for the therapeutic immunomodulation of allergic diseases? *Exp. Dermatol.* 2001: 11; 128-140. IF: 2.23 |
| 2. | Henz, B. M., **Maurer, M.**, Lippert, U., Worm, M., and Babina, M.: Mast cells as initiators of immunity and host defense. *Exp. Dermatol.* 2001: 10; 1-10. IF: 2.23 |
| 1. | Galli, S. J., **Maurer, M.**, and Lantz, C. S.: Mast cells as sentinels in innate immunity. *Curr. Opin. Immunol.* 1999: 11; 53-59. IF 11.03 |

|  |  |
| --- | --- |
| Number of original publications in peer-reviewed journals: |  580 |
| Number of reviews in peer-reviewed journals: |  210 |
| Number of publications (original work and reviews) in peer-reviewed journals: |  790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |

Total number of citations: 36,836; h-index: 99 (Web of Science December 2023)

## Book Chapters

|  |  |
| --- | --- |
| 53. | **Maurer, M.**\*, Kolkhir, P.\*, Ramanauskaite, A.\*, and Cherrez-Ojeda, I.\*: Digital health and chronic urticaria: In: Matricardi, P. and Dramburg, S., editors: Digital Allergology, 1st ed. Berlin: Springer Nature, *in press*, 2023 |
| 52.  | **Maurer, M.** and Metz, M.: Akute und chronische spontane Urtikaria. In: Kerbl. editor: Referenz Pädiatrie, 1st ed. Thieme, *in press* 2023 |
| 51. | **Maurer, M.** and Metz, M.: Akute und chronische spontane Urtikaria. In: Ludwig, R. and Boehncke, W., editors: Referenz Dermatologie. Thieme, *in press* 2023 |
| 50. | Kolkhir, P., Muñoz, M., Terhorst-Molawi, D., Church, M. K., and **Maurer, M.**+: Chronic urticaria. In: Kenakin, T. editor: Comprehensive Pharmacology. Elsevier, 2022 |
| 49. | **Maurer, M.**+, Zuberbier, T., and Metz, M.: The classification, pathogenesis, diagnostic workup and management of urticaria – an update. In: Traidl-Hoffmann, C., Werfel, T., and Zuberbier, T., editors: Handbook of Experimental Pharmacology on Allergy, 2nd ed., Munich: Springer Nature, 2022 |
| 48. | Church, M. K., Frischbutter, S., Kolkhir, P., and **Maurer, M.**: The pharmacology of antihistamines. In: Reference Module in Biomedical Sciences. Elsevier, 2022 |
| 47. | **Maurer, M.**: Urtikaria. In: Jarisch, R., editor: Histamin Intoleranz. Thieme, 2022 |
| 46. | **Maurer, M.**+, Metz, M., and Zuberbier, T.: Urticaria and Angioedema. In: Lebwohl, M., Heymann, W., Coulson, I., and Murrell, D. editors: Treatment of skin disease. 6th ed., London: Elsevier, 2022 |
| 45. | Grattan, C., Zuberbier, T., and **Maurer, M.**: Other interventions for chronic urticaria. In: Zuberbier, T. Grattan, C., and Maurer, M.,editors: Urticaria and Angioedema. 2nd ed., Switzerland: Springer, 2021 |
| 44. | Kolkhir, P. and **Maurer, M.**: Chronic spontaneous urticaria and comorbidities. In: Zuberbier, T. Grattan, C., and Maurer, M.,editors: Urticaria and Angioedema. 2nd ed., Switzerland: Springer, 2021 |
| 43. | Zuberbier, T., **Maurer, M.**, and Grattan, C.: Management principles in urticaria. In: Zuberbier, T. Grattan, C., and Maurer, M.,editors: Urticaria and Angioedema. 2nd ed., Switzerland: Springer, 2021 |
| 42. | Zuberbier, T., Dörr, T., Grattan, C., and **Maurer, M.**: Omalizumab in the treatment of urticaria. In: Zuberbier, T. Grattan, C., and Maurer, M.,editors: Urticaria and Angioedema. 2nd ed., Switzerland: Springer, 2021 |
| 41. | Terhorst-Molawi, D. and **Maurer, M.**: Chronic spontaneous urticaria. In: Zuberbier, T. Grattan, C., and Maurer, M.,editors: Urticaria and Angioedema. 2nd ed., Switzerland: Springer, 2021 |
| 40. | **Maurer, M.** and Siebenhaar, F.: Mastocytosis. In: Plewig, G., Landthaler, M., Burgdorf, W., Hertl, M. and Ruzicka, T., editors: Braun-Falco’s Dermatology. 4. ed., Heidelberg: Springer, 2020 |
| 39. | **Maurer, M.**: Management of chronic urticaria and angioedema. In: Agache, I., Brockow, K., and Mortz, C., editors: Global atlas of skin allergy. EAACI, 2019 |
| 38. | **Maurer, M.**, Fluhr, J., and Weller, K.: Solar Urticaria. In: Amagai, M., Bruckner, A., Enk, A., Margolis, D., McMichael, A., Orringer, J., and Kang, S., editors: Fitzpatrick‘s Dermatology 9th ed., New York: McGraw-Hill Education, 2019 |
| 37. | **Maurer, M.**:Cold Urticaria. In: Saini, S. and Callen, J., editors: UpToDate. Massachusetts: Wolters Kluwer Health, 2019 |
| 36. | **Maurer, M.** and Siebenhaar, F.: Mastozytose. In: Plewig, G., Landthaler, M., Burgdorf, W., Hertl, M. and Ruzicka, T., editors: Braun-Falco’s Dermatologie, Venerologie und Allergologie. 7. ed., Heidelberg: Springer, 2018 |
| 35. | **Maurer, M.**, and Zuberbier, T.: Urticaria and Angioedema. In: Lebwohl, M., Heymann, W., Berth-Jones, J., and Coulson, I. editors: Treatment of skin disease. 5th ed., London: Elsevier, 2018 |
| 34. | Zuberbier, T. and **Maurer, M.**: Urtikaria und Angioödem. In: Schultze-Werninghaus, G., Fuchs, T., Bachert, C., and Wahn, U., editors: Manuale allergologicum. Dustri, 2016 |
| 33. | Schoepke, N., Doumoulakis, G.\*, and **Maurer, M.**+: Diagnosis of urticaria. In: Godse, K., editor: Urticaria. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd., 2016 |
| 32. | **Maurer, M.**, Magerl, M., Zuberbier, T., and Weller, K.: Urticaria. In: Kabashima, K., editor: Immunology of the skin. Japan: Springer, 2016 |
| 31. | Weller, K. and **Maurer, M.**:Chronic urticaria. In: Naldi, Williams, H., Bigby, M., Herxheimer, A., Naldi, L., Rzany, B., Dellavalle, R., Ran, Y., and Furue, M., editors: Evidence-based dermatology. 3rd ed., Oxford: Wiley, 2014 |
| 30. | **Maurer, M.**, Siebenhaar, F., Schmetzer, O., and Metz, M.: Mast cell biology and its role in the immediate skin contact reactions. In: Maibach, H. I. and Gimenez-Arnau, A., editors: Contact urticaria syndrome. 2nd ed., CRC Press, 2014 |
| 29. | Magerl, M. and **Maurer, M**.: Bradykinin-vermittelte Angioödeme. In: Burg, R. and Gollnick, H., editors: Dermokrates, 2014 |
| 28. | **Maurer, M.**:Cold Urticaria. In: Saini, S. and Callen, J., editors: UpToDate. Massachusetts: Wolters Kluwer Health, 2014 |
| 27. | Zuberbier, T. and **Maurer, M.**: EAACI-GA²LEN-EDF-WAO – Guideline on urticaria. In: Akdis, C. A. and Agache, I., editors: Global atlas of allergy. EAACI, 2014 |
| 26. | **Maurer, M.** and Zuberbier, T.: Hypersensitivity vasculitis. In: Akdis, C. A. and Agache, I., editors: Global atlas of allergy. EAACI, 2014 |
| 25. | **Maurer, M.** and Cazan, D.: Mastzellen und Frühphasenreaktion. In: Klimek, L., Pfaar, O., Rietschel, E., and Wallstein, E., editors: Allergologie bei Kindern und Jugendlichen. Stuttgart: Schattauer, 2014 |
| 24. | **Maurer, M.**: Urtikaria, Angioödem. In: Wahn, U., Bachert, C., Bayerl, C., Klimek, L., Renz, H., and Werfel, T., editors: Handbuch Allergologie. 2014 Allergo-Update 2014. Wiesbaden: Med Publico, 2014 |
| 23. | Church, M. K. and **Maurer M.**: Action protectrice des éthers phénoliques au course de l'intoxication histaminique (Protective action of phenolic ethers on the course of histamine intoxication) D Bovet and Mlle A-M Staub (20). In: Sheikh, A., Platts-Mills, T., and Worth, A., editors: Landmarks in Allergy Seminal Papers in Allergy with Expert Commentaries. Oxford: University Press, 2013 |
| 22. | **Maurer, M.**, Zuberbier, T., and Siebenhaar, F.: Mastozytose. In: Burg, and R. Gollnick, H., editors: Dermokrates, 2013 |
| 21. | **Maurer, M.**:Cold Urticaria. In: Saini, S. and Callen, J. editors: UpToDate. Massachusetts: Wolters Kluwer Health, 2012 |
| 20. | **Maurer, M.**: Urtikaria, Angioödem. In: Wahn, U., Bachert, C., Bayerl, C., Klimek, L., Renz, H., and Werfel, T., editors: Handbuch Allergologie 2012 Allergo-Update 2012. Wiesbaden: Med Publico, 2012 |
| 19. | **Maurer, M.**: Mastozytose. In: Plewig, G., Landthaler, M., Burgdorf, W., Hertl, M. and Ruzicka, T., editors: Braun-Falco’s Dermatologie, Venerologie und Allergologie. 6. Auflage, Heidelberg: Springer, 2012 |
| 18. | **Maurer, M.**, Grattan C., and Zuraw, B.: Urticaria and angioedema without wheals (12). In: Holgate S. T., Church, M. K., Broide, D. H., and Martinez, F. D., editors: Allergy: Principles and Practice. 4th Edition, London: Elsevier, 2012 |
| 17. | Mrabet-Dahbi, S. and **Maurer, M.**:Innate immunity in atopic dermatitis. In: Shiohara T., Amagai, M., Homey, B., Nakanishi, K., Woodfolk, J. A., Bieber, T., Flohr, C., Schittek, B., Hayakawa, J., Yu, H.-S., Oranje, A. P., Schmid-Grendelmeier, P., and Akdis, C. A., editors: Current Problems in Dermatology „Atopic Dermatitis“. Basel: S. Karger Publishers, 2011 |
| 16. | **Maurer, M.**: Chronic urticaria. In: Zuberbier, T. Grattan, C., and Maurer, M.,editors: Urticaria and Angioedema. Heidelberg: Springer, 2010 |
| 15. | Zuberbier, T. and **Maurer, M.**: Antihistamines in the treatment of urticaria. In: Thurmond, R. L., editor: Histamine in inflammation. Texas: Springer Science + Business Media, LLC, Landes Bioscience, 2010 |
| 14. | Siebenhaar, F., Metz, M., and **Maurer, M.**:Mast cell-driven skin responses beyond type I allergic reactions. In: Zierhut, M., Biedermann, T., and Ono, S. J., editors: Immunology of Ocular Allergy. New Delhi: Jaypee Bro. Publisher, 2010 |
| 13. | **Maurer, M.**: Allergische Erkrankungen: Angioödem. In: Sterry, W., Burgdorf, W., and Paus, R., editors: Checkliste Dermatologie. 6. Auflage, Stuttgart: Thieme, 2010 |
| 12. | **Maurer, M.**: Allergische Erkrankungen: Urtikaria. In: Sterry, W., Burgdorf, W., and Paus, R., editors: Checkliste Dermatologie. 6. Auflage, Stuttgart: Thieme, 2010 |
| 11. | **Maurer, M.**: Allergische Erkrankungen: Immunologische Grundlagen. In: Sterry, W., Burgdorf, W., and Paus, R., editors: Checkliste Dermatologie. 6. Auflage, Stuttgart: Thieme, 2010 |
| 10. | **Maurer, M.**: Mastozytosen/Tumoren der Mastzellen. In: Sterry, W., Burgdorf, W., and Paus, R., editors: Checkliste Dermatologie. 6. Auflage, Stuttgart: Thieme, 2010 |
| 9. | Zuberbier, T., Haas, N., and **Maurer, M.**: Urtikaria und Angioödem. In: Schultze-Werninghaus, G., Fuchs, T., and Bachert, C., editors: Manuale allergologicum. Dustri, 2008 |
| 8. | **Maurer, M.**: Mastocytosis. In: Burgdorf, W. H. C., Plewig, G., Wolff, H. H., and Landthaler, M., editors: Braun-Falco’s Dermatology. 3rd ed., Heidelberg: Springer, 2008 |
| 7. | Siebenhaar, F. and **Maurer, M.**: Mastozytose. In: Schöfer, H. and Baur-Beger, S., editors: Derma-Net-Online: Aktuelle Dermatologie für Dermatologen und dermatologisch Interessierte ([www.derma-net-online.de](http://www.derma-net-online.de)), 2007 |
| 6. | Magerl, M. and **Maurer, M.**: Hereditäres Angioödem, In: Schöfer, H. and Baur-Beger, S., editors: Derma-Net-Online: Aktuelle Dermatologie für Dermatologen und dermatologisch Interessierte ([www.derma-net-online.de](http://www.derma-net-online.de)), 2007 |
| 5. | **Maurer, M.**, Worm, M., and Zuberbier, T.: Antihistamines in atopic dermatitis. In: Reitamo, S., Luger, T. and Steinhoff, M., editors: Textbook of atopic dermatitis. London: Informa UK Ltd, 2007 |
| 4. | **Maurer, M.** and Staubach, P.: Einführung. In: Maurer, M. and Staubach, P., editors: Juckreiz, Quaddeln, Nesselsucht. Hamburg: Akademos, 2006 |
| 3. | **Maurer, M.**:Allergie vom Soforttyp (Typ I) – Mastzellen und Frühphasenreaktion. In: Saloga, J., Klimek, L., Buhl, R., Mann, W., and Knop, J., editors: Allergologie-Handbuch Grundlagen und klinische Praxis. Stuttgart: Schattauer, 2006 |
| 2. | **Maurer, M.**: Insektengiftallergie. In: Henning, T. and Maurer, M., editors: Allergien im Kindesalter. Neuwied: Luchterhand, 1998 |
| 1. | **Maurer, M.**: Allergie - was ist das? In: Henning, T. and Maurer, M., editors: Allergien im Kindesalter. Neuwied: Luchterhand, 1998 |

## Books

|  |  |
| --- | --- |
| 8. | Zuberbier, T., Grattan, and **Maurer, M.** editors: Urticaria and Angioedema. 2nd ed., Switzerland: Springer, 2021 |
| 7. | Stebut, E., Berneburg, M., **Maurer, M.**, and Steinbrink, K. editors: Facharztprüfung Dermatologie und Venerologie – 1000 kommentierte Prüfungsfragen. 2nd ed. Stuttgart: Thieme, 2020 |
| 6. | **Maurer, M.** and Redegeld, F., editors: The pharmacological modulation of mast cells and basophils. Vol. 778; 1-176 European Journal of Pharmacology, Elsevier, 2016 |
| 5. | Stebut, E., Berneburg, M., **Maurer, M.**, and Steinbrink, K. editors: Facharztprüfung Dermatologie und Venerologie – 1000 kommentierte Prüfungsfragen. 1st ed.,Stuttgart: Thieme, 2014 |
| 4. | Zuberbier, T., Grattan, C., and **Maurer, M.**, editors: Urticaria – A Practical Manual. Heidelberg: Springer, 2009 |
| 3. | **Maurer, M.** and Staubach, P., editors: Urtikaria: 100 Fragen – 100 Antworten. Hamburg: Akademos, 2006 |
| 2. | **Maurer, M.** and Staubach, P., editors: Juckreiz, Quaddeln, Nesselsucht. Hamburg: Akademos, 2006 |
| 1. | Henning, T. and **Maurer, M.**,editors: Allergien im Kindesalter. Neuwied: Luchterhand, 1998 |